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ABSTRACT 
Haemostasis is the result of a fine balance of interactions between the endothelium, 
plasma proteins and blood cells under a wide range of flow rates. To mimic these 
conditions in vitro, a parallel plate flow chamber with human umbilical vein 
endothelial cells (HUVEC) or extracellular matrix (ECM) has been developed. A 
method to investigate thrombin generation (TG) in platelet rich defibrinated plasma 
was validated and used to investigate inhibition by two distinct classes of 
antithrombotic agents: anti-platelet antibodies and anticoagulants, including 
unfractionated heparin (UFH), low molecular weight heparin (LMWH) and hirudin. 
Increasing flow rates increased TG, which was higher in the presence of ECM than 
in the presence of HUVEC. All anti thrombotic agents investigated were less 
effective in the presence of ECM. 
The monoclonal anti-platelet glycoprotein (GP) lIb/IlIa antibody, RFGP56, partially 
inhibited TG under static or arterial flow conditions and was less effective under 
venous flow conditions. The monoclonal anti-platelet GP Iba antibody, RFGP37, 
did not inhibit TG under flow or static conditions. A combination of the two 
antibodies showed no further activity than RFGP56 alone. 
UFH, which has equal anti-factor Xa and anti-thrombin activity, was able to inhibit 
TG under static and flow conditions. On an anti-Xa unit basis, comparatively more 
LMWH (with a 10: 1 ratio of anti-factor Xa to anti-thrombin activity) was required to 
inhibit TG under static and venous conditions, but under arterial conditions LMWH 
was as effective as UFH. Hirudin, a thrombin specific inhibitor, was totally effective 
under static conditions, but was only able to inhibit up to 40 % ofTG under flow. 
This study shows that some anti-platelet agents can inhibit coagulation and this may 
contribute to their antithrombotic efficacy under certain flow conditions. Although 
both the anti-factor Xa and anti-thrombin activities of anticoagulants are effective, 
anti-factor Xa activity may play a more important inhibitory role under flow 
conditions. 
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CHAPTER! 
INTRODUCTION 
1.1 Haemostasis 
Haemostasis is the process that prevents blood loss when the wall of a blood vessel is 
damaged. A rapid reaction is required to seal the breach and allow repair 
mechanisms to operate and the constant flow of blood over the wound site means 
that reactants are constantly being washed away from where they are most needed. 
Efficient capture and activation mechanisms facilitate a localised coagulation 
response, followed by inhibitory mechanisms that inactivate reactants downstream in 
order to prevent excessive and obstructive clotting, and finally mechanisms that 
break down the clot once tissue repair has been completed. In the absence of injury, 
the fluidity of the blood is maintained by a number of active processes and dynamic 
interactions between components of plasma, blood cells and the endothelial cells that 
line the internal surface of blood vessels. 
There are two classic pathways that may be followed for blood coagulation to occur. 
The intrinsic pathway is the process by which blood clots following contact 
activation of certain coagulation factors by interaction with 'foreign' surfaces. It is 
called the intrinsic pathway as all the substances required for coagulation are present, 
or 'intrinsic', in the blood (Saito, 1994). This is in contrast with the extrinsic 
pathway of coagulation that is stimulated when damage to the vessel wall causes the 
exposure of the procoagulant lipoprotein tissue factor (TF) that is 'extrinsic' to the 
vasculature (Broze, 1994). The intrinsic and extrinsic pathways of coagulation do 
not operate exclusively, and combine to form the common pathway that ultimately 
leads to the formation of a fibrin clot. 
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1.1.1 Intrinsic pathway 
The contact activation phase of the intrinsic pathway involves four plasma proteins _ 
factor XII (FXII), factor XI (FXI), prekallikrein (PKA) and high molecular weight 
kininogen (HMWK; see Figure 1.1). The initial interaction is the adsorption of the 
zymogen factor XII onto a negatively charged foreign surface where it may become 
activated by limited proteolysis. PKA and HMWK circulate in the plasma as a 
complex that is also easily adsorbed onto negatively charged surfaces, where PKA is 
activated to form kallikrein by activated factor XII (FXIIa). The reciprocal reaction 
also occurs, with kallikrein being the major activator of FXII, and it is therefore clear 
that amplification of the coagulant response occurs at this stage. Kallikrein also 
cleaves HMWK to release bradykinin, a vasoactive peptide that can stimulate 
endothelial cell mediated vasodilation and prostacyclin and tissue plasminogen 
activator (t-PA) release from the endothelium (Pearson, 1994; Smith et ai, 1994; 
Bachmann, 1994). As well as binding to PKA, HMWK binds to FXI (although with 
a lower affinity than does PKA) and acts as an anchor holding FXI in close proximity 
to FXIIa, which cleaves the zymogen FXI to the active enzyme FXIa. Following the 
contact activation phase of the intrinsic pathway, FXIa activates factor IX (FIX) to 
FIXa that may then combine with activated factor VIII (FVIIIa) on a phospholipid 
surface in the presence of calcium to form the 'tenase' complex that cleaves and 
activates factor X (FX) at the start of the common pathway (Saito, 1994). 
Patients with a deficiency of one of the four proteins involved in the contact 
activation pathway tend not to have severe bleeding problems, with the exception of 
FXI which can lead to variable bleeding tendencies (Bolton-Maggs, 2000). 
However, the absence or inhibition of these proteins leads to prolonged clotting times 
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in the diagnostic activated partial thromboplastin time (APTT) assay, which uses a 
negatively charged surface (such as a kaolin suspension) to stimulate coagulation. 
This suggests that there are in vivo mechanisms that compensate, such as the 
feedback activation of FXI by thrombin or a reliance on the extrinsic pathway. 
Patients that are deficient in FIX or FVIII do have bleeding tendencies (haemophilias 
B and A respectively), suggesting that although contact activation may be bypassed, 
the intrinsic coagulation pathway is important for haemostasis. The observation that 
platelets bind FXII, FXI, FX and HMWK suggests they may play a role in contact 
activation, possibly providing a catalytic surface for contact activation within the 
confines of the aggregate (Saito, 1994). 
1.1.2 Extrinsic pathway 
The principal component of the extrinsic pathway of blood coagulation is tissue 
factor (TF), a transmembrane lipoprotein constitutively present on the membrane of 
most extravascular cells. When TF is exposed to blood as a consequence of vessel 
wall damage, it binds to factor VII (FVII) making it more susceptible to proteolysis 
by FXa, converting it to the active enzyme FVIIa. The proteolytic activity of the 
TF-FVIIa complex is much greater than that of FVIIa alone, presumably due to a 
conformational change that results from binding to TF, which is acting as a cofactor. 
FVIIa is able to activate FX both directly and indirectly as it is able to cleave FX 
itself, to give activated factor X (FXa), and also to cleave FIX to FIXa that is then 
incorporated into the 'tenase' complex, marking the start of the common pathway of 
coagulation (Broze, 1994). 
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In addition to its expressIOn by extravascular cells, TF has been detected in 
leukocytes in circulating blood (Giesen et ai, 1999; Konigsberg et ai, 2001) from 
where it may be transferred to platelets following stimulation (Rauch et ai, 2000). It 
remains unclear whether the circulating TF is in an active or cryptic form, or whether 
it is present in sufficient quantities to initiate coagulation, but the transfer of TF to 
platelets within a thrombus will facilitate the coagulation process by localising FIXa 
and FXa, the products of the action of the TF-FVIIa complex, to the phospholipid 
surface that catalyses their activity (Giesen et ai, 1999). TF is also expressed by 
endothelial cells following stimulation with cytokines (see Section 1.3.9). 
1.1.3 The common pathway 
Once FX is activated, via either the intrinsic or extrinsic pathways, it may itself 
become incorporated into the prothrombinase complex. The prothrombinase 
complex consists of FXa and FVa on a phospholipid surface in the presence of 
calcium, and it cleaves prothrombin (FII) to produce thrombin (FIla). Thrombin is 
the major procoagulant protein, and it has numerous procoagulant effects including 
the activation of the cofactors FV and FVIII and the conversion of fibrinogen to 
fibrin, which forms the basis of the clot. Factor XIII (FXIII) is a proenzyme that 
circulates bound to fibrinogen. Once the fibrinogen has been converted to fibrin, 
thrombin is able to activate FXIII to FXIIIa which then forms covalent bonds 
between fibrin molecules and cross-links fibrin to other proteins such as collagen and 
fibronectin, thus stabilising the network of fibrin and strengthening the clot 
(Ichinose, 2001). 
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1.1.4 Inhibition of the coagulation process 
There are a number of circulating serine protease inhibitors (serpins) of coagulation 
proteases, such as antithrombin (AT) and heparin cofactor II (HC II), which are dealt 
with in more detail later in this chapter (see Section 1.3.2). Other relevant serpins 
include C I-inhibitor (the major plasmatic inhibitor of FXIa, FXIIa and kallikrein), 
aI-antitrypsin and a2-antiplasmin (Wuillemin et aI, 1996). The other major inhibitor 
of coagulation proteases is a2-macroglobulin, which binds to thrombin (Hemker, 
1994), FXa (Meijers et aI, 1987) and kallikrein (Harpel et aI, 1985). 
In addition to these constitutive inhibitors, coagulation stimulates inhibitory 
mechanisms that 'turn off the process of coagulation by negative feedback. 
Although tissue factor pathway inhibitor (TFPI) is a constitutive plasma protein that 
inhibits coagulation by neutralising the TF-FVIIa complex, it becomes more 
effective in the presence of FXa once coagulation has proceeded to a sufficient 
degree (see Section 1.3.4). TFPI may also be found on the endothelial surface, 
alongside thrombomodulin (TM), which is a receptor for an anionic region of 
thrombin known as exosite I, where procoagulant substrates of thrombin, such as 
fibrinogen and FV need to bind to facilitate their presentation to the proteolytic site 
of thrombin. The binding of thrombin to thrombomodulin therefore blocks its 
procoagulant activity, but bound thrombin is able to cleave the zymogen Protein C to 
form the serine protease activated protein C (APC). Together with its cofactor 
Protein S, APC proteolytically inactivates FVa and FVIIIa (with FV as an additional 
cofactor), thus effectively switching off the coagulation process (see Section 1.3.3 
for more detail). 
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1.1.5 The current concept of blood coagulation 
The relative contributions of the extrinsic and intrinsic pathways of blood 
coagulation have been outlined by Broze (1995) and Morrissey (2001). The 
contributions of cell surface phospholipids have been studied by Monroe et al (2002) 
and the stoichiometry of the initial phase of coagulation modelled by Hockin (2002). 
It has now been established that coagulation is stimulated via the extrinsic pathway 
by the exposure of the plasma protein FVII to sub-endothelial membrane-bound TF. 
This results in the formation of the TF -FVIIa (extrinsic tenase) complex, which then 
activates FX and FIX, leading to the generation of FXa. The rate of this reaction is 
governed by the concentrations of FVII and TFPI. In solution, FXa is rapidly 
inhibited by AT and TFPI but it is protected when bound to cell surface 
phospholipids, where it also has the ability to cleave prothrombin. The small amount 
of thrombin generated in this way provides positive feedback activation of FV and 
platelets, resulting in the assembly of the prothrombinase complex on the platelet 
membrane and propagation of thrombin generation. This phase lasts 12 seconds in 
Hockin's model, assuming 5 pM TF as the stimulus for coagulation. As more FXa is 
generated the inhibitory effect of TFPI becomes more apparent and, for coagulation 
to continue, the intrinsic tenase complex involving FIXa and FVIIla (activated by 
thrombin) must generate FXa. The limiting component in the assembly of 
prothrombinase is FXa, and the switch in dominance of FX cleavage from extrinsic 
to intrinsic occurs at around 300 seconds in Hockin's model. The intrinsic tenase 
complex is fifty-fold more efficient than extrinsic tenase, and peak thrombin 
generation occurs soon after the intrinsic tenase peak at 600 seconds. The 
importance of intrinsic tenase is demonstrated by the bleeding tendencies of FVIII 
and FIX deficient patients. The role of FXI in this scheme is not entirely clear, but it 
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is possible that its activation by thrombin enables FXIa to activate FIX, maintaining 
the contribution of the intrinsic pathway (Keularts et ai, 2001). The dissociation of 
the A2 domain of FVIII is the main reason for the decline of intrinsic tenase function , 
allied to the inhibition of FIX a by AT. In addition to this, the inactivation ofFVa by 
Protein C and of free thrombin by AT and other serpins leads to termination of the 
coagulant response. 
1.1.6 Fibrinolysis 
Thrombin also has feedback effects on fibrinolysis, which is the mechanism that 
breaks down and removes the clot once the damage to the vessel has been repaired. 
Initially, thrombin inhibits fibrinolysis via the thrombin-activatable fibrinolysis 
inhibitor (TAFI), an enzyme that interferes with the cofactor activity of fibrin on the 
activation of plasminogen to plasmin, an enzyme that cleaves fibrin (Bajzar et ai, 
1996). This inhibition may allow the clot to form in the early stages of haemostasis, 
but following establishment of the clot, the increased amount of thrombin may 
activate the contact coagulation factors FXII, kallikrein and FXI, enabling them to 
activate plasminogen. HMWK has also been shown to be required for this reaction. 
Kallikrein also cleaves plasma pro-urokinase to urokinase (u-PA), which in tum 
activates plasminogen. The main initiator of fibrinolysis is tissue-type plasminogen 
activator (t-PA), which is released from endothelial cells activated by exposure to 
agonists including thrombin (Booth, 1999). Thrombin therefore plays an important 
role in both the formation and destruction of the clot. 
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1.2 Platelets 
Platelets are di sc shaped, non-nucleated blood cells that are usuall y 2 - 5 11 m in 
diameter. They are formed by the p inching off of sections of the membrane of 
megakaryocytes, which are large cell s found in the bone marrow. The normal count 
in human blood is in the range 150 - 400 x 106 platelets/ml and they have a lifespan 
of 7 - 10 days. Important structural features of platelets are shown in Figure 1. 2 and 
include i) the glycocalyx , which is comprised of a coll ection of receptors fo r 
adhesion and activation of the platelet; ii) a -granules , the contents of which are 
released after activation of the platelet; iii ) the microtubul e and microfi lament 
systems, which lie just inside the platelet membrane and are invo lved in the shape 
change process of the activated platelet; iv) the phospholipid membrane that can lose 
its asymmetry and provide a catalytic surface for coagulation reactions to occur 
upon; and v) the open canalicular system (OCS), which is a series of interconnected 
canals formed by invaginations of the membrane, allowing the transport of 
membrane bound receptors and bound ligands to and from the surface of the platelet. 
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Figure 1.2 Platelet structure in equatorial and transverse section. 
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1.2.1 Platelets and primary haemostasis 
Primary haemostasis is the process by which a breach in the vessel wall is sealed 
, 
preventing excessive blood loss. Platelets play a critical role, with specialised 
glycoprotein (GP) receptors enabling them to adhere to proteins exposed in areas of 
vascular damage. The process of adhesion and/or the interaction of soluble agonists 
with receptors on the platelet activates the platelets, which are then able to aggregate 
together to form a platelet plug that seals the breach in the vessel wall. Platelet 
aggregometry and studies of thrombus growth under flow conditions have 
determined the platelet activation time to be of the order of 0.1 second (Born & 
Richardson, 1980). A recent in vivo study detected platelet recruitment to the arterial 
wall 4 seconds after injury, demonstrating the efficiency of the capture and activation 
mechanisms that lead to the development of a platelet thrombus (Falati et ai, 2002). 
The process by which platelets adhere to areas of vascular damage is a sequence of 
events that involves a number of receptors and both direct and indirect interaction 
with the exposed sub-endothelium. The removal of endothelial cells from the lining 
of the blood vessel exposes a number of proteins that may act as ligands for platelet 
receptors. The most important is probably collagen, for which platelets have a 
number of specific receptors, but it is von Willebrand Factor (vWF) bound to the 
exposed collagen that makes initial contact with the platelet via the GP Ib/IXIV 
complex (Eldor et ai, 1985; Sakariassen et ai, 1986; McCrary et ai, 1995). Once this 
contact has been made, the other types of collagen receptors may bind to the exposed 
collagen, and yet more receptors are able to bind specifically to ligands such as 
fibronectin, vitronectin and laminin. Some of these receptors are coupled to 
intracellular signalling systems that lead to the activation of the platelet, and notably 
1 1 
to the conversion to an active conformation of GP lIb IlIa, the receptor that is the 
main mediator of platelet aggregation. 
1.2.1.1 The GP IbllXlV complex 
The GP Ib/IXN complex is composed of GP Iba (CD42b), GP IbP (CD42c). GP IX 
(CD42a) and GP V (CD42d), currently thought to be arranged as shown in Figure 1.3 
(Lopez et ai, 1998), at a density of around 25 000 copies per platelet (Andrews et ai, 
1999). Using platelets from a patient with Bernard-Soulier Syndrome (BSS; a 
condition where the GP Ib/IXN complex is deficient) and an antibody that blocked 
the complex, it was shown that the interaction between the complex and the 
sub endothelium became more significant as shear rates were increased (Sakariassen 
et ai, 1986). vWF is an endogenous component of the subendothelium (Sporn et ai, 
1989) that is also adsorbed by collagen and fibrin when they are exposed to flowing 
blood (Pareti et ai, 1987; Savage et ai, 1998; Beguin et ai, 1999). Three regions of 
the terminal 282 amino acids of the GP Iba subunit of the GP Ib/IXIV complex bind 
to vWF - the leucine rich repeats 2 to 4 (Shen et ai, 2000), the two disulphide loops 
formed by 4 cysteine residues at 209, 211, 248 and 264 (Katagiri et ai, 1990), and 
three highly sulphated tyrosine residues at positions 276, 278 and 279 (Tait et ai, 
2002). This binding forms a link between the platelet and the extracellular matrix 
(ECM) under high shear conditions (Weiss et ai, 1978). This was confirmed with a 
recombinant fragment of the vWF molecule that competed with vWF for binding to 
GP Iba and inhibited subsequent platelet adhesion to ECM (Dardik et ai, 1993). The 
GP Ib/IXIV complex is able to bind to surface-bound vWF even when the platelet is 
moving quickly in flowing blood, facilitated by the macroglycopeptide stalk of 
GP Iba that holds the binding regions of the receptor clear of the other cell surface 
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receptors (Li et ai, 2002) In conditions similar to those fo und in arterial blood flow 
(shear rate in the range of 300 - 1000 S-I; see Section 3.1. 1 for an explanat ion of 
shear rate) the GP Ib/IXIV complex provides the first interaction between platelet 
and subendothelium and facilitates further, less transient interactions between other 
ligands and receptors such as GP lIb/IlIa (Frojmovic et ai, 1997; Kasirer-Friede & 
Frojmovic, 1998; Sugimoto et ai, 1999; Wu et ai, 2000) and GP Ia/lla (Verkleij et 01, 
1999; Moroi et ai, 2000). The reason for the mechanistic difference between high 
and low shear rates has not been established. The conventional theory is that the 
high shear conditions alter the conformation of the vWF molecule, exposing a ite 
that is able to bind to the GP Ib/IXN complex. However, two reports ugge t that 
the conformational change induced by high shear may be on the platelet it elf a the 
exposure of vWF to high shear prior to adhe ion e periment under c ndition of 
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low shear did not lead to adhesion (Fredrickson et ai, 1998; v,,"u et ai, 2000). The 
interaction of GP Iba and vWF has been demonstrated to lead to the activation of Src 
kinase in platelets (Wu et ai, 2002c), indicating a stimulatory pathway for platelet 
activation. 
The GP Ib/IXIV complex also functions as a high affinity receptor for thrombin 
(Harmon & Jamieson, 1986) and a binding site for thrombin has been identified to be 
between residues 271 - 284 (De Marco et ai, 1994), at the top of the 
macroglycopeptide 'stalk' region of GP Iba (see Figure 1.3). An additional binding 
site has also been identified between residues 219 - 240 (McKeown et ai, 1996) 
where inhibitory peptides were able to prevent platelet aggregation via GP Iba or the 
main thrombin receptor on the platelet membrane, protease activated receptor 1 
(PAR-I). Monoclonal antibodies that bind to this region have been shown to inhibit 
the activation of platelets (LJIb-l0; Soslau et ai, 2001) and the development of 
platelet procoagulant activity in response to thrombin (SZ2; Dormann et ai, 2000). 
Thrombin cleaves GP V from the surface of the platelet (Lopez & Dong, 1997), 
possibly following its interaction with GP Iba, and this may serve to position 
thrombin in an optimal way to cleave PAR -1 (De Candia et ai, 2001). It has also 
been suggested that heparin is able to bind to GP Iba and inhibit thrombin-mediated 
platelet activation (Jandrot-Perrus et ai, 1999), but results from a different group 
indicate that the inhibitory effect may be due to antithrombin-independent binding of 
thrombin to heparin (De Cristofaro et ai, 1998; De Candia et ai, 1999). GP Iba has 
structural similarity to the P-selectin glycoprotein ligand 1 (PSGL-l) on neutrophils 
and has been demonstrated to be a functional counter-receptor for P-selectin (Romo 
et ai, 1999). Unactivated platelets are therefore able to roll on the surface of 
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activated endothelial cells and to adhere to activated platelets, perhaps initiating 
thrombosis at sites of inflammation. GP Iba is also able to bind to Mac- L a 
neutrophil integrin that includes a vWF-like I domain in its a subunit. and mav 
therefore recruit inflammatory cells to the growing thrombus. 
Signalling via the GP Ib/lX/V complex is summarised in detail by Berndt et al 
(2001). Under resting conditions, the cytoplasmic tails of the receptor subunits are 
attached to actin-binding protein (ABP), anchoring the complex to the cytoskeleton, 
and the adaptor protein 14-3-3~, in association with phosphatidylinositol-3 (PI-3) 
kinase. Following the interaction of the receptor with an agonist, PI-3 kinase is able 
to interact with other signalling molecules, such as the Src kinases (Wu et aI, 2002c), 
and the receptor complex becomes able to move laterally across the membrane 
surface. This lateral movement may lead to localisation of GP Ib/IXN complexes 
into clusters, where they are re-incorporated into the cytoskeleton, and downstream 
signalling that may independently activate the platelet (Kasirer-Friede et aI, 2002). 
There is controversy in the literature regarding the change in surface expression of 
the complex following platelet activation. The majority of reports that study platelets 
in suspension suggest that the complex is temporarily removed to the OCS following 
platelet activation, in what is possibly a mechanism to down-regulate the platelet's 
responsiveness to further stimuli (reviewed by Nurden, 1997). However, studies that 
used adherent platelets appear to give the opposite result, with the complex 
remaining on the surface of the platelet (reviewed by Escolar & White, 2000). 
Functions of the other subunits of GP Ib/IXN have also been investigated. It has 
been shown that GP V is involved in slowing down the rolling of the platelet on the 
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substratum, therefore facilitating other receptor-ligand interactions (Fredrickson et 
ai, 1998). GP Ib~ has been shown contribute to the adhesi\"e properties of the 
complex (Perrault et ai, 2001) and to be important to the expression (Lopez et ai, 
1992) and stability of the complex (Lopez et ai, 1994; Moran et ai, 2000). 
1.2.1.2 GP lIb/IlIa 
The integrin GP lIb/IlIa (aIIb~3; CD411CD61), shown in Figure lA, is a promiscuous 
receptor that is able to bind a number of ligands, such as fibrinogen, vWF, 
vitronectin and fibronectin (Beumer et ai, 1994). This is primarily due to its ability 
to recognise the Arg-Gly-Asp (RGD) sequence of amino acids, although it is also 
able to bind to a sequence of 12 amino acids on the y-chain of fibrinogen (Nurden, 
1994). GP lIb/IlIa is usually present on the platelet in a resting form that binds its 
ligands poorly, but becomes activated following the interaction of a signal-
transducing receptor such as GP Ib/IXIV with its ligand. The activation of 
GP lIb/lIla by intracellular signalling pathways, reviewed by Shattil et al (1998), 
involves the opening up of the two subunits to reveal the ligand-binding pocket that 
is concealed within the three dimensional structure of the two subunits. This is often 
referred to as an 'inside-out' signal. There are reported to be around 80 000 copies 
of this receptor on the platelet membrane (Wagner et ai, 1996) and this number may 
be doubled by the mobilisation of internal stores following activation of the platelet 
(Michelson & Barnard, 1987; Nurden, 1997). Functional deficiency of GP lIb/IlIa 
results in Glanzmann's Thrombasthenia (GT), a condition with severe bleeding 
symptoms that may occur as the result of a wide range of mutations in the genes for 
either subunit of the receptor (reviewed by French & Seligsohn, 2000). 
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GP lIb/IlIa plays a role both in adhesion of the platelet to the substratum and in 
platelet-platelet binding (aggregation). It fonns strong bonds with its ligand in the 
subendothelium but these bonds may only be fonned at venous shear rates (be low 
100 S-I). Where the shear rate is higher, as in arteries (300 - 800 S- I) and capillaries 
(up to 2800 S-I) , this is made possible by the shear-resistant , transient binding of 
platelet GP Ib/IXIV complexes to vWF. These interactions allow the platelet to roll 
across the surface at a rate low enough to facilitate binding via GP lIb/IlIa (Savage et 
aI, 1992; Frojmovic et aI, 1997). The main function of GP lIb/IlIa is platel et 
aggregation, which is achieved by the binding of receptors on multiple platelets to 
the same multivalent ligand molecule, resulting in the assembly of a platelet plug that 
produces primary haemostasis, preventing blood loss by sealing breaches in the 
vasculature. 
Figure 1.4 
GP ilia GP lib 
Schematic view of the GP lIb/lIla receptor. 
Adapted fro m Bache/at et a/ (/995). 
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1.2.1.3 Collagen receptors 
The receptor currently thought to be most important for direct adhesion of platelets to 
collagen is GP IallIa (a2~1' CD49b/CD29, VLA-2, see Figure l.5), another member 
of the integrin family of receptors. Antibody studies have shown that GP IalIIa is 
able to interact with collagen under flow conditions (Verkleij et ai, 1999; Siljander & 
Lassila, 1999) and that inhibition of GP IallIa leads to an increased velocity of 
platelet rolling across the collagen surface (Moroi et ai, 2000). This suggests that 
GP IallIa is involved in the tight binding of tethered platelets to the collagen surface 
and that activation of the platelet may be occurring as it continues its way across the 
surface. As the platelet becomes more activated, other receptors will become able to 
interact with the surface leading to arrest of the platelet. 
It has been shown that there are two distinct activation states of GP IalIIa, and that 
the state of the integrin can be influenced by the presence of the soluble platelet 
agonists ADP and thrombin (lung & Moroi, 2000). The Ia subunit of GP IalIIa is 
where the specificity for collagen is defined, and it has an I domain insert that has 
homology with the A domain of vWF, suggesting its suitability for interaction with 
collagen. The IIa subunit is also important, and studies have shown that antibodies 
to different epitopes can cause either activation of the integrin or inhibition of its 
collagen-binding potential, suggesting that the IIa subunit has a role in maintaining 
the active conformation of the integrin (Moroi & lung, 1997). 
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Figure 1.5 
GPlia GPla 
Schematic view of the CP 101110 receptor. 
Adapted from Santoro and Zutter (1995) 
Collagen binding s ite 
and I domain 
Glycoprotein VI (P62) has been demonstrated to be a receptor for col lagen (Moroi et 
aI, 1989; Ishibashi et aI, 1995) that reacts with an amino acid sequence (glycine-
proline-hydroxyproline) that is highly specific to collagens (Knight et aI, 1999). 
Deficiency of this receptor does not lead to profound bleeding complications (Moroi 
& lung, 1997), probably due to the presence of functional GP lalIIa on the platelets 
(Ichinohe et aI, 1997). Although this receptor plays only a minor role in adhesion , 
the activation of tyrosine kinases, phospholipases and focal adhesion kinases 
following platelet exposure to collagen has been shown to be dependent on GP lalIIa, 
but possibly with the co-operation of GP VI (Keely & Parise, 1996; Ichinohe et ai, 
1997; Kehrel et ai, 1998). This cooperative action may be related to it ignificance 
to the procoagulant response of activated platelets (Heemskerk et ai, 1999) . 
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Glycoprotein IV (CD36) has been shown to be involved in the binding of platelets to 
subendothelial surfaces at physiological shear rates (Diaz et ai, 1996) and to be 
mobilised to the membrane from internal stores following activation of the platelet 
(Berger et ai, 1993; Diaz et ai, 2000). It has been identified as a receptor for 
collagen and thrombospondin (Nurden, 1994) but patients who are genetically 
deficient in this receptor do not present with bleeding problems (Tandon et ai, 1991). 
1.2.1.4 Other adhesive receptors 
Platelets possess a number of other receptors for proteins that are found in the 
subendothelium. Glycoprotein Ieilla (a5~" VLA-5) is an integrin receptor for 
fibronectin, an adhesive protein that is secreted from platelet a-granules and binds to 
collagens and other subendothelial proteins in damaged vessel walls. GP Ieilla has 
been shown to support platelet adhesion at high shear rates (Polanowska-Grabowska 
et ai, 1999). 
Vitronectin is another subendothelial protein, and its integrin receptor (VnR, aV~3) is 
present in low numbers (around 50 copies) on the platelet membrane (Lam et ai, 
1989). Like GP IIblllIa, the vitronectin receptor is a promiscuous receptor able to 
bind to other RGD-containing ligands such as fibrinogen, fibronectin, and vWF in 
addition to vitronectin (Cheresh et ai, 1989). Glycoprotein Ie'llIa (a6~1' VLA-6) has 
been shown to be a receptor for laminin, which is a three chain adhesive protein that 
is found in the sub endothelium (Sonnenberg et ai, 1988). GP Ie' IlIa is able to bind 
to laminin at shear rates below 1000 S-I (Polanowska-Grabowska et ai, 1999) but 
there are no reports to suggest that platelets become activated following binding to 
laminin via this receptor. 
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The combination of all these interactions has the effect of firmly anchoring the 
platelet to the vessel wall, facilitating its next contributions to haemostasis _ 
aggregation and procoagulant activity. 
1.2.1.5 Platelet aggregation 
The adherence of platelets to the vessel wall, or their interaction with soluble agents 
such as thrombin and ADP that may be present at the site of tissue damage, leads to 
the generation of intracellular signals. These are sometimes referred to as 'outside-
in' signals, and their common effect is the engagement of the cytoskeleton, and the 
shape change and spreading of the platelet across the substrate. 
The 'inside-out' signal that results from the unmasking of the ligand-binding pocket 
on the GP lIb subunit of GP lIb/IlIa leads to an increased affinity of the receptor for 
its ligands and marks a change in the character of the platelet from adhesive to 
aggregatory. Its multivalent ligands such as fibrinogen and vWF can bind to copies 
of GP lIb/IlIa on adjacent platelets, creating a cross-linked matrix of platelets and 
proteins (Shattil et ai, 1998). This leads to amplification of the response and the 
recruitment of platelets to the site of damage, forming a platelet plug that is the first 
line of defence in the prevention of blood loss from damaged blood vessels. 
1.2.2 Platelets and secondary haemostasis 
The second line of defence in the prevention of blood loss is the formation of a fibrin 
clot. This clot is built on the scaffold of aggregated platelets that form the platelet 
plug and there are a number of ways in which platelets facilitate the formation of the 
clot. Activated platelets undergo a rearrangement of their membrane structure, and 
21 
negatively charged phospholipids such as phospatidylserine CPS) become exposed at 
the outer leaflet (Zwaal et ai, 1989). This process is often referred to as a 'flip-flop' 
of the membrane or 'membrane scrambling' and is the result of the action of the 
enzyme scramblase (Zwaal & Schroit, 1997). The exposed phospholipids provide a 
catalytic template for the interaction of FIXa and FVIIla to form the tenase complex, 
and for the interaction of FXa and FVa to form the prothrombinase complex. 
Platelets facilitate these reactions further by carrying some of the relevant enzymes 
and cofactors on or inside their membrane or on parts of their membrane that become 
'pinched off after activation to form microparticles. Factor VIII, which is a cofactor 
in the tenase complex, circulates bound to vWF and the local concentration of FVIII 
will therefore increase at sites of vessel wall damage when vWF binds to collagen 
exposed in the sub endothelium. Factor VIII can then bind to receptors on the platelet 
membrane, the expression of which is increased following activation of the platelet 
(Gilbert et ai, 1991), suggesting that there is an active recruitment of this cofactor to 
the membrane. Similarly, receptors for FV have been detected on microparticles 
(Sims et ai, 1988), and platelets have been shown to synthesise and secrete this 
coagulation cofactor (Monkovic & Tracy, 1990; Camire et ai, 1998) showing that the 
formation of the prothrombinase complex is also facilitated by platelets. 
Prothrombin, the substrate of this complex, is the zymogen of thrombin, the most 
potent enzyme of the coagulation cascade. Prothrombin is also carried on the 
membrane of resting platelets; the relatively small size of the prothrombin molecule 
allows it to enter the ligand-binding pocket of unactivated GP lIb/IlIa, which is 
inaccessible to the larger fibrinogen molecule, and bind via its RGD sequence 
(Byzova & Plow, 1997). It has also been reported that FXI may bind to GP Ib/IXIV 
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in a way that facilitates its activation by thrombin, but this occurs after platelet 
activation suggesting that it may be a feedback effect in the propagation phase of 
coagulation (Baglia et ai, 2002). 
We can therefore envisage a sequence of platelet-mediated haemostatic events that 
follow damage to the endothelium (illustrated in Figure 1.6). Platelet activation by 
interaction with sub endothelium-bound vWF leads to platelet shape change, 
membrane 'flip-flop' and the activation of GP lIb/IlIa. As this happens, the cofactor 
FVIlla (released from the vWF) binds to the membrane with FIXa to form tenase 
that cleaves FX to create FXa that then combines with FV released from the platelet, 
activated by thrombin, and is bound to the platelet membrane to create 
prothrombinase. Prothrombin is displaced from the now activated GP lIb/IlIa, which 
can now bind the larger fibrinogen molecule for which it has a higher affinity, and 
the prothrombin is cleaved to create thrombin that in tum cleaves the fibrinogen to 
create the fibrin that forms the clot. 
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1.3 The endothelium and inhibitors of coagulation 
The maintenance of a non-thrombotic state in normal blood vessels is largely 
dependent on the integrity of the endothelium. The endothelium usually presents a 
non-thrombogenic surface and expresses a variety of anticoagulant factors. although 
procoagulant activity may be induced. 
1.3.1 Inhibition of intrinsic activation 
Factor XII and HMWK have been found to compete for a binding site on the surface 
of endothelial cells, suggesting that the cell membrane may provide a template for 
the interaction of these molecules and thereby stimulate the intrinsic pathway of 
coagulation, especially as bound FXII was shown to be gradually cleaved to its 
active form FXIIa that was able to cleave prekallikrein (Reddigari et ai, 1993). The 
assembly of a FIX activating complex on the endothelial cell membrane following 
the binding of HMWK and FXI in the presence of FXIIa has also been demonstrated 
(Berrettini et ai, 1992). Contrary to this, it has been demonstrated that endothelial 
cells are able to inhibit the formation of FXa and kallikrein in plasma, indicating 
inhibition of the intrinsic pathway of coagulation in a process independent of 
Protein C and suggested to be via inactivation of FVIII (Kleniewski & Donaldson, 
1993; Bombeli et ai, 1996; Bombeli et ai, 2001). 
Endothelial cells may also enhance the inhibition of FXIa by the plasmatic inhibitors 
antithrombin and C I-inhibitor and of kallikrein by antithrombin. In vitro the action 
of both of these inhibitors is enhanced by interaction with heparin (Olson et al. 1993; 
Wuillemin et ai, 1995) and it has been suggested that glycosaminoglycans (GAG) on 
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the luminal surface of endothelial cells may provide this potentiation in vivo, adding 
to the inhibitory properties of the endothelium (Wuillemin et al. 1996). 
1.3.2 Heparan sulphate, heparin and antithrombin 
The major antithrombotic component of endothelial cells is the heparan sulphate 
proteoglycan (HSPG) molecules that are abundant on the cell membrane (Busch & 
Owen, 1982; Pearson, 1994). These negatively-charged GAG have the ability to 
potentiate the inhibitory action of a number of inhibitors, such as antithrombin and 
C I-inhibitor. 
1.3.2.1 Antithrombin 
Antithrombin (AT) is one member of a group of serine protease inhibitors (serpins) 
that function by acting as pseudosubstrates for their target enzymes, which become 
covalently bound and are removed from the circulation. It is able to inhibit a number 
of coagulation proteases such as FXIa and FIXa but most important is its inhibition 
of thrombin and FXa, proteases in the common pathway of coagulation (Bauer & 
Rosenberg, 1991; Harper & Carrell, 1994). 
AT is a single chain glycoprotein of 432 amino acids with three disulphide bonds, 
and a molecular weight of 58 200 (Lane et ai, 1994). It exists in two isoforms, AT-a 
with four carbohydrate side-chains and AT -p with three side-chains and an increased 
affinity for heparin, which leads to greater inhibitory activity (Swedenborg, 1998). 
AT circulates in the plasma at a concentration of2.5 JlM or 125 Jlg/ml (Murano et al. 
1980) and 90 % is present as the AT-a isoform (Peterson & Blackburn, 1985). This 
is in contrast to the vessel wall where the proportions of AT -a and AT -p are equal. 
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suggesting that the high-affinity AT -P isoform preferentially binds to heparin-like 
molecules on the endothelium before being transferred through the endothelium and 
into the vessel wall (Bock et ai, 1997). 
1.3.2.2 Heparin 
The action of antithrombin is greatly enhanced by binding to the polysaccharide 
heparin, a heterogeneous mixture of polysaccharide chains of varying lengths that is 
naturally found in the granules of mammalian mast cells in tissues such as lung, skin, 
ileum, lymph nodes and thymus. No evidence has been found to demonstrate that 
endogenous heparin plays a role in maintaining blood flow, but it has proved to be an 
effective therapeutic agent for this purpose and is most commonly prepared from 
porcine intestinal mucosa (Sarret, 1999). The interaction of heparin with 
antithrombin leads to a conformational change that exposes the reactive centre of 
antithrombin, and neutralisation of its positive charge that allows it to interact more 
easily with other positively charged molecules. These changes lead to a 10 OOO-fold 
increase in antithrombin's inhibitory rate against thrombin (Harper & Carrell, 1994). 
The length and precise composition of each heparin chain influences its biological 
activity, and enables it to act as a catalyst for the inhibition of FXa and FIla 
(thrombin) by antithrombin. The interaction of heparin with antithrombin is highly 
specific and the sequence that defines this specificity has been identified as a 
pentasaccharide sequence (Choay et ai, 1983). Within this sequence, a 3-0-sulphate 
group on the glucosamidine residue in position 3 of the pentasaccharide is critical for 
the binding of antithrombin (Lindahl et ai, 1980; see Figure 1.7). Not all of the 
polysaccharide chains will contain the pentasaccharide sequence. but some long 
polysaccharide chains may contain several repeats, meaning that the activity of the 
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heparin mixture is influenced by its molecular weight. The mean molecular \\:eight 
of an unfractionated heparin (UFH) preparation is around 15 000, representing chains 
of up to 50 saccharide units. 
o 
Figure 1.7 
o 
NHR OH 
o o 
OSO -3 
The structure of the heparin pentasaccharide with high affinity for antithrombin. 
R =AcorS03-
Reproducedfrom Mulloy & Forster (2000). 
Once antithrombin has bound to heparin, and its binding affinity for FXa therefore 
increased, FXa is prevented from being incorporated into the prothrombinase 
complex, inhibiting the action of the complex in the conversion of prothrombin to 
thrombin. However, for heparin to enhance antithrombin's direct inhibition of 
thrombin it is necessary for a ternary complex to be formed, with thrombin binding 
to the heparin chain alongside antithrombin (see Figure 1.8). Thrombin binds to 
heparin via an anion binding domain known as exosite II (Sheehan & Sadler, 1994; 
Gan et ai, 1994), and a chain length of thirteen saccharides is required for this 
interaction, meaning that a minimum chain length of 18 saccharides is required for 
the inhibition of thrombin compared to the five required for inhibition of FXa (Lane 
et ai, 1984; Danielsson et al. 1986). An 18 saccharide chain will have a molecular 
weight of around 5 400. and this is often referred to as the critical chain length for 
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potentiation of antithrombin activity against thrombin (Bray et aI, 1989). The 
probability of the critical pentasaccharide sequence occurring next to a 13 saccharide 
sequence increases as the length of the chain increases and it follows that 
preparations of heparin with higher molecular weight will have a greater anti-lla 
activity than low molecular weight preparations. Antithrombin's inhibition of 
thrombin prevents the formation of fibrin clots and also serves to inhibit the positive 
feedback thrombin-mediated activation ofFV, FVIII, FXIII and platelets. 
a 
b 
Figure 1.8 
Xa 
Thrombin 
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The template model for the potentiation of a) factor Xa and 
b) thrombin inhibition by heparin. 
The pentasaccharide sequence (5) is required for the in.t~raction of hepa~in with 
antithrombin (AT), increasing its affinity for Xa. An additIOnal 13 saccharides are 
required for the binding of thrombin. 
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1.3.2.3 Heparin and cells 
Heparin binds to two sites on endothelial cells in a slow and saturable manner. 
although these sites are not specific receptors for heparin (Barzu et aI, 1984). The 
molecular weight of the heparin and the source of the endothelial cells are known to 
influence this process and may have implications for the pharmacokinetics of these 
compounds (Barzu et aI, 1984; Barzu et aI, 1986). Intemalisation and the subsequent 
release of heparin molecules may account for the delayed increase in activity 
following subcutaneous administration. Heparin bound to the endothelium may be 
thought to act as an immobilised anticoagulant, but the activity of endothelial-bound 
heparin is seen to be at least partially neutralised, possibly by endocytosis and 
intracellular degradation (Barzu et aI, 1986; Tobelem, 1989). Heparin also binds to 
platelets, and two binding sites on the molecule have been proposed. Both sites have 
the ability to bind both platelets and antithrombin, but do so with different 
preferences (Barrowcliffe & Thomas, 1994). The size of the heparin molecules 
means that they are multivalent for these sites and therefore have the effect of 
crosslinking platelets, leading to a fall in the number circulating. Another, more 
serious form of heparin induced thrombocytopenia (HIT) is due to the development 
of antibodies against the heparin-platelet complex (Barrowcliffe & Thomas, 1994). 
Although there have been reports of patients who have developed HIT whilst 
receIvmg UFH being successfully switched to low molecular weight heparin 
(reviewed by Barrowcliffe et aI, 1992), a more recent investigation did not show any 
difference between UFH and LMWH in the development of HIT (Amiral et aI, 
1996). 
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1.3.2.4 Clinical use of unfractionated heparin 
UFH is well established as a treatment for venous thrombosis and pulmonary 
embolism, and has been used for this purpose for over 60 years. It has also been 
successfully used in the treatment of acute coronary artery syndromes such as 
unstable angina and myocardial infarction and as an adjunct to thrombolysis. When 
UFH is infused, it binds to a large number of plasma proteins, endothelial cells and 
macrophages, which clear it from the circulation in a rapid and saturable manner. 
The kidneys also remove heparin in a slower, non-saturable manner. This means that 
the anticoagulant response to therapeutic doses of heparin is non-linear, and 
laboratory monitoring is required as frequently as every six hours. UFH also has 
poor bioavailability when injected subcutaneously, probably due to poor absorption 
of the high molecular weight material, meaning that continuous intravenous infusion 
is preferred (Bell & Hennebry, 1999; Hirsh et ai, 2001). 
1.3.2.5 Low molecular weight heparin 
Low molecular weight heparin may be prepared from the parent compound by 
separation of the different length chains (eg by gel filtration) or by cleavage of the 
longer chains (by chemicals such as nitrous acid or enzymatically by heparinase). 
The mean molecular weight of LMWH preparations is between 3 000 and 6 000, 
representing chain lengths of 10 to 20 saccharide units, in comparison with UFH 
preparations of mean molecular weight 15 000, representing around 50 saccharide 
units (see Figure 1.9). The anticoagulant profile of LMWH preparations will differ 
depending upon the exact distribution of the chain lengths that they contain. In terms 
of potencies, all have a higher activity against FXa (anti-Xa activity) than against 
thrombin (anti-lla activity) - a preparation with a 10: 1 ratio of anti-Xa to anti-lla 
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activities will have a high proportion of short polysaccharide chains that are unable 
to provide the template needed for inhibition of thrombin (Pineo & Hull, 1999). 
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Molecular weight distributions of un fractionated (UFH) and low molecular weight 
heparin (LMWH). 
UFH was the 4'h International Standard (821502), LMWH was Dalteparin, measured 
by gel p ermeation chromatography. Reproduced from Mulloy (2002). 
LMWH is now the preferred drug for prevention of venous thrombosis in surgical 
and medical patients, following trials that showed it to be as safe and effective as 
UFH. LMWH has also proven to be as effective as UFH in the treatment of acute 
coronary syndromes and venous thrombosis (Hirsh et aI, 2001). The clinical 
advantages of LMWH over UFH are the requirement for only once-daily injection 
and infrequent monitoring, meaning that in-patient treatment is not required. The 
improved pharmacokinetics of LMWH are due to the predominance of shorter 
polysaccharide chains that have less negative charge, and therefore reduced affinity 
for non-specific binding to proteins , and to the molecular ie ing effect of 
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subcutaneous tissues (Bendetowicz et ai, 1994; Cosmi et ai, 1997; see Figure 1.9). 
This results in increased bioavailability from subcutaneous injection, a longer half-
life and more predictable clearance (Dawes et ai, 1986; Barrowcliffe et ai, 1992; 
Pineo & Hull, 1999). 
1.3.2.6 Pentasaccharide 
In contrast to heparin preparations derived from animal tissue, a synthetic form of the 
antithrombin-binding pentasaccharide sequence of heparin IS now clinically 
available. Fondaparinux sodium is chemically synthesised to yield a single 
pentasaccharide molecule with molecular weight of 1 728 Daltons (Da) that 
potentiates the anti-Xa activity of antithrombin 270-fold but has no appreciable effect 
on the anti-lla activity (Olson et ai, 1992). Clinical trial results show that it may be 
more effective than pre- or post-operative LMWH in the prevention of venous 
thrombosis following orthopaedic surgery (Turpie et ai, 2002; Lassen et ai, 2002). 
Advantages of fondaparinux over LMWH include more predictable 
pharmacokinetics and bioavailability following a once daily subcutaneous injection 
(Boneu et ai, 1995), and no cross-reaction with HIT antibodies to the heparin-PF4 
complex (Amiral et ai, 1997), but concerns have been raised over an increased 
bleeding tendency that was seen in two trials (Bounameaux & Perneger, 2002). 
1.3.2.7 Heparin cofactor II 
Heparin cofactor II (HC II) is a serpin with molecular weight 66 000. Thrombin is 
the only procoagulant to be inhibited by HC II and its specificity is due to the 
presence of a leucine-serine peptide group in its reactive site compared with an 
arginine-serine group in antithrombin. Thrombin attacks this bond and forms a 
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stable stoichiometric complex with the inhibitor. Binding to glycosaminoglycans 
such as heparin, heparan sulphate (HS) and dermatan sulphate (DS) increases the 
inhibitory action of HC II. The binding of HC II to heparin is of a lower affinity than 
antithrombin and 10-fold more heparin is required to accelerate thrombin inhibition 
by HC II. HC II - heparin binding is non-specific, in that it binds to heparin chains 
longer than 4 saccharides regardless of their composition (Tollefsen, 1995), but 
greater inhibition of thrombin is achieved with heparin chains at least 20 saccharides 
long, corresponding to a molecular weight above 8 000. This is longer than the 
critical chain length for heparin potentiation of antithrombin (18 saccharides and 
molecular weight above 5 400), probably due to the larger size of the HC II 
molecule, and is independent of the presence of the specific pentasaccharide 
sequence (Bray et ai, 1989). 
The N-terminal of HC II resembles the C-terminal of the specific thrombin inhibitor 
hirudin (see Section l.3.7.1) and includes a tandem repeat of two highly acidic 
regions, each containing a sulphated tyrosine residue. The deletion of the first of 
these repeats leads to a marked reduction in the rate of thrombin inhibition in the 
presence, but not the absence, of a GAG suggesting that a conformational change 
may occur following the HC II - GAG interaction that allows the acidic N-terminal 
region of HC II to bind to the anion binding exosite I of thrombin, in competition 
with fibrinogen and fibrin. HC II acts independently of exosite II of thrombin, in 
contrast to antithrombin whose inhibitory action at this site is potentiated by the 
template mechanism of heparin (Tollefsen, 1997). 
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The physiological significance of He II in the inhibition of thrombin appears to be as 
a back-up to antithrombin, which circulates at 2.5 J.lM (Murano et ai, 1980) 
compared to He II at 1.2 J.lM in normal patients (Tollefsen & Pestka, 1985). 
Increased levels of He II - thrombin complexes were found in patients with 
congenital A T deficiency, and in pre- and post-delivery plasma samples from 
pregnant women (Liu et ai, 1995). 
1.3.2.8 Heparinoids 
The term 'heparinoid' may be used to describe all heparin-like compounds, including 
heparin, but it is commonly used to describe those other than heparin itself such as 
HS and DS. Heparan sulphate is less highly sulphated than heparin and is found on 
the surface of a number of cell types, including endothelium. This is in contrast to 
heparin, which is only synthesised in mast cells where it is stored in secretory 
granules. 
Dermatan sulphate is a naturally-occurring potentiator of the He II - thrombin 
interaction and is usually found in the extracellular matrix of the skin and deeper 
tissues of the vascular wall where it may inhibit extravascular coagulation following 
injury (Bell & Hennebry, 1999). DS is also expressed in the placenta where it may 
oppose the hypercoaguable effects of pregnancy, playing a key role in maintaining 
the patency of the placental microvasculature (Delorme et ai, 1998) and 
counteracting the increase in maternal thrombin generation that is observed after 
delivery (Andersson et ai, 1996). He II is the only serpin that is able to bind to OS, 
but requires molecules of at least six saccharides that contain a specific structure 
consisting of a triple repeat of a disaccharide, iduronic acid-2-sulphate linked to 
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N-acetyl galactosamine 4 sulphate. Binding of He II to this sequence results in a 
1 OOO-fold increase in the affinity of HC II for thrombin (Maimone & Tollefsen, 
1990). Clinical trials of DS have shown it to be effective in the prevention of post-
operative thrombosis, where it may be at least as effective as UFH with a possible 
reduction in haemorrhagic side effects (Agnelli et ai, 1992; Prandoni et ai, 1992; Di 
Carlo et ai, 1999) and these beneficial effects may be due to the ability of DS to 
inhibit clot-bound thrombin (Bendayan et ai, 1994). 
Danaparoid is a mixture of HS, DS and chondroitin sulphate (CS) that is derived 
from porcine mucosa following the removal of heparin. One would expect its mode 
of action to be potentiation of the HC II mediated inhibition of thrombin, but it 
appears to have higher anti-Xa than anti-lla activity. Only 55 % of the HS in 
danaparoid includes the pentasaccharide sequence with high affinity for 
antithrombin, and the low affinity material is critical to the compound's activity, but 
its function is not fully understood. Danaparoid is licensed in the USA for use in the 
prevention of post-operative deep vein thrombosis (DVT), but is frequently used as 
an alternative treatment for patients who have developed HIT (Acostamadiedo et ai, 
2000). 
Pentosan polysulphate is a heparinoid derived from the wood of beech and birch 
trees, where it is a component of the structural xylans. The extracted xylan is 
sulphated by chemical treatment and is able to inhibit FXa and thrombin 
independently of antithrombin or HC II (Fischer et ai, 1982) but interaction with the 
serpins may also have an effect, reviewed by Maffrand (1991). Pentosan has been 
used clinically for the prevention of thrombosis, and its non-animal origin may be 
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advantageous in light of recent caution regarding transmissible diseases, but negative 
results in a study of its oral bioavailability may limit its future potential (Faaij et ai, 
1999). 
1.3.3 Thrombomodulin and protein C 
The activation of coagulation leads to the generation of thrombin, which has potent 
procoagulant effects but also binds to the endothelial cell membrane protein 
thrombomodulin (TM), initiating an anticoagulant mechanism. Thrombomodulin 
binds to the anion binding exosite I of thrombin and a secondary interaction occurs 
between thrombin and a CS moiety in the TM structure, conferring a higher affinity 
of TM for thrombin, although there is debate over whether all TM molecules include 
the CS moiety (Esmon, 1999). In an additional anticoagulant function, the CS 
moiety may also bind to AT and increase its affinity for thrombin, facilitating the 
formation of thrombin-antithrombin complexes that then dissociate from TM 
(Preissner et ai, 1987). Once bound to TM, thrombin is no longer procoagulant due 
to the occupation of exosite I by TM, preventing the binding of other substrates such 
as fibrinogen, FV and FXIII. However, the TM-bound thrombin becomes able to 
activate Protein C, a zymogen of a serine protease, by cleaving a dodecapeptide from 
the amino terminal of the heavy chain of Protein C, resulting in the creation of a new 
amino terminal with leucine as the final residue (Kisiel, 1979). Protein C binds to 
cell membrane phospholipids in the presence of Ca2+, facilitating its interaction with 
TM. However, Protein C also binds with increased affinity to its specific receptor on 
the endothelial cell membrane - the endothelial cell protein C receptor (EPCR) 
(Fukudome & Esmon, 1994). This binding is mediated via the y-carboxyglutamic 
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acid (gla) domain of Protein C and enhances the rate of its activation by TM 
(Steams-Kurosawa et aI, 1996). 
Following the activation of Protein C to activated Protein C (APC), and in 
association with its cofactors Protein Sand FV, APC becomes able to inactivate the 
membrane bound coagulation cofactors FVa and FVIIla. Endothelial cells have been 
shown to be a more efficient site of inhibition ofFVa compared to activated platelets 
(Oliver et aI, 2002). This may be because endothelial cells synthesise and secrete 
Protein S (Stem et aI, 1986), which enhances the affinity of APC for the 
phospholipid membrane surface (Walker, 1981), increases the rate of inactivation of 
FVa and FVIIla (Dahlback, 1986; Koedam et aI, 1988) and prevents the 
incorporation of these activated cofactors into enzymatic complexes with other 
clotting factors (Solymoss et aI, 1988; Regan et aI, 1994). Interestingly, FV is also 
secreted by endothelial cells and has been shown to act synergistically with Protein S 
in increasing the inactivation of FVIIla (Shen & Dahlback, 1994). The physiological 
role of the Protein C pathway is likely to be the inhibition of coagulation downstream 
of the site of vascular damage, where activated coagulation factors need to be 
scavenged and inactivated to prevent pathological extension of the clot. TM, EPCR, 
Protein Sand FV on undamaged endothelial cells will remove thrombin from the 
bloodstream and activate PC to inactivate essential coagulation cofactors FVa and 
FVIIla, thus preventing coagulation downstream. EPCR, which has the effect of 
increasing the affinity of PC for thrombin, is primarily found on the endothelium of 
large vessels and not in capillaries, where thrombotic complications are often found 
in Protein C deficiency (Laszik et aI, 1997). TM has a more uniform distribution, 
and in the capillaries where there is a higher ratio of surface area to blood volume, 
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the capillary blood is therefore exposed to a sufficient number of the lower affinity 
inhibitor complexes (TM-thrombin-APC without EPCR) to prevent thrombosis 
without the risk of haemorrhage (Esmon, 2000). 
The interaction of thrombin with TM has been shown additionally to potentiate 
1 OOO-foid the effect of thrombin on the thrombin-activatable fibrinolysis inhibitor 
(Bajzar et ai, 1996). Once activated, this enzyme inhbits fibrinolysis by interfering 
with the cofactor activity of fibrin on plasminogen activation indicating a 
procoagulant effect of TM, contrary to its other anticoagulant activities. However, 
this effect would be downstream of the site of coagulation, where thrombin needs to 
be inhibited to prevent further coagulation whilst any pre-formed fibrin needs to be 
protected from premature lysis, allowing wound healing to be completed. This 
suggests a balanced down-regulatory effect on both the coagulation and the 
fibrinolytic cascades with the aim of focussing the site of coagulation and 
fibrinolysis. 
APC has a longer half-life (15 - 20 minutes) than many serine proteases that are 
potentiators of coagulation rather than inhibitors and it is slowly inactivated by 
Protein C inhibitor, aI-antitrypsin and armacroglobulin (Scully et ai, 1993; 
Dahlback & Stenflo, 1994). Deficiencies in Proteins C or S lead to major thrombotic 
problems, and the most common inherited thrombophilia is due to a single nucleotide 
polymorphism in the FV gene that makes FVa resistant to inactivation by APC. This 
mutation is known as Factor V Leiden (De Stefano et ai, 1998) and indicates the 
significance of this negative feedback loop and the critical role played by the 
endothelium in the maintenance of fluidity of the blood. In addition, homozygotes 
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for the R2 haplotype of FV, which is a series of linked polymorphisms, have a 
thrombotic tendency resulting from lower plasma concentrations of FV and lower 
cofactor activity in APC-catalysed inhibition of FVIIIa (Hoekema et ai, 2001). 
Deficiency of Protein S also leads to thrombophilia, indicating that its cofactor 
activity to Protein C has an important role in the inhibition of coagulation (Gandrille 
et ai, 1997). Deletion of the thrombomodulin gene has been shown to be lethal in 
mice, due to a developmental function of TM (Healy et ai, 1995), but targeted 
mutation of the TM gene has led to the production of viable mice with a 
prothrombotic tendency towards fibrin deposition in certain tissues (Weiler-Guettler 
et ai, 1998). 
The anti thrombotic functions of TM and Protein C make them ideal candidates for 
use as antithrombotic drugs. Recombinant soluble thrombomodulin (r-TM) is able to 
inhibit clot-bound thrombin and has an antithrombotic effect in animal models of 
endotoxin-induced disseminated intravascular coagulation (DIC), a coagulopathy 
where clotting factors and their inhibitors are rapidly consumed (Maruyama, 1999). 
Safety trials have been completed in humans and the results of phase II clinical trials 
are awaited. Both Protein C and APC have been used in the treatment of DIC 
resulting from bacterial sepsis, where endogenous plasma levels are seen to fall 
rapidly, and in addition to their anticoagulant effects Protein C and APC inhibit the 
endotoxin-induced nuclear translocation of nuclear factor kappa B (NFKB), the first 
stage of many inflammatory responses (White et ai, 2000). A possible limitation of 
this effect is the downregulation of TM and EPCR following stimulation with 
inflammatory cytokines (Esmon, 2001), but nonetheless the PROWESS phase III 
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clinical trial showed a significant decrease in mortality in patients with severe sepsis 
treated with APC (Bernard et ai, 2001). 
1.3.4 Tissue factor pathway inhibitor 
Tissue factor pathway inhibitor (TFPI) is a 276 ammo acid protein synthesized 
primarily by the microvascular endothelium, but also by megakaryocytes. 
Endothelial cells constitutively express TFPI and the level of expression by 
endothelial cells and other cell types, such as monocytes, may increase following 
stimulation. The majority of TFPI (80 - 85 %) is found on the luminal surface of 
endothelial cells, where its highly basic C-terminal binds to cell surface HSPGs, in 
addition to non-specific binding elsewhere on the molecule (Iversen et ai, 1996). 
Full length TFPI is released from the endothelium following the administration of 
heparin and other anionic molecules, independent of the presence of an antithrombin 
binding sequence on the molecule (Cella et ai, 2001). This effect is dependent on the 
molecular weight of the heparin, with UFH releasing more full-length, free TFPI 
from the endothelium than LMWH (Alban & Gastpar, 2001; Brown & Kuter, 2001). 
The release of TFPI from the endothelium contributes to the anti thrombotic effect of 
heparin, which has also been shown to act synergistically with TFPI (Wun, 1992; 
Bregengaard et ai, 1993). The interaction of TFPI with heparin is charge dependent, 
with the high density of negative charge on UFH allowing it to bind with higher 
affinity to the basic C-terminal of TFPI than LMWH (Valentin et ai, 1994). Around 
10 % of the total TFPI circulates in the plasma associated with lipoproteins in a less 
active C-terminal truncated form, and the remainder is found in platelets (Bajaj et ai, 
2001). The level of circulating TFPI is higher during pregnancy and lower in the 
neonate and the level of mRNA expression is at its highest in the placenta and its 
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lowest in the brain. This suggests that a compensatory mechanism is in operation, 
countering the relatively thrombophilic condition of pregnancy but not 
compromising haemostasis where bleeding would cause major problems (Bajaj et ai, 
1999). 
As its name suggests, TFPI inhibits one of the major complexes in the extrinsic 
coagulation pathway. TFPI has three Kunitz type protease inhibitory domains, and 
the first stage of its inhibitory action is to bind to and inhibit FXa via the Kunitz 2 
domain. This binary complex then binds to FVIIa in the TF-FVUa complex on the 
cell surface, via the Kunitz 1 domain on TFPI, to form a quaternary complex. The 
rapid formation of the quaternary complex may be slowed down by the presence of 
FVIII and FIX, in a mechanism that may allow the extrinsic pathway of coagulation 
to become established and the absence of which leads to bleeding in haemophiliacs, 
where there is increased reliance on the extrinsic pathway (Broze, 1994; Bombeli et 
ai, 1997; Verstraete, 1998). The dampening effect of TFPI in an intact coagulation 
system, by inhibiting the actions of FX and FXa, serves to prolong the lag time of 
thrombin generation where feedback activation of coagulation factors by trace 
amounts of thrombin would amplify the response, and to reduce the rate of thrombin 
generation once the burst phase has been reached (van't Veer & Mann, 1997). 
TFPI-2 is a structural homologue ofTFPI that has been found to have similar activity 
against the TF-FVIIa complex and FXa and to have its activity potentiated by 
heparin (Sprecher et ai, 1994). TFPI-2 is expressed in the placenta, where it has 
previously been identified as placental protein 5 (PP5) or matrix associated serine 
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protease inhibitor (MSPI) and is presumed to have a role in maintaining the blood 
flow through the TF rich villi (Udagawa et aI, 2002). 
1.3.5 Protease nexin 1 and 2 
Endothelial cells synthesise protease nexin 1 (PN-1; Eaton & Baker, 1983; Leroy-
Viard et aI, 1989), a serpin that is structurally homologous to AT (Sommer et aI, 
1987) and C-1 inhibitor (Van Nostrand et aI, 1988). PN-1 forms a stoichiometric 
complex with thrombin, FXa, FXIa and trypsin at a rate that is markedly accelerated 
by heparin, regardless of the presence of the antithrombin-specific pentasaccharide 
sequence (Evans et aI, 1991; Knauer et aI, 2000). In solution, PN-1 is also able to 
inhibit urokinase and plasmin, but loses this ability when bound to the cell surface or 
ECM, (Wagner et aI, 1989) possibly due to interaction with a cofactor suggested to 
be collagen type IV (Donovan et aI, 1994). Surface-bound PN-1 remains able to 
bind thrombin and FXIa and the PN-1 - protease complex is internalised by the cell 
and degraded (Knauer et aI, 1983; Knauer et aI, 2000). The increased affinity of 
cell-bound PN-1 as a result of its interaction with cell surface HSPG and its altered 
specificity when bound to ECM suggests that PN-1 is important in the inhibition of 
cell surface or extravascular coagulation. 
Protease nexin 2 (PN-2) is the secreted form of the amyloid ~-protein precursor 
(APP), implicated in senile plaques in diseases such as Alzheimer's disease. It is 
predominantly found in the a-granules of platelets (Van Nostrand et aI, 1990) and its 
mRNA may be detected in other cell types, including endothelial cells (Van Nostrand 
et aI, 1991). PN-2 inhibits FXIa (Smith et aI, 1990), FXa (Mahdi et aI, 1995) and is 
a more potent inhibitor of FIXa than antithrombin (Schmaier et aI, 1993). Heparin 
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potentiates the inhibitory effect of PN-2 on FXIa (Van Nostrand et ai, 1990) and 
FIXa (Schmaier et ai, 1993). PN-2 is able to inhibit FIXa in its function as part of 
the intrinsic tenase complex on platelets and endothelial cells (Schmaier et ai, 1995). 
to inhibit FXa in the prothrombinase complex (Mahdi et ai, 1995), and also to inhibit 
FVIIa in the extrinsic tenase complex with TF (Mahdi et ai, 2000). 
1.3.6 Protein Z-dependent protease inhibitor 
The protein Z dependent protease inhibitor (PZI) is a 72 000 Da serine protease 
inhibitor whose activity against FXa is increased 1 000 fold by binding, in the 
presence of phospholipids and calcium, to the cofactor Protein Z (PZ), a 62 000 Da, 
vitamin K dependent plasma protein. PZI is also able to inhibit FXIa regardless of 
the presence of PZ, phospholipids or calcium. Interaction with either FXIa or FXa, 
following intrinsic or extrinsic activation respectively, leads to proteolytic cleavage 
and inactivation of PZI in what may be a regulatory mechanism that dampens the 
coagulation response in areas of minor vascular damage, but allows coagulation to 
proceed where the stimulation is greater. The clinical implications of PZI or PZ 
deficiency remain to be established (Broze, 200 I). 
1.3.7 Other antithrombotic drugs 
In addition to the naturally occurring inhibitors of coagulation mentioned above, 
numerous exogenous agents have been developed for use as anti thrombotic agents in 
clinical situations where drugs such as heparin may have limitations, for instance an 
inability to inhibit clot-bound thrombin. Many small molecule inhibitors of 
coagulation proteases have been developed and trialled in a number of clinical 
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situations, and five direct thrombin inhibitors have recently proven to be safe and 
effective alternatives to heparin in acute coronary syndromes (The Direct Thrombin 
Inhibitor Trialists' Collaborative Group, 2002). 
1.3.7.1 Hirudin 
Hirudin is a potent and selective inhibitor of thrombin that was originally isolated 
from the saliva of the medicinal leech (Hirudo medicinalis). It is a 65 amino acid 
protein, with three disulphide bonds and a molecular weight of around 7 000, which 
forms a slowly reversible, stoichiometric complex with thrombin through an 
electrophilic interaction. It binds to both the fibrinogen-binding site and the catalytic 
site of thrombin, thereby preventing the conversion of fibrinogen to fibrin and 
disrupting the positive feedback effects of thrombin on coagulation (Badimon et ai, 
1991). It is commonly produced in a recombinant form missing a sulphate residue 
on tyrosine 63 (and therefore known as desulfato hirudin), with no loss of activity 
(Lauer & Lincoff, 1999; Prisco et ai, 2001). Other analogues of hirudin with lower 
affinities for thrombin have been manufactured with the aim of reducing the potential 
side effects of such a potent inhibitor. Hirugen is a 12 amino acid peptide, based on 
the C terminal fragment of hirudin, which binds to the exosite of thrombin thus 
interfering with substrate recognition (Verstraete et ai, 1998; Lauer & Lincoff, 
1999). Hirulog is the brandname for bivalirudin, a 20 amino acid chimeric molecule 
made by linking the C terminal and the N terminal of hirudin with a sequence of four 
glycines. Clinical trials using hirulog for the prevention of DVT in orthopaedic 
patients, in coronary angioplasty and as an adjunct to thrombolytic therapy have all 
given encouraging results (Verstraete et ai, 1998; Kimball, 1999). Hirunorms are 
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peptide analogues of bivalirudin that are designed to resist proteolytic cleavage for 
longer and to be more specific for thrombin (Verstraete et ai, 1998). 
Hirudin has been found to have beneficial effects when compared with heparin in the 
prevention and treatment of DVT following surgery (Harker et ai, 1997; Prisco et ai, 
2001) and is indicated as an anti thrombotic agent in patients with HIT, where an 
immune reaction leads to the elimination of platelets (Prisco et ai, 2001). The ability 
of hirudin to inhibit clot-bound thrombin may also prevent the growth of existing 
clots in vessels that have been reperfused following thrombolytic therapy, where 
thrombin may become re-exposed following the dissolution of layers of a clot 
(Harker et ai, 1997). Hirudin has an advantage over heparin in this situation as the 
heparin-antithrombin complex is unable to inhibit clot-bound thrombin because the 
binding site for heparin (thrombin exosite II) is inaccessible (Weitz et ai, 1990). 
Another advantage of hirudin over heparin is that the direct action of hirudin means 
that there is no dependence on the availability of plasma cofactors such as 
antithrombin, which may be congenitally absent or depleted due to long-term heparin 
therapy (Lauer & Lincoff, 1999). The drawback may be bleeding complications with 
no direct antidote (Prisco et ai, 2001). 
1.3.7.2 Other thrombin inhibitors 
Other reversible inhibitors of thrombin include argatroban, napsagatran, inogatran 
and efegatran. Argatroban is a direct thrombin inhibitor based on the amino acid 
L-arginine. It binds reversibly to the catalytic site of thrombin and has been shown 
to be an effective anti thrombotic in venous and arterial models of thrombosis. 
Clinical trials suggest that argatroban is effective as an adjunct to thrombolytic 
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therapy (Kimball, 1999) and is beneficial as an alternative to heparin therapy in 
patients with HIT (Lewis et ai, 2001) although there is concern that a rebound 
prothrombotic state may occur when the therapy is stopped and active thrombin 
dissociates from the inhibitor (Kimball, 1999). Napsagatran is a selective and 
reversible 559 Da inhibitor of the active site of thrombin that delays thrombin 
generation more effectively than hirudin, but less effectively than UFH (Kimball, 
1999; Bounameaux et ai, 1999). Unlike hirudin, it has higher affinity for clot-bound 
thrombin than for fluid phase thrombin, suggesting a particular suitability for 
treatment of arterial thrombosis or thrombolysis (Gast et ai, 1994). Inogatran is a 
synthetic dipeptide of 439 Da that is another competitive and reversible inhibitor of 
thrombin. It performed no better than heparin in trials and clinical development has 
ceased (Verstraete et ai, 1998; Kimball, 1999). Efegatran, a tripeptide aldehyde is 
also a reversible inhibitor of the anion-binding site of thrombin but it has poor 
selectivity for thrombin and also binds to FXa and other serine proteases. Clinical 
trials using this inhibitor as an adjunct to thrombolysis have shown no benefit over 
current therapy (Fung et ai, 1999; The PRIME Investigators, 2002). 
Inhibitors that bind covalently to thrombin include CVS-1123 and DuP714. 
CVS-1l23 is a 575 Da peptide that binds slowly and tightly to thrombin and its 
bioavailability profile suggests that it has potential as an oral antithrombotic drug, 
although no information is available regarding clinical studies (Verstraete et ai, 
1998; Kimball, 1999). DuP714 is a potent active site inhibitor of thrombin that may 
be orally active, but may cause problems by inhibiting plasmin leading to impaired 
fibrinolysis, and has an undesirable kinetic profile that shows slow, tight binding 
(Verstraete et ai, 1998: Kimball, 1999). 
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Ximelegatran is an oral direct thrombin inhibitor that is metabolised to the active 
form melagatran which has been shown to reduce thrombin generation in blood shed 
from bleeding time wounds (Sarich et ai, 2002). The first clinical study of oral 
ximelegatran, subcutaneous melagatran or LMWH showed it be the equal of LMWH 
in the prevention of venous thromboembolism following orthopaedic surgery 
(Eriksson et ai, 2002). This is an encouraging result in the search for an oral 
anti thrombotic agent to replace the widespread use of the oral anticoagulant warfarin 
and the non-specific anti-inflammatory drug, aspirin. 
1.3.7.3 Factor X inhibitors 
Factor X can be activated by the intrinsic tenase complex or the extrinsic complex of 
TF-FVIIa and is the beginning of the common pathway of coagulation, making it an 
attractive target for direct inhibition. The involvement of FXa in the prothrombinase 
complex means that its inhibition will prevent the amplification of this stage of the 
coagulation cascade in the generation of thrombin, and this may be a more effective 
strategy than attempting to neutralise pre-existing thrombin and all its positive 
feedback effects. 
As previously mentioned (Section 1.3.2.6), a synthetic form of the pentasaccharide 
sequence of heparin is clinically available and is used to potentiate the anti-Xa 
activity of endogenous antithrombin. In addition, a number of naturally occurring 
direct inhibitors of FXa have been isolated and characterised. The tick anticoagulant 
protein (TAP), isolated from the soft tick (Ornithodorus mubata) , and its 
recombinant form (rT AP) are 60 amino acid, 6 850 Da monomeric peptides that bind 
slowly to FXa in a two-step mechanism to form a tightly bound complex. It has a 
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much higher affinity for FXa assembled into the prothrombinase complex, and has 
been shown to be an effective anti thrombotic agent in animal models of venous and 
arterial thrombosis, reocclusion and restenosis (Samama et ai, 1998; Kunitada et ai, 
1999). Antistasin, a 119 amino acid, 17 000 Da polypeptide isolated from the 
Mexican leech (Haementeria officinalis) also binds slowly and tightly to FXa in a 
two-step mechanism. It was able to inhibit extrinsic coagulation in an animal model 
of venous thrombosis (Vlasuk et ai, 1991) but has proven to be antigenic and 
therefore of limited clinical potential (Samama et ai, 1998; Kunitada et ai, 1999). 
The hookwonn Ancylostoma caninum has also been found to produce a family of 
anticoagulant proteins (AcAP; or nematode anticoagulant peptides, NAP). The 
recombinant fonn of nematode anticoagulant peptide 5 (rNAP-5) is an 8 700 Dalton 
peptide inhibitor of FXa that has been shown to inhibit arterial thrombosis in an 
animal model (Kunitada et ai, 1999) and NAP-6 has similar inhibitory activity 
(Stanssens et ai, 1996). Another member of this family of peptides is rNAPc2, an 85 
amino acid peptide serine protease inhibitor, which has been shown to inhibit the 
TF-FVIIa complex following its initial binding to FX or FXa (Stanssens et ai, 1996), 
and has been shown to be effective in the prevention of DVT following orthopaedic 
surgery (Lee et ai, 2001). 
The main function of the 43 000 Dalton endogenous protein TFPI is the inhibition of 
the TF-FVIIa complex, as discussed in Section 1.3.4, but it is also reported to have a 
direct inhibitory effect on FXa (Prager et ai, 1995). A clinical trial has shown 
treatment with TFPI (compared to placebo) to reduce mortality in the treatment of 
patients with sepsis (Abraham et ai, 2001), and the results of further trials are 
awaited. 
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A non-peptide derivative of propanoic acid, known as DX-9065a, is a rapid-binding, 
specific, direct competitive inhibitor of FXa. It is able to inhibit both fluid phase 
FXa and FXa that has been incorporated into the prothrombinase complex, and it 
inhibits the intrinsic generation of thrombin more effectively than the extrinsic. As it 
competes for the binding of FXa with the other components of the prothrombinase 
and the TF-FVIIa complexes, sufficient thrombin is generated to activate platelets at 
sites of vascular damage, although fibrin formation does not occur, and this may 
prevent excessive bleeding whilst preventing thrombosis (Samama et ai, 1998; 
Kunitada et ai, 1999). Initial clinical results show that the drug is well tolerated and 
has a promising pharmacokinetic profile worthy of further study (Dyke et ai, 2002). 
1.3.7.4 Anti-platelet agents 
Platelets playa major role in haemostasis and are therefore ideal targets for inhibitors 
of coagulation. The best known and most widely used platelet inhibitor is aspirin, 
which irreversibly inactivates platelet cyclooxygenase, preventing the conversion of 
arachidonic acid to endoperoxides and thromboxane A2. The potentiating effect that 
thromboxane A2 has on the action of other agonists is therefore lost, effectively 
blocking the activation of the platelet (Bennett, 2001). Unfortunately, the inhibition 
of cyclooxygenase is not confined to platelets, and unwanted effects such as gastric 
bleeding and an increased bleeding time preclude some patients using it (Scrip, 1998; 
FitzGerald & Patrono, 1998). For this reason, there has been much interest in the 
development of a specific, preferably oral, inhibitor of platelet function that does not 
have bleeding side effects. Antagonism of the P2Y 12 receptor for adenosine 
diphosphate (ADP), a potent activator of platelets, has been the subject of high-
profile clinical trials. Metabolites of oral drugs such as clopidogrel and ticlopidine 
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are able to irreversibly modify the structure of the receptor, rendering it insensitive to 
ADP. The benefits of clopidogrel over aspirin in certain indications studied in the 
CAPRIE trial have been reported (Bennett, 2001). 
An alternative approach to the inhibition of platelet-mediated thrombosis is the 
inhibition of aggregation and many drugs targeted at inhibition of the main 
aggregatory receptor GP lib/IlIa are in development (Topol et ai, 1999). Perhaps the 
best-known of these drugs is abciximab (c7E3, ReoPro™), which is a fragment of a 
humanised monoclonal antibody against this receptor. Abciximab has been studied 
extensively in a number of clinical situations and is now licensed in the US for use in 
acute coronary care (Califf et ai, 1995; EPILOG Investigators, 1997; CAPTURE 
Investigators, 1997; Swainger, 1997; Scrip, 1998; FitzGerald & Patrono, 1998; 
Bennett, 2001). In addition to the anti-aggregatory effect of the drug, it has been 
found to inhibit in vitro platelet-dependent generation of thrombin - in other words, 
it also acts as an anticoagulant (Reverter et ai, 1996). This work has been repeated 
with peptide and non-peptide antagonists of the receptor (Pedicord et ai, 1998; 
Herault et ai, 1998) and the mode of action shown to be an inhibition of the exposure 
of negatively charged phospholipids on the outer leaflet of the membrane of 
activated platelets (Pedicord et ai, 1998). Abciximab is also known to cross-react 
with the vitronectin receptor on platelets and other cells (Reverter et ai, 1996), and 
with the Mac-l receptor on monocytes, interfering with monocyte adhesion to 
fibrinogen and ICAM-l. This indicates an inhibitory effect on cell adhesion to the 
subendothelium (Simon et ai, 1997). 
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At present there are no licensed products that inhibit adhesion, the first stage of 
platelet-mediated thrombosis. Primate models of arterial thrombosis have 
demonstrated inhibitory effects of antibodies against GP Iba (in combination with an 
anti-GP lib/IlIa antibody; Wu et ai, 2002a) and vWF (Wu et ai, 2002b), suggesting 
that this is a potential target for anti thrombotic therapy. Polymorphisms in the 
collagen receptors of platelets are currently being studied in the hope that inhibitory 
agents may be developed that inhibit collagen-mediated platelet adhesion and 
activation (Kunicki, 2002). 
1.1.1 Endothelial cell effects on platelets 
Agents secreted by endothelial cells also have effects on platelets. Prostacyclin and 
nitric oxide (NO) are released from endothelial cells in response to agonists such as 
thrombin, ATP, ADP, bradykinin and histamine, most of which are secreted from or 
associated with activated platelets. Endothelial cells are a major source of 
prostacyclin, and its synthesis and secretion is rapidly upregu1ated following stimuli 
that lead to an increase in intracellular calcium levels. This leads to the 
phosphorylation of the extracellular-signal regulated protein kinase (ERK) that then 
phosphorylates phospholipase A2, which mediates the first step in the prostanoid 
synthetic pathway (Wheeler-Jones et ai, 1996). Prostacyclin synthesis tends to be 
brief due to the burst of calcium required from intracellular stores. Prostacyclin 
stimulates adenyl ate cyclase in platelets, therefore increasing cAMP levels and 
inhibiting platelet activation (Pearson, 1999). Deficiency of the prostacyclin 
synthase enzyme has been found to be prothrombotic in humans (Nakayama et ai, 
2002). 
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Nitric oxide is expressed by endothelial cells following its synthesis by the calcium-
dependent nitric oxide synthase (NOS) in response to a similar range of agonists to 
that which stimulates prostacyclin release. The most important physiological 
regulator is shear stress, discussed in Section l.4.3. Increased intracellular calcium 
concentrations stimulate the action of NOS in generating NO from arginine. This 
requires a lower level of calcium than prostacyclin synthesis and may therefore be 
maintained for a longer period as intracellular calcium stores do not become 
exhausted. NO acts by elevating guanylate cyclase activity leading to increased 
intracellular levels of cGMP that in tum inhibit calcium influx into the platelet, thus 
inhibiting its activation (Smith et ai, 1994). Endothelial-derived NO may not have a 
significant effect on platelets due to its brief half-life, but knockout mice lacking 
NOS in platelets and endothelial cells have decreased bleeding times, indicating a 
loss of inhibition (Freedman et ai, 1999) and NO released from endothelial cells 
effectively inhibits platelet adhesion to the endothelium (Radomski et ai, 1987). 
This negative feedback loop, where agonists released from activated platelets cause 
endothelial cells to release inhibitors that prevent further platelets becoming 
activated, may act as a dampening mechanism to inhibit the coagulation or 
inflammation response to low levels of stimulation. 
1.1.2 Procoagulant activity of endothelial cells 
Procoagulant tissue factor is synthesised by endothelial cells and although it is not 
constitutively expressed at the cell surface, it is expressed in response to stimulation 
by a number of factors. Thrombin activates endothelial cells by its interaction with a 
family of G-protein linked protease activated receptors (PAR), which have part of the 
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N terminus cleaved by the enzyme to reveal a new sequence that then acts as a 
tethered ligand for the receptor (Vu et ai, 1991). The main thrombin receptor on 
endothelial cells and platelets is PAR-I, but endothelial cells also express PAR-2 
(Molino et ai, 1997) and PAR-3 (Schmidt et ai, 1998). Endothelial cells also express 
tissue factor following their exposure to endotoxin (LPS; Lyberg et ai, 1983; Brox et 
ai, 1984) tumour necrosis factor (TNF; Bevilacqua et ai, 1984), and interleukin-l 
(IL-l; Bevilacqua et ai, 1986). This is particularly important in bacterial sepsis, 
where interaction between the coagulation and inflammation systems can lead to 
DIe, multiple organ failure and high rates of mortality (Esmon, 2001). In addition to 
the expression of tissue factor, thrombin activated endothelial cells express platelet-
activating factor (P AF), a phospholipid that is involved in the adhesion of 
polymorphonuclear leukocytes to endothelial cells in the early stage of inflammation 
(Zimmerman et ai, 1990). 
In addition to their possible role in activation of the intrinsic pathway of coagulation, 
discussed in Section 1.3.1, endothelial cells may promote coagulation in a number of 
ways. A specific receptor for FIX and FIXa has been identified on the endothelial 
cell membrane (Rimon et ai, 1987) and the binding affinity of FIXa increases in the 
presence of FVIII and FX (Stem et ai, 1985), enhancing procoagulant activity. 
Blocking the active site of FIXa prevents the generation of FXa in the presence of 
TF -expressing TNF -activated endothelial cells or their TF -containing extracellular 
matrix, indicating a cooperative role for the intrinsic and extrinsic tenase complexes 
(Tijburg et ai, 1991). Specific binding sites for FXa have been identified on 
endothelial cells (Bono et ai, 1997) that can facilitate the activation of FVII (Rao et 
ai, 1988); and the synthesis, expression and binding of FV and FVa (Maruyama et al. 
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1984; Cerveny et aI, 1984) can enhance the fonnation of the prothrombinase 
complex on the cell surface. 
Endothelial cells are the source of at least 90 % of circulating vWF (Bowie et aI, 
1986), a protein that acts as a stabilising protein for circulating FVIII and as a ligand 
for the adhesion of platelets to components of the extracellular matrix, as discussed 
earlier. As well as constitutively secreting a dimeric fonn ofvWF from their cytosol, 
endothelial cells release their stores of multimeric vWF from Weibel-Palade bodies 
following stimulation with thrombin (Levine et aI, 1982). The release of stored vWF 
accompanies a transient expression of P-selectin on the cell membrane, as the 
granule membrane fuses and is exposed. It is unclear whether the increased 
circulating vWF levels may be implicated in prothrombotic tendencies during 
infection or are just a marker of endothelial activation (Pearson, 1999). 
1.1.3 Fibrinolytic activity of endothelial cells 
Endothelial cells also play a role in the initiation of fibrinolysis following clot 
fonnation, primarily by the synthesis of tissue-type plasminogen activator (t-PA). In 
addition to constitutive secretion, agonists such as thrombin stimulate the release of 
t-PA from storage sites in endothelial cells (Emeis et aI, 1997). The function oft-PA 
is to cleave plasminogen to the active plasmin, the major fibrinolytic protein, and 
plasminogen and t-PA both bind to the surface of endothelial cells, thus localising 
plasmin generation and therefore fibrinolysis to the cell surface (Hajjar, 1995). 
Plasminogen activator inhibitor 1 (PAl-I) is the major inhibitor of t-PA and is also 
secreted primarily by endothelial cells. Under resting conditions the plasma 
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concentration of PAl -1 is 400 pM compared to 80 pM for t -P A, resulting in complex 
formation and rapid clearance from the plasma (Booth, 1999). Inflammatory 
agonists such as LPS, TNF-a and IL-1 lead to an increase in the level of PAI-1 
secretion but not in t-PA thus prolonging the life of the clot (Schleef et ai, 1988). 
Platelet a-granules are also rich in PAI-1 which is released on activation, inhibiting 
fibrinolysis in the early stages of clot formation (Booth, 1999). 
1.2 Flow 
In vivo the blood is rarely stationary and the constant movement of the circulation 
has effects on the components of blood and the vessels through which it flows. 
These effects range from the mechanical effects of the stretching of the vessel and 
the flow of blood across the luminal surface, to the physical effects of the interaction 
of fluid phase cells and proteins with the luminal surface, and the biochemical effects 
of the interactions of these cells and proteins. Many studies have been undertaken in 
vivo, ex vivo and in vitro to attempt to understand the isolated or combined effects of 
these processes. Details on how these conditions have been modelled in the 
laboratory and explanations of the terminology used can be found in Chapter 3. 
1.2.1 Flow and coagulation 
The influence of flow is particularly relevant in studies of blood coagulation, as 
certain circulating clotting factors need to adhere to phospholipid surfaces before 
they can interact, for example the tenase and prothrombinase complexes. The 
phospholipid surfaces involved here are usually provided by activated platelets that 
have adhered to, and spread upon, areas of damaged vessel wall. The 'two-
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dimensional' model of blood coagulation on a surface has been elegantly explained 
by Nemerson (1995). Briefly, when an enzyme, for example the prothrombinase 
complex, is attached to the wall of a vessel in static conditions, the delivery of the 
substrate, in this case prothrombin, is achieved by diffusion. Interactions will occur 
between enzyme and substrate, leading to a zone of substrate depletion near the 
vessel wall and also a zone of product accumulation. If the enzyme is 100 % efficient 
at converting every molecule of substrate that it encounters, then the rate limiting 
step will be the diffusion of the substrate to the enzyme - this is termed the 'transport 
rate limit'. If, however, the medium is stirred or flowing, the limit is shifted, and the 
flux of substrate to the enzyme is increased in proportion to the one-third power of 
the wall shear rate. 
This model of coagulation under flow conditions was the result of numerous studies 
by Nemerson and colleagues on the activation of FX that was perfused with FVII 
through glass capillaries coated with phospholipids and TF. It was found that FVIIa 
bound tightly to TF on the vessel wall and this complex converted FX to FXa at a 
rate that was limited by the rate of substrate delivery, which in tum was a function of 
the substrate concentration and the wall shear rate (Gemmell et ai, 1988; Gemmell et 
ai, 1991; Andree et ai, 1994; Andree & Nemerson, 1995; Gentry et ai, 1995). 
Studies on the assembly of the prothrombinase complex on phospholipid vessel wall 
surfaces have reported similar results, with factor FVa inserted into a phospholipid 
bilayer combining with FXa in the perfusate and then activating prothrombin as it is 
delivered to the vessel wall, at a rate limited by substrate concentration and wall 
shear rate (Schoen et ai, 1990; Billy et ai, 1995a). 
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The kinetics of the inhibitors of coagulation in flow conditions have also been 
studied. Studies on the inhibition of FX activation by TFPI, and the anti-thrombin 
activity of surface bound heparin have agreed with the theories on transport of 
reactants to and from the boundary layer (Lindhout et ai, 1992; Lindhout et ai, 1995). 
The consumption of antithrombin in the boundary layer has been shown to limit the 
effectiveness of unfractionated and pentasaccharide heparin, suggesting that their 
main inhibitory action is prevention of the activation of the components of the 
prothrombinase complex (FXa and FVa) in the fluid phase rather than inhibition of 
the surface-bound complex itself (Schoen & Lindhout, 1991). Confirming this, it has 
also been shown that prothrombinase bound to lipid membranes is protected from 
inactivation due to competition between antithrombin and prothrombin for the active 
site ofFXa (Billy et ai, 1995b). 
1.2.2 Flow and platelets 
Flow conditions are known to have profound effects on platelets, which must be able 
to perform their haemostatic function under a wide variety of conditions. As 
discussed in Section 1.2.1, platelets have a wide range of adhesive receptors and 
have the specific ability to adhere to thrombogenic surfaces under conditions of high 
shear stress and are therefore able to mediate haemostasis in damaged blood vessels. 
Shear induced platelet aggregation (SIP A) is a recognised phenomenon although the 
precise mechanism is not understood. It has been hypothesized that the receptors for 
vWF (probably GP Ib/IXN rather than GP lIb/IlIa) on the platelet surface are 
somehow affected by conditions of high shear and become able to bind to vWF, 
allowing a microaggregate to form, where agents such as ADP and adrenaline 
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released from activated platelets may become concentrated leading to a positive 
feedback activation of platelets and the development of a full aggregate. The 
collision frequency and collision efficiency (the number of collisions that lead to 
aggregation) of platelets is directly proportional to the shear rate, indicating the 
importance of shear in primary haemostasis (Kroll et ai, 1996). 
As discussed in Section 1.2.2, activated platelets facilitate coagulation by increasing 
the local concentration of clotting factors at their cell membrane - platelets carry 
certain clotting factors and following activation the expression of negatively-charged 
phospholipids on their outer membrane provides a catalytic surface for coagulation. 
1.2.3 Flow and the endothelium 
Endothelial cells are constantly exposed to shear stress in vivo and there have been 
numerous studies on the effects of shear on the structure and function of the 
endothelium. The endothelium's constitutive expression of a non-thrombogenic 
surface and secretion of agents that inhibit platelet aggregation may be affected by 
the increased shear rate that can occur when the vessel lumen has narrowed as a 
result of atherosclerosis or neointimal hyperplasia. 
Shear stress affects the morphology and orientation of endothelial cells. The 
cytoskeleton has been shown to be reorganised over a period of 24 hours in order to 
streamline the cells and to align them with the direction of the flow (Dewey et ai, 
1981; Levesque & Nerem, 1989; Levesque et ai, 1989; Barbee et ai, 1994). These 
cytoskeletal changes have also been shown to affect the clustering of endothelial cell 
receptors for ECM proteins and reorganisation of the ECM under endothelial cells 
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also occurs, with increased levels of adhesive proteins, thickening of fibrils of 
collagen, laminin and fibronectin, and fibril alignment with flow occurring within 
hours (Thoumine et ai, 1995a; Thoumine et ai, 1995b). Endothelial cell proliferation 
and migration have been shown to increase following exposure to shear stress in a 
disturbed flow model, suggesting that remodelling occurs at stenoses or branches in 
the vasculature (Tardy et ai, 1997). 
Flow can alter the non-thrombogenic characteristics of the endothelium by affecting 
the expression and secretion of a number of factors. Endothelial cells exposed to 
steady or pulsatile flow have been shown to dramatically and immediately increase 
their secretion of the vasodilators and platelet inhibitors prostacyc1in and nitric oxide 
(Frangos et ai, 1985; Kanai et ai, 1995). The prolonged increase in NO synthesis in 
response to shear stress has been demonstrated without a detectable increase in 
intracellular calcium levels, which is surprising as NOS is a calcium-dependent 
enzyme. This may be explained by changes in the phosphorylation pattern of NOS 
in response to stimulation, leading to an increased affinity for calcium such that 
intracellular stores are sufficient for the response. Shear stress activates protein 
kinase B (also known as Akt) to phosphorylate Serine ll77 of NOS, facilitating 
activation of the enzyme by calmodulin (Dimmeler et ai, 1999; Fulton et ai, 1999). 
Soluble agonists bradykinin and histamine can activate calmodulin-dependent 
kinase II (CaMKII) to phosphorylate Serine 1177, and also stimulate a phosphatase to 
dephosphorylate Threonine495 , further facilitating calmodulin binding to NOS and 
stimulating production of NO (Fleming et ai, 2001). 
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Synthesis and release of the coagulation inhibitor TFPI have also been reported to 
increase in an endothelial cell line that was subjected to shear stress (Westmuckett et 
ai, 2000). The fibrinolytic activity of endothelial cells is also affected by shear 
stress, with an increase in the secretion of tissue-type plasminogen activator (tPA) 
being observed in endothelial cells subjected to arterial shear stresses for more than 
six hours (Diamond et ai, 1989). These responses indicate that endothelial cells have 
a protective response to increased shear stress, whereby they act to limit the impact 
of the shear stress on the other components of the vasculature. 
Endothelial cells can also regulate the expression of adhesion molecules on their cell 
membrane in response to shear stress and the signalling pathways involved in 
communicating shear stress to the nucleus of endothelial cells are reported to include 
ion channels, G proteins, focal contact-associated proteins, protein kinases and 
transcription factors (Papadaki & Eskin, 1997) and caveolae at the cell surface have 
been identified as specific organelles that may act to convert mechanical stress into 
chemical signals within the endothelial cell (Rizzo et ai, 1998). The effect of 
increased shear has been shown to lead to the transient up-regulation of ICAM-l and 
down regulation of vascular cell adhesion factor 1 (VCAM-l), receptors which are 
implicated in the adhesion and infiltration of leukocytes in the development of 
atherosclerosis. These effects were mediated at the mRNA level, indicating an effect 
on gene transcription (Sampath et ai, 1995), and the reason for the different response 
may be the presence of a shear stress response element (SSRE) in the promoter for 
the gene for ICAM-l but not VCAM-l (Nagel et ai, 1994). This is also the case for 
platelet derived growth factor B (PDGF-B), the gene for which has a SSRE that 
interacts with NFKB, a DNA binding protein, leading to increased transcription 
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following exposure to shear stress (Khachigian et ai, 1995; Resnick & Gimbrone, 
1995; Resnick et ai, 1997). The ability of endothelial cells to down-regulate 
receptors implicated in atherosclerosis as a response to increased shear, as is found in 
partially occluded vessels, suggests the existence of a self-regulating defence 
mechanism. Conversely, an increase in the rate of uptake of low density lipoproteins 
(LDL) by pinocytosis, implicated in the formation of atherosclerotic plaques, may 
occur (Davies et ai, 1984; Levesque et ai, 1989) and endothelial cells exposed to 
shear stress in vitro release increased amounts of vWF, which may contribute to 
platelet adhesion and coagulation (Galbusera et ai, 1997). 
Steady laminar flow is considered to produce the optimal anti thrombotic state in 
endothelial cells and it has been demonstrated that oscillatory or disturbed flow 
conditions, as may be found at bifurcations in the vasculature, can lead to a 
prothrombotic state and altered gene expression (Garcia-Cardena et ai, 2001). 
Upregulation of proatherosclerotic genes in individual endothelial cells may provide 
the initial focus for atherosclerosis at these high-risk locations (Davies et ai, 2001). 
Examples of potential triggers include i) the increased transcription and expression of 
procoagulant TF in disturbed flow in comparison to the upregulation of the inhibitor 
TFPI in the presence of unidirectional flow (Mazzolai et ai, 2001); ii) a relative 
increase in the oxidative stress of the endothelium (Silacci et ai, 2001); iii) increased 
expression levels of NF-KB (Hajra et ai, 2000); and iv) increased expression of 
VCAM-l (Brooks et ai, 2002). These results suggest that the defence mechanisms of 
endothelial cells may not always be able to cope with the entire range of shear stress 
encountered in vivo. 
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The influence of the vessel wall on coagulation occurring under flow conditions in 
polyethylene capillary tubes has also been studied. The ECM of endothelial cells 
activated to express TF by exposure to TNF -u was able to support FXa generation in 
the presence of FVIIa. This was blockable by TFPI or inactivated FVII (FVIIai) 
confirming that activation of the extrinsic pathway was occurring (van't Veer et aI, 
1994; Valentin et aI, 1995). The ECM of the activated endothelial cells increased 
FXa generation 20-fold in comparison to the activated cells, indicating that even 
activated endothelium is much less procoagulant than the matrix that is exposed 
following vessel wall damage (Lindhout et aI, 1992). Similar results have been 
obtained with inactivated Factor IX (IXai), indicating that the intrinsic pathway also 
contributes to coagulation in the presence of activated endothelium and its ECM 
(Tijburg et aI, 1991). Experiments investigating the effect of varied shear rates on 
coagulation during the perfusion of blood over collagen, a component of ECM, or 
activated endothelial cells found that fibrin thrombi formed on procoagulant 
endothelial cells with most deposition occurring at low shear rates, whereas the 
collagen surface encouraged platelet deposition at high shear rates (Diquelou et aI, 
1995a). These studies confirm the important influence of shear stress on the 
condition of the endothelium or its matrix, and the important influence that this has 
in tum on the coagulation process. 
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1.3 Summary and aims of thesis 
Active processes that involve numerous components of plasma, platelets and 
endothelial cells combine to keep the blood fluid and prevent unwanted coagulation 
that may occlude vessels and impair the circulation. However, when the vessel wall 
is damaged, the highly complex coagulation system reacts rapidly to prevent blood 
loss, with explosive generation of thrombin leading to a platelet plug and then a 
fibrin clot. Built in to this system are inhibitory pathways that switch off the 
coagulant response in order to prevent unlimited growth of the clot. All these 
processes occur as the blood is flowing through the vessels that are in need of repair, 
both delivering and washing away the components of the response. Platelets are 
effectively captured on to damaged surfaces where they then provide a catalytic 
surface for the interaction of coagulation enzymes that eventually form the fibrin 
clot. Downstream of the site of damage, any excess thrombin that is washed out of 
the clot is captured and inhibited by thrombomodulin on endothelial cells, where it 
becomes able to inactivate coagulation cofactors, thus preventing extension of the 
clot. 
Antithrombotic drugs are used to treat and prevent thrombosis, with the aim of 
preventing unwanted coagulation but without compromising haemostasis. Inhibitors 
of specific coagulation factors such as heparin, low molecular heparin and hirudin 
are widely used to dampen the coagulation response in at-risk individuals. Anti-
platelet antibodies are a relatively new class of drug that are under investigation as 
inhibitors of adhesion and aggregation of platelets and for their apparent 
anticoagulant activity. 
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It is clearly important that these drugs are able to function under the precIse 
conditions that they will encounter in the body, where endothelial cells, plasma and 
platelets are interacting under flow conditions. The aim of this thesis is to establish a 
test system that can mimic these conditions in the laboratory and to examine several 
classes of drug in order to elucidate their relative effectiveness under the flow 
conditions that may be found in different sized blood vessels, and in the presence of 
intact or damaged endothelium. 
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CHAPTER 2 
MATERIALS & METHODS 
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2.1 Introduction 
The design, procurement and assembly of the flow system followed by the 
assessment and validation of its performance are described in detail in Chapter 3. 
The results of the studies on anti thrombotic agents are detailed in Chapters 4 and 5. 
Certain materials and methods are common to all three chapters and to avoid 
repetition their details are presented together in this chapter. 
2.2 Buffers 
Tris-buffered saline (TBS) was used as the dilution and washing buffer for all 
experiments. It comprised: 0.05 M Tris (hydroxymethyl) aminomethane, 0.15 M 
NaCI, pH 7.4 (BDH reagents from Merck, Poole, UK). 
Thrombin generation was measured in samples taken into a collection buffer which 
comprised: 0.05 M Tris (hydroxymethyl) aminomethane, 0.175 M NaCI, 0.0075 M 
ethylenediaminetetraacetic acid disodium salt dihydrate (Na2EDTA.2H20; all 
chemicals from BDH as before), pH 8.4 with 1 % v/v human serum albumin (HSA; 
from BPL, Elstree, UK). 
2.3 Tissue factor 
RecombiPlasTin®, recombinant tissue factor (TF) from Ortho Diagnostics, Raritan, 
NJ USA reconstituted with water. Each batch was calibrated in a prothrombin time , , 
(PT) assay against an in-house standard (NIBSC preparation 941738) that had been 
calibrated against American Diagnostica Lipidated Recombinant Tissue Factor 
(Product 4500L Greenwich, CT, USA) as follows. Doubling dilutions of the 
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RecombiPlasTin® and American Diagnostica TF preparations were prepared in TBS 
and 100 III of each dilution was added to 100 III of pooled normal plasma in a test 
cuvette of an Amelung KC-4A coagulometer (Brownes, Reading, UK). Following a 
1 minute incubation at 37°C, 100 III of 25 mM CaCh was added and the clotting 
time was recorded. Parallel line analysis (using NIBSe in-house software) was 
performed on duplicate determinations on linear sections of the dose response 
curves, and an accurate potency relative to the in-house standard could therefore be 
assigned to each batch of RecombiPlasTin®. 
Two concentrations of TF were used in subsequent experiments and are referred to as 
'high' and 'low' TF. Based on the product information from American Diagnostica, 
and using the data obtained from the calibration prodecure, the final concentration in 
the 'high' and 'low' TF reaction mixtures used were 630 and 35 pM, respectively. 
When these concentrations of TF were used in a PT, clotting times were 245 ± 4 and 
339 ± 21, for 'high' and 'low' TF respectively (mean ± sd, n = 5). 
2.4 Collection of blood 
Blood was collected from healthy volunteers, who denied taking non-steroidal 
anti-inflammatory drugs in the previous seven days, by venepuncture of the 
antecubital vein. Blood was anticoagulated in the ratio of 8.5 ml of blood to 1.5 ml 
of acid-citrate-glucose formula A (ACD-A; 0.07 M sodium citrate, 0.04 M citric 
acid, 0.12 M glucose, pH 5.0). 
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2.5 Preparation of normal plasma pools 
Blood was collected as above from a minimum of 20 randomly selected donors, who 
denied taking non-steroidal anti-inflammatory drugs in the previous seven days, and 
centrifuged at 30 000 g for 15 minutes at 20°C within 20 minutes of collection. The 
plasma was carefully aspirated from between the cell layer and any floating lipid. 
The plasma was pooled and centrifuged at 17 000 g for a further 15 minutes at 4 °C 
and aliquots were snap frozen in liquid nitrogen and stored at -40 °C. 
2.6 Defibrination of normal plasma 
Defibrinated normal plasma (DNP) was prepared immediately before use. Aliquots 
of pooled normal plasma were thawed at 37°C and defibrinated using ancrod 
(1 st International Reference Preparation, 74/581) 0.5 IU per ml of plasma for 
20 minutes at 37°C. The fibrin was removed by winding onto wooden sticks 
followed by centrifugation at 1 000 g for 5 minutes. Other methods of defibrination 
were also investigated and are discussed in Sections 4.2.6 and 4.3.8. 
2.7 Preparation of 'platelet plasma' 
Group 0 donors were selected for platelet donation in order to avoid reaction of 
anti-A and anti-B antibodies in the pooled normal plasma with the donor platelets. 
Blood was collected as above and centrifuged at 150 g for 10 minutes. The resulting 
layer of platelet rich plasma (PRP) was carefully aspirated and acidified by the 
addition of III 0 volume of ACD-A. The PRP was then centrifuged at 1 000 g for 
5 minutes to sediment the platelets. The platelet poor plasma was removed and the 
platelets were resuspended in 1 ml of DNP. The platelet count was measured using a 
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Coulter Act-T 8 cell counter (Beckman-Coulter, High Wycombe, UK) and adjusted 
by the addition of more DNP to give the required count. This is referred to as 
'platelet plasma' (PP). A previous study (Reverter et aI, 1996) found 
300 x 106 platelets/ml to give near maximal thrombin generation in a static system 
and this count was therefore adopted in these studies, although different results were 
found in the flow system (see Section 3.3.3.2). The platelet count was adjusted to 
375 x 106 platelets/ml, giving a final concentration in the reaction mixture of 
300 x 106 platelets/ml. The normal range in blood is 150 - 400 x 106 platelets/ml 
(Kay, 1998). 
2.8 Thrombin generation test 
In order to measure the effects of the antithrombotic agents to be studied, a suitable 
assay was needed. In vitro diagnostic tests that are used in the clinical laboratory are 
usually based on the clotting time (or the chromogenic activity equivalent) of a 
sample of citrated platelet poor plasma. These tests, such as the prothrombin time 
(PT) and the activated partial thromboplastin time (APTT) are useful as indicators of 
specific deficiencies or inhibition. The PT detects deficiencies in the extrinsic or 
common pathway by activating coagulation with tissue factor and calcium ions, and 
prolongation of the clotting time indicates a deficiency of any of fibrinogen, 
prothrombin, or FV, FVII, FIX or FX. The PT may also detect the use of oral 
anticoagulants such as warfarin, which results in incomplete synthesis of the 
vitamin K dependent clotting factors mentioned. In the APTT, the intrinsic pathway 
of coagulation is initiated by a 'surface activator', such as kaolin, in the presence of 
phospholipid and calcium ions. A prolonged clotting time may indicate a deficiency 
in any clotting factor except FVII and the APTT is frequently used to monitor 
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heparin therapy, although its relevance for this has been questioned (Kay, 1998; 
Hirsh et ai, 2001). The endpoint of both of these tests is the fonnation of a fibrin 
clot, which is the result of the generated thrombin cleaving fibrinogen. The 
concentration of thrombin required for this is around 20 nM or 2 international units 
(IU) per ml and this concentration is achieved very quickly following activation of 
coagulation. 
The PT and APTT have been referred to as measures of the lag time of thrombin 
generation, where trace amounts of thrombin activate FV, FVIII and FXI in a 
positive feedback loop that amplifies the coagulation response (Hemker, 1994). 
However, it may be the case that sufficient thrombin is generated to produce a clot 
without positive feedback and that these tests measure only the first phase of 
prothrombin conversion to thrombin and not the second, amplified phase. The 
insensitivity of the PT to heparin is an indication of this, as inhibition of the feedback 
activation of FV by thrombin would lengthen the clotting time if the second phase of 
thrombin generation were occurring. 
The coagulation process does not end with the production of a fibrin clot, and 
thrombin continues to be fonned, to concentrations as high as 250 nM or 25 IU/ml, 
driving the second phase of the coagulation response with positive feedback effects. 
In addition to its procoagulant effects thrombin also activates Protein C and, 
indirectly, the TFPI inhibitory pathway. These inhibitory mechanisms switch off the 
coagulation process and allow the circulating inhibitors of thrombin (antithrombin, 
a2macroglobulin and ai-antitrypsin) to neutralize the remaining thrombin and bring 
the process of coagulation to an end (Hemker, 1994). The amount of thrombin that 
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can be detected at any point during the coagulation process therefore represents the 
balance between thrombin that is being generated and that which has been inhibited. 
The curve that can be plotted of the concentration of thrombin against time provides 
information on several parameters of the coagulation process (see Figure 2.1). The 
area under the curve (AUC) indicates the total amount of thrombin that has been able 
to contribute to the promotion and inhibition of coagulation. The AUC is expressed 
in IV.seconds/ml, taking into account both the concentration of thrombin and the 
time for which it is active - this can be compared to the 'man-hours' of work that the 
enzyme is able to perform. The thrombin generation curve may be affected in 
different ways by the presence of different inhibitors such as heparin and hirudin. 
The height of the curve at its peak and the time at which it occurs also provide 
information regarding the progression of the first and second phases of the 
coagulation response and its natural or artificial inhibition (Hemker, 1994). 
The thrombin generation test was therefore considered to be the most appropriate test 
to use for the study of coagulation and its inhibition under flow conditions, due to its 
provision of data covering the whole coagulation process rather than the single 
'snap-shot' view provided by clotting tests such as the PT and APTT. The flow 
experiments were designed to allow the collection of timed subsamples for thrombin 
determination at the outlet of the flow chamber, and this collection regime was 
reproduced with manual subsampling in static experiments. 
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Figure 2.1 
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Thrombin generation curve. 
The curve shows data from a representative static experiment performed using the 
clotting method. The total amount of thrombin generated can be calculated from the 
area under the curve. The height of the curve at its peak and the time at which this 
occurs are also useful indicators of the coagulation process. 
2.8.1 Reaction mixture 
2.8.1.1 Intrinsic method 
This method was only used in the study of anti-platelet antibodies (see Chapter 5). 
800 /J-I of platelet plasma was placed in a polystyrene tube (Depex brand, Deltalabs, 
Barcelona, Spain) to which was added 25 /J-I of TBS, or TBS containing the antibody 
to be studied, and 100 /J-I of 100 mg/ml kaolin (Sigma, Poole, UK) suspension in 
TBS. This mixture was incubated at 37°C for 20 minutes in order to allow antibody 
binding to platelets to reach equilibrium, and for contact activation of coagulation to 
occur. Thrombin generation was initiated by the addition of 75 /J-I of 200 mM CaCh 
to give a final concentration of 15 mM. This concentration of calcium is equal to the 
73 
amount of calcium chelated by the citrate anticoagulant, resulting in an 
approximately physiological system and is similar to that used in previous studies 
(Reverter et ai, 1996; Herault et ai, 1998). In some assays, the volume of reagents 
used varied, but the final concentrations were unaffected and plasma was always 
80 % of the reaction mixture. 
2.B.1.2 Extrinsic method 
This method was used in the study of anti-platelet antibodies (see Chapter 4), heparin 
and hirudin (see Chapter 5). The same principle was followed as the intrinsic 
method, but the platelet plasma was incubated with the inhibitor alone for 30 minutes 
(during the subsampling period of the previous assay). Although unlikely to be 
necessary for the binding of heparin or hirudin to platelets, in order to maintain 
consistency with the studies of anti-platelet antibodies, all experiments retained this 
pre-incubation. Thrombin generation was initiated with 175 III of recombinant tissue 
factor diluted in 100 mM CaCh (TF ICa2+). Tissue factor was used at final 
concentrations of either 630 or 35 pM ('high' or 'low', as described in Section 2.3) 
and CaCh was at a final concentration of 17.5 mM. Assays were also performed in 
the absence of platelets using the lower concentration of TF. 
2.8.2 Static conditions 
In experiments that included HUVEC or ECM, following the addition of TF ICa2+ to 
the plasmalbuffer/inhibitor mixture, the reaction mixture was added to a culture well 
containing the washed HUVEC or ECM. The culture plate and the 96 well sample 
plate (Greiner, Frickenhausen, Germany) were maintained at 37°C using heating 
blocks (Techne, Cambridge, UK). In experiments that did not include HUVEC or 
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ECM, the reaction mixture remained in the polystyrene tube. In some experiments 
with high concentrations of inhibitors, the start of subsampling was delayed by up to 
30 minutes, as no thrombin generation was seen during this period in preliminary 
experiments. The time course was up to 64 minutes, with subsamples being taken at 
60 second intervals. Thrombin was measured as described below. 
2.8.3 Flow conditions 
Thrombin generation was initiated by the addition of TFICa2+ to the 
plasmaibuffer/inhibitor mixture, and the reaction mixture was then aspirated into a 
syringe, connected to the flow chamber and mounted on the syringe pump. The 
syringe pump and flow chamber were mounted on an XYZ-translation table that was 
set to collect subsamples at 60 second intervals for between 32 and 64 minutes. The 
entire system was housed in a custom-built incubator set to 37°C. For full details of 
the flow system, see Section 3.2. 
2.8.4 Thrombin detection 
Two methods were used to detect the concentration of thrombin in activated plasma, 
based on clotting or chromogenic assay systems (summarised in Figure 2.2). The 
clotting method was used in the first set of static experiments that studied anti-
platelet antibodies. These experiments were performed before the software required 
for interpretation of the chromogenic data had been written. Subsequent 
experiments, and all of the flow experiments, used the chromogenic system. 
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2.8.4.1 Clotting system 
Fifty J.lI subsamples of the activated plasma were taken every 60 seconds into 200 J.lI 
of fibrinogen solution (Diagen bovine fibrinogen, Diagnostic Reagents, Thame, UK) 
and the clotting time measured using Amelung KC-4A coagulometers (Brownes, 
Reading, UK). The clotting times were compared with a standard curve prepared 
with the fibrinogen solution and the 1 st International Standard for human a thrombin 
(89/558, NIBSC, UK) in order to determine the concentration of thrombin in each 
subsample. 
2.8.4.2 Chromogenic system 
Subsamples of either 20 or 30 J.lI were taken into 150 J.lI of EDT A-stop buffer. This 
buffer chelates the calcium in the reaction mixture, preventing any further thrombin 
generation from occurring. At the end of each time course the thrombin 
concentration of the subsamples in collection buffer was assayed by the addition of 
40 J.lI of 3 mM chromogenic substrate S2238 (Chromogenix-Instrumentation 
Laboratory, Milan, Italy) at 37°C to each well. Colour development was allowed to 
proceed for 3 minutes before the reaction was stopped using 80 J.lI of 50 % (v/v) 
acetic acid (Merck, Poole, UK) and the optical density read at 405 nm using a 
Thermomax platereader (Molecular Devices, Menlo Park, CA, USA). 
The optical density data were converted into thrombin units using standard curves 
prepared with the 1 st International Standard for human a-thrombin (89/588, NIBSC, 
UK). As the biologically inactive thrombin-a2macroglobulin complex can still 
cleave this substrate, the data were then analysed using a program that calculates and 
subtracts the amidolytic activity of this complex (Hemker et ai, 1986). Details of the 
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Reaction mixture 
800 ~l defibrinated normal plasma + platelets 
+ 
Clotting system 
50 ~l subsamples every 60 s 
200 ~l fibrinogen 
." 
clotting time recorded 
compared with standard curve 
25 ~l TBS ± inhibitor 
+ 
175 ~l TFICa2+ 
." 
Chromogenic system 
~, 
-----, 
20 or 30 ~l subsamples every 60 s 
150 ~l EDT A stop buffer 
+ 40 ~13 mM S2238 
3 minutes @ 37°C 
reaction stopped 
A405 measured 
compared with standard curve 
calculation to remove u2M -IIa 
.... thrombin generation curve 
Figure 2.2 Flow chart to illustrate clotting and chromogenic thrombin generation test methods 
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calculations for the chromogenic correction and the area under the curve are found in 
Appendix 1, and an example of the corrected chromogenic thrombin generation 
curve is shown in Figure 2.4. 
Despite the fivefold dilution and the change in pH to 8.4, there is a possibility that 
further inhibition of free thrombin may continue in the stop buffer prior to 
chromogenic thrombin detennination. Assays were therefore perfonned where 
subsamples were taken both into stop buffer (for chromogenic thrombin 
detennination at the end of the experiment) and into buffer that contained the 
chromogenic substrate (with the reaction being allowed to proceed for 3 minutes 
before stopping with acetic acid as before). Thrombin generation was initiated with 
low TF in a reaction mixture that contained 0, 0.125 or 0.25 ill/ml UFH, the highest 
concentration being sufficient to inhibit AUC by more than 50 % in the presence of 
HUVEC under static conditions (see Table 5.1, Chapter 5). Heparin would continue 
to potentiateany inhibition by antithrombin that was occurring in the stop buffer, and 
the lag time (defined as the time to reach 0.5 ill/ml thrombin) would therefore be 
longer in the stopped samples than in those assayed immediately. No significant 
differences in the lag time were seen between the stopped and immediate assays 
(Figure 2.3). In addition, there were no differences in the area under the curve, the 
peak thrombin concentration or the time of the peak. This indicates that there was no 
further inhibition of thrombin by antithrombin in the stopped chromogenic system. 
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Figure 2.3 Stopped or immediate chromogenic determination of thrombin concentration. 
Defibrinated plasma containing 300 x J 06 platelets/ml was preincubated with varied 
concentrations of unfractionated heparin and thrombin generation was initiated 
with 35 pM TF and calcium. Th e time at which 0.5 JU/ml thrombin was first 
detected was defined as the 'lag time '. Mean :t standard deviation, n = 3, no 
Significant differences. 
2.8.5 The thrombin generation curve 
Thrombin generation curves were prepared by plotting the thrombin concentration of 
subsamples against the time at which they were taken. The area under the thrombin 
generation curve (AUe) was calculated as a measure of the total thrombin 
generation, and has the units "IU.seconds/ml". The height of the thrombin 
generation curve at its peak and the time at which the peak occurred were also 
recorded. The amount of thrombin generated by platelet plasma with TBS and no 
inhibitors was taken to be 100 % in each case. An example of a thrombin generation 
curve from a clotting assay is shown in Figure 2.1 and from a chromogenic assay in 
Figure 2.4. 
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Thrombin generation curve from a chromogenic assay. 
Th e raw data are analysed and the component that is due to the activity of the 
biologically inactive a2macroglobulin-thrombin complex is calculated and 
subtracted to give the corrected data. 
2.8.5.1 Comparison of clotting and chromogenic methods of thrombin detection. 
The clotting and chromogenic methods for thrombin detection were directly 
compared in a series of experiments. Subsamples were taken from a single reaction 
mixture, following low TF stimulation, into either fibrinogen or stop buffer for 
chromogenic determination. 
The thrombin generation curves plotted from clotting and chromogenic 
determinations were different in shape, with a significantly higher thrombin peak 
seen in the clotting system than the chromogenic system (22 .0 ± 2.6 and 
8.2 ± 0.5 IU/ml respectively mean ± standard deviation, n = 3; p < 0.05 ' Figure 2.5). 
The difference in the area under the curves was not significant (7611 ± 1497 and 
o 
4581 ± 681 IU .seconds/ml for clotting and chromogenic respecti ve ly), and neither 
was the time of the thrombin peak (630 ± 108 and 740 ± 195 seconds for clotting and 
chromogenic respectively). The lower peak of thrombin generation curves prepared 
from a chromogenic system compared to a clotting system has been noted 
previously. The presence of EDT A was identified as the cause of the delay, and the 
inhibitory effect of EDT A on the thrombin - S2238 reaction suggested as a reason 
for the lower peak, its effect being amplified by the high dilution of the subsample in 
the buffer (Houbouyan et aI, 1996). 
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Figure 2.5 
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Thrombin generation curves to compare clotting and chromogenic methods of 
thrombin detection. 
Data are from a Single experiment where thrombin generation was initiated in 
defibrinated plasma containing 300 x 106 plateletlml with 35 pM TF and calcium. 
Timed subsamples were taken from the plasma into both fibrinogen and stop buffer, 
for clotting and chromogenic determination of thrombin concentration, respectively. 
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When the thrombin generation test is used to analyse the effect of inhibitors, each 
experiment includes a curve prepared In the absence of any inhibitor. The 
measurements of this curve are defined as 100 % and the curves prepared in the 
presence of inhibitors are measured against it. This means that data may be 
compared across experiments and that variations in the profile of the curves in each 
experiment are controlled for. In order to confirm this , concurrent clotting and 
chromogenic determinations were made on subsamples from a reaction mixture 
containing 20 /-lg/ml of RFGP56, an inhibitory antibody (see Chapter 4). No 
significant differences were seen in the AUC, peak thrombin concentration and time 
of peak thrombin between the clotting and chromogenic systems (Figure 2.6) . 
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Inhibition of thrombin generation measured by clotting and chromogenic methods. 
Defibrinated plasma containing 300 x 106 plateletslml was preincubated \\'ith 
20 j.1glml RFGP56 and thrombin generation .vas initiated with 35 pM TF and 
calcium. Tim ed subsamples were taken fro m the plasma into both fibrinogen and 
stop buffer, for clotting and chromogenic determination of thrombin concentration, 
respectively. Mean:t standard deviation , n = 3, no significant differences. 
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2.9 Endothelial cell culture 
Fresh human umbilical cords were collected (with ethical committee approval and 
patient consent) from Queen Elizabeth II Hospital, Welwyn Garden City, UK and 
from Chase Farm Hospital, Enfield, UK. Human umbilical vein endothelial cells 
(HUVEC) were harvested using a 1 % (w/v) collagenase A (Roche Diagnostics 
GmbH, Mannheim, Germany) solution in Medium 199 (Sigma, Poole, UK) as 
previously described (Jaffe et ai, 1973). The cells were cultured in RPMI 1640 
growth medium (Gibco, Life Technologies, Paisley, UK) supplemented with 15% 
heat-inactivated human serum (group AB, pooled from at least 4 donations, Welsh 
Blood Service, Cardiff, UK). First passage cells were used, and were cultured in 
Falcon 24 well plates (Meylan, France) for static experiments or on 10.5 x 22 mm 
Thermanox coverslips in 8 well plates (both Nalge Nunc International, from Life 
Technologies, as before). The cells were used when they had become confluent, 
usually at 3-5 days after seeding. The culture medium was aspirated and the cells 
gently washed with warm TBS before use. 
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2.10 Preparation ofECM 
Two methods for the preparation of ECM were investigated. In both cases, HUVEC 
were allowed to grow for 5 - 7 days after seeding. The culture medium was aspirated 
and the cells were removed either by blotting them with a polyvinylidene (PVD) 
membrane (Immobilon-P, Millipore, Watford, UK) as described by Aznar-Salatti et 
al (1991) or using a cell scraper (Falcon, Meylan, France). The ECM was then 
washed with warm TBS and the removal of endothelial cells confirmed by light 
mIcroscopy. The quality of the ECM was investigated by immunofluorescent 
staining with rabbit polyclonal antibodies to human vWF or fibronectin and a 
fluorescein isothiocyanate conjugated (FITC) swine anti-rabbit IgG (all antibodies 
from Dako, Glostrup, Denmark). 
It was noted that a more even covering of vWF and fibronectin was present on 
coverslips prepared using the membrane method (as shown in Figure 2.7) than the 
cell scraper (not shown). The membrane method of cell removal was therefore 
chosen for use in future experiments. 
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Figure 2.7 Immunofluorescent staining of extracellular matrix. 
ECM was prepared by blotting with PVD membrane. Polyclonal rabbit antibodies 
to A) vWF or B) fibronectin were added and detected with FlTC . .,.-vine anti-rabbit 
/gG polyclonal antibodies, as previously described (Aznar-Salatti et ai, /99/ J. 
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2.11 Immunofluorescent staining of platelets and HUVEC 
In order to visualise the effects of shear stress on endothelial cells and platelets 
(Chapter 3) and the binding of antibodies to platelets and HUVEC (Chapter 4), 
immunofluoresence was performed as follows. 
For studies of platelets in suspension, platelet plasma was prepared as detailed in 
Section 2.7 and incubated for 30 minutes at 37°C with 20 ~g/ml of the primary 
antibody, diluted in 6-salt PBS (137 rnM NaCl, 3 rnM KCI, 9 rnM CaCh, 5 rnM 
MgCh, 80 rnM Na2HP04 and 10 rnM K2P04; all reagents from BDH, Poole, UK) . 
A drop of the cell suspension was then applied to a glass coverslip that had been pre-
treated with 10 mg/ml poly DL lysine (Sigma, Poole, UK). After 30 minutes, the 
coverslip was washed with 6-salt PBS and fixed with 2 % paraforrnaldehyde (BDH, 
Poole, UK) in 6-salt PBS for 15 minutes at room temperature. After fixing, the 
coverslips were washed in 6-salt PBS including O.l % glycine (to quench aldehyde 
groups; BDH, Poole, UK). HUVEC were cultured on Thermanox coverslips as 
described in Section 2.9, washed, fixed and incubated with antibodies, as before. 
The covers lips were then incubated for 60 minutes at room temperature with a 
10 ~g/ml solution ofFITC secondary antibody in 6-salt PBS + 1 % v/v Triton X-IOO 
(Sigma, Poole, UK), and 66 nM Alexa Fluor 532 phalloidin (Molecular Probes, 
Eugene, USA) to stain actin. Coverslips were washed three times in 6-salt PBS, once 
in 6-salt PBS containing the nuclear stain Hoechst 33342 (Molecular Probes, as 
before) and washed three further times in 6-salt PBS. 
The fixed and stained cell preparations were examined and images captured using a 
Leica TCS SP2 confocal microscope with an acoustic optical beam splitter (Leica 
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Microsystems AG, Wetzlar, Germany), operated by Dr Roland Fleck of the Cell 
Biology and Imaging Section, NIBSC. 
2.12 Statistical analysis 
All data quoted are from n ~ 3 and are arithmetic mean ± standard deviation, unless 
otherwise stated. Statistical significance was determined using one-way analysis of 
variance (ANOY A) with Dunnett's post test using GraphPad InStat version 3.05 for 
Windows 95, (GraphPad Software, San Diego, USA). 
Mr Peter Rigsby of the Informatics Laboratory, NIBSC performed all comparisons of 
AUC, peak-height and time of peak values by ANOY A and the calculations of ICso 
data, which were calculated from weighted regression of logit response on log dose. 
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CHAPTER 3 
THE FLOW SYSTEM 
88 
3.1 Introduction 
The majority of in vitro studies of blood coagulation have been performed under 
static conditions in test tubes where the fluid dynamics and the flux of substrates and 
products that result from in vivo blood flow are not present. These studies provide 
only limited information and different in vitro approaches are required to model the 
in vivo process of coagulation. The use of flow chambers has become widespread 
since the mid 1970s and a number of different approaches have yielded interesting 
data, as summarised in Section 1.4. It is now accepted that the flow of blood has 
effects on the cells of the vessel wall, on blood cells such as platelets, and on the rate 
at which fluid phase enzymes, substrates and products are delivered to or removed 
from sites of coagulation at the vessel wall. 
This chapter will outline the physical effects of blood flow, the types of flow 
chambers that have previously been developed to study these effects, and the design, 
construction and validation of the NIBSC flow system. 
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3.1.1 Shear stress and shear rate 
When a fluid of a suitable viscosity is pumped through a tube, laminar flow is 
observed. In laminar flow the fluid is considered to be behaving as a number of 
concentric cylinders slipping over each other (see Figure 3.1). 
Figure 3.1 Schematic of fluid flow through a cylinder. 
The velocity profile is parabolic and is zero at the vessel wall and highest at the 
centre line. r = radius of the cylinder. 
The rate at which the layers of fluid slip over each other is known as the shear rate 
(y). This is calculated as the derivative of the velocity profile dV/dr (where V is the 
flow velocity and r is the radius of the vessel lumen) and is expressed in inverse 
seconds (S-I). The velocity profile of the fluid is such that the fluid in contact with 
the wall (the 'boundary layer') is considered to be stationary, whilst the fluid in the 
centre of the vessel flows the fastest. This means that the shear rate is greatest at the 
vessel wall, and zero at the centre of the vessel (Sakariassen et ai, 2001). The shear 
rate at the vessel wall may be calculated using Equation 3.1. 
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r = shear rate (seconds-I) 
Q = flow rate (mllsecond) 
d = diameter of vessel (cm) 
Equation 3.1 To calculate shear rate in a cylindrical vessel. 
Another commonly used term is shear stress ('r), which is a measure of the force 
exerted on the adjacent lamina of fluid (or, in the case of the boundary layer, the 
force exerted on the vessel wall) by the flowing fluid. This is expressed as force per 
unit area, usually in dynes/cm2 (where 1 dyne = 1 g.cm-1s-2). The viscosity of the 
fluid influences the shear stress that it exerts, and assumptions are often made 
regarding the viscosity of blood, which varies with haematocrit and temperature. 
Assuming physiological conditions of a 45 % haematocrit at 37°C, a wall shear rate 
of 1500 S-I would exert shear stress on the vessel wall of 57 dynlcm2 (Alevriadou & 
McIntire, 1995). 
As described in Section 1.4.1, blood flow influences the interactions of clotting 
factors and inhibitors. The variety of flow rates, vessel diameters, occlusions and 
valves that are found throughout the vasculature mean that a wide range of shear 
rates and shear stresses are found at the vessel wall (see Table 3.1) and these have 
significant effects on the kinetics of blood coagulation. 
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Table 3.1 Typical ranges of wall shear rates and shear stresses. 
(Goldsmith & Turitto, 1986; Alevriadou & McIntire, 1995) 
Blood vessel Wall shear rate (S-I) Wall shear stress (dyn/cm2) 
Large arteries 300 - 800 11.4 - 30.4 
Arterioles 500 - 1600 19.0 - 60.8 
Veins 20 - 200 0.76 -7.6 
Stenotic vessels 800 - 10000 30.4 - 380 
The variability of these conditions means that it is very difficult to mimic in vivo 
blood flow in an experimental environment but a number of devices have been 
developed that provide defined flow conditions. These devices may be used for in 
vitro studies, where an anticoagulant is usually present, or ex vivo studies using 
native blood, to investigate the influence of blood flow on coagulation. 
3.1.2 Types of flow chamber 
A number of different systems can be used to investigate the effect of shear on blood 
coagulation. Each has its advantages and disadvantages and a particular suitability to 
certain investigations depending on, for example, the need for continuous or endpoint 
sampling, the surface to be studied, the volume of perfusate available, ex vivo or in 
vitro. 
Viscometers are probably the simplest system used for the study of the effects of 
shear on fluid phase reactants. The basic principle is of a rotating cylinder or cone 
contained within a stationary cylinder or dish. The 'Couette' viscometer consists of 
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coaxial cylinders and mimics the theoretical notion of shear stress generated between 
two flat plates of infinite size, one of which is stationary and one of which is moving 
with constant linear velocity thus generating a steady state fluid velocity profile 
(Slack & Turitto, 1994). A more widely used viscometer is the 'cone and plate' 
device where a rotating cone with a very shallow angle is lowered into a stationary 
flat-bottomed dish. The higher rotational speed of the outer region of the cone 
compensates for the increased gap between the cone and the plate, resulting in a 
near-constant shear stress throughout. The cone and plate viscometer has been 
widely used in the study of shear induced platelet aggregation and has also been used 
with endothelial cells grown in the plate (Malek et ai, 1993). This system is not 
suitable for the continuous measurement of coagulation parameters as it is not 
possible to take samples of the medium during the course of the experiment. 
Annular chambers have been used as a method to study coagulation in the presence 
of ex vivo vessels. In annular systems, an everted segment of a blood vessel is 
mounted on a central rod and surrounded by the outer cylinder of the perfusion 
chamber (Baumgartner et ai, 1976; Weiss et ai, 1991). Blood, or other perfusates, 
may then be passed through the chamber where the shear rate at the surface of the 
vessel segment is dependent upon the flow rate and the distance between the 
chamber wall and the segment surface. Different types of surface may be studied in 
this system, although it is unlikely that the process of everting the vessel would leave 
the endothelial cells intact, and studies of differing forms of subendothelial matrix 
are more common. 
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Tubular chambers work on a similar principle, but consist of a cylindrical chamber 
with a cut-out window through which a patch of test material is presented to the 
flowing medium. The material acts as a gasket to seal the window and this system is 
therefore unlikely to be suitable for the study of endothelial cells, as they would need 
to be cultured on to a flexible material and remain firmly attached when the material 
was under tension (Badimon et ai, 1987). 
A column-based flow system has been used to study the release of nitric oxide by 
endothelial cells exposed to shear stress. The cells were grown on microcarrier 
beads and then packed into a column, with the assumption that at a constant fluid 
viscosity the shear stress is a function of the column flow rate (Buga et ai, 1991). 
While this may be a reasonable assumption, the system would be laborious to 
prepare and it would be difficult to establish the condition of the cells during and 
after a perfusion experiment, as damage may occur during the packing and 
unpacking processes. 
Flow systems that use capillary tubes to mimic the in vivo environment have not 
been widely used. One group has succeeded in seeding endothelial cells into a 
capillary and studying their influence on coagulation (Lindhout et ai, 1992). The 
drawback to this is that it is very difficult to establish whether or not a continuous 
monolayer of endothelial cells has been laid down within the capillary, and 
examination of the cells during or after the experiment can be difficult. In 
preliminary assessments of the flow system, similar problems were encountered and 
are described in Section 3.2.4.1. 
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An alternative to coating a capillary tube with endothelial cells is the use of 
phospholipid bilayers into which proteins of interest, such as tissue factor, have been 
inserted (Contino et aI, 1991). This enables the influence of shear stress to be 
studied in a purified coagulation system. The small internal diameter of the tube 
means that relatively high shear rates can be generated with small amounts of 
medium and also that longer-term perfusions can be performed without recirculation 
or the consumption of precious reagents. Small volume samples can be collected at 
the outlet by 'plucking' drops of medium from the end of the capillary by touching 
the drop onto the meniscus of an aliquot of a collection buffer. Sample sizes as small 
as 6 III have been reported using this technique (Contino et aI, 1991). Timed 
samples may then be assayed for various parameters to determine the time course of 
coagulation. 
Parallel plate systems are perhaps the most commonly used in the study of 
coagulation. They consist of two plates held parallel to each other with a narrow gap 
between them through which fluid is driven. When fluid with a constant viscosity is 
driven between the plates a parabolic velocity profile is seen, indicating that laminar 
flow is occurring (illustrated in Figure 3.2). The wide range of shear stresses that are 
experienced throughout the fluid means that these chambers are unsuitable for 
studying the effects of shear on cells or proteins in suspension. Analogous to parallel 
plate flow chambers are capillary tube microslides with a rectangular cross-section, 
which have been used to study platelet and neutrophil adhesion to endothelial cells 
(Cooke et aI, 1993; Kirton & Nash, 2000). 
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Figure 3.2 Schematic of fluid flow through a parallel plate flow chamber. 
The plates are separated by distance h and are w wide. The velocity profile of the 
fluid is parabolic. 
The height and width of the slit through which the fluid flows and the rate at which it 
is flowing detennines the wall shear rate, which may be calculated using 
Equation 3.2. These chambers are therefore well suited to the study of shear on the 
delivery of suspended entities to the mass transfer boundary layer at the vessel wall. 
This is ideal for coagulation studies, where the influences of the endothelium and the 
subendothelium are important. The base of the chamber may be fonned by a slide or 
coverslip onto which endothelial cells have been cultured or a specific matrix protein 
has been applied. The surface may be examined for morphological changes or 
adhesion of fluid borne elements after, and, depending of the construction of the 
chamber, during the perfusion. Sampling of the perfusate at the outlet of the 
chamber is straightforward, and small sample volumes may be collected using the 
'plucking' method described above. This system does not mimic in vivo conditions 
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exactly, as the perfusate is only exposed to cells on one side of the chamber and an 
asymmetric flow velocity profile may be seen, but laminar flow is still considered to 
be present. 
r 
y = shear rate (seconds·1) 
Q = flow (mVsecond) 
w = slit width (cm) 
h = slit height (cm) 
2 
Equation 3.2 To calculate shear rate in a parallel plate flow chamber. 
The parallel plate system has been further developed to include a stenosis that 
mimics those found in diseased vessels. These can be used to generate very high 
localised shear stresses and the stenosis can also be coated with material similar to 
that found in vessel wall plaques, allowing the effect of various anti thrombotic drugs 
to be evaluated in vitro (Barstad et aI, 1994). A chamber where the shear stress 
decreases linearly along the length of the chamber has also been developed (U sami et 
aI, 1993). These adaptations are suitable for the study of adhesion of fluid phase 
reactants, such as platelets, but are not suitable for the study of the effects of specific 
shear rates on the perfusate. 
The available volume of the perfusate has a significant bearing on the experiments 
that may be perfonned with particular flow chambers, as the flow rate of the fluid is 
critical to the shear rate generated. When fresh blood or its purified components are 
to be used, the volume that can be used in each experiment may be limited and this is 
particularly the case when a number of 'runs' are to be perfonned, for example when 
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preparing a dose-response curve (see Table 3.2 in Section 3.2.4.2). This problem 
may be overcome by recirculating the perfusate rather than pumping it straight 
through the chamber for collection of samples at the outlet. However, there are 
drawbacks to this method, as the concentration of soluble factors in the perfusate 
(released from activated endothelial cells or platelets) may rise above physiological 
levels and begin to interfere with normal reaction kinetics. The opposite effect may 
also occur, with depletion of soluble reactants, adhesion of platelets or product 
accumulation. Recirculating systems are useful in certain situations, such as in 
studies of gene regulation where long term exposure to flow is needed to allow 
transcription level effects to occur, but a single-pass system is preferable for the 
study of enzyme-based systems such as coagulation. 
When a high shear rate is required, the alternative to a high flow rate is a smaller 
chamber. When parallel plate chambers were first developed, they had quite large 
internal dimensions, necessitating the use of large volumes of perfusate for realistic 
shear rates to be generated (Sakariassen et aI, 1983). More recent studies have 
employed much smaller chambers that allow single-pass perfusions with the 
generation of realistic arterial shear rates (Usami et aI, 1993; Sixma et aI, 1998). 
Taking into account all these issues, it was decided that the most suitable system for 
the analysis of thrombin generation under flow conditions was a parallel plate flow 
chamber with no recirculation of the perfusate. In order to generate a sufficiently 
high shear rate without using a large volume of plasma, flow chambers with small 
dimensions would be preferable. A suitable flow system was therefore designed and 
built for this project. 
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3.2 The NIBSC Flow System 
The flow system was custom built using three major components (the syringe pump, 
the table and the incubator) and a number of other components that were used in the 
assembly of the system. 
3.2 .1 Syringe pump 
The Harvard 33 double syringe pump (Harvard Apparatus, Edenbridge, Kent, UK) , 
shown in Figure 3.3 , is capable of pumping two syringes independently wi th flow 
rates from 0.0073 ~lIhour to 53 mllminute. It is pre-programmed to calculate flow 
rates from the diameter of the syringes used. An additional benefit of thi s pump is 
the ability for remote control using a personal computer and the RS-232C port, 
allowing it to be synchronised with the XYZ table. 
Figure 3.3 The Han1ard 33 double syringe pump. 
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3.2.2 XYZ translation table 
The Techno Isel 'Da Vinci' XYZ table (Unimatic Engineers, London, UK), shown in 
Figure 3.4, is a precision machine tool designed for use in industrial applications 
such as computer aided machining, engraving and other functions. For these 
applications, the appropriate tool is mounted to the Z-axis and the movement of this 
tool in three dimensions is controlled via the serial port of a personal computer. For 
construction of the flow system, the parallel plate flow chamber is mounted to the 
Z-axis in a vertical orientation. The 96 well plate into which samples of perfusate 
are to be collected is placed onto the X-axis. As the perfusion experiment 
progresses, precisely timed movements of both the X- and Y-axes position the outlet 
tubing of the chamber over subsequent wells of the collection plate. Movement of 
the Z-axis at the end of each sampling period enables the outlet tubing to be dipped 
into the meniscus of the collection buffer in the wells of the plate, stopping the 
reaction and allowing the collection of samples less than the size of one drop (see 
Figure 3.5). The reproducibility of the smallest sample volume used (20 Jll) was 
detennined by chromogenic analysis of 30 samples of a standard solution of 10 
IV/ml thrombin (NIBSC reagent 941708) and the coefficient of variation (CV) was 
found to be 4.3 0/0. The syringe pump was mounted on a shelf attached to the Z-axis, 
with tubing of sufficient length to connect the syringes to the inlets of the flow 
chamber. 
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Figure 3.4 
Figure 3.5 
The Techno lsel 'Da Vinci ' XYZ table. 
Photograph provided by Techno In c, New York, USA. 
The parallel plate flow chamber mounted to the Z-axis of the XYZ table. 
Timed subsamples are collected by dipping the outlet tubing into a 96 well plale 
containing stop buffer. 
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3.2.3 Custom-built incubator 
In order to keep the reactants at a phys iological temperature during the perfu ion 
experiment, it was necessary to enclose the complete system in an incubator. It was 
not possible to purchase an incubator that would allow the required access to the 
equipment and so an incubator was custom built in the NIDSC laboratory workshop 
(see Figure 3.6). The incubator housing was constructed of twin-wall plastic sheets 
(usually used for greenhouses) and sliding Perspex doors (adapted from a 
commercial secondary glazing kit). A fan heater connected to a thermocouple was 
installed in order to regulate the temperature. The thermocouple was mounted on the 
gantry of the XYZ table at the same level as the flow chamber, ensuring that the 
chamber was maintained at 37 ± 2 DC. 
Figure 3.6 Th e IBSCjlow system. 
Th e sliding doors have been removed to aid photography. 
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3.2.4 Flow chambers 
3.2.4.1 Capillary tubing 
In order to mimic the in VlVO environment as accurately as possible, initial work 
focussed on establishing a protocol for the seeding of endothelial cells on to the 
inside of polytetrafluoroethylene (PTFE) capillary tubing. The protocol followed 
that of Lindhout et al (1992), and involved coating the inside of the tubing with 
3 /-Lglcm2 fibronectin (Sigma, Poole, UK) at 37 °C for 1 hour and then seeding with a 
suspension of 0.4 x 106 endothelial cells per cm2. The tubing was capped and placed 
inside a modified hybridisation chamber that maintained a temperature of 37 °C and 
rotated the tubing for up to 3 hours at a rate of 0.5 revolutions per minute , with the 
aim of attaching an even covering of cells to the inside of the tubing. The tubing was 
then perfused with growth medium overnight at a low shear rate « 10 S-l) in order to 
allow the cells to spread. The cells were then fixed with 2.5% glutaraldehyde and 
examined by electron microscopy (see Figure 3.7). This method was very labour 
intensive and not entirely successful , as intact mono layers of cells were not obtained, 
although cells seeded in this way appeared to resist detachment when the shear rate 
was increased (up to 67 S-l). 
Figure 3.7 S anning electron microaraph of endothelial cells lining a PTFE capillary rube. 
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3.2.4.2 Parallel platejlow chambers 
Two types of parallel plate flo w chambers were used in these studies. Both were 
based on the same principle and are represented by the cross section shown in 
Figure 3.8. 
Fluid flow path 
, I I 
f----- - -~ l I [I 
- -
i 
Recess for coverslip 
Figure 3.8 Vertical cross section of a parallel plate flow chamber. 
Timed 
subsamples 
-
1 
-------. 
The fluid flow path and the position of the coated coverslip are indicated. 
Type 1: This chamber was a gift from Glaxo (Greenford, UK) and was constructed of 
a Perspex block that screwed to a metal base using wingnuts (see Figure 3.9). The 
floor of the chamber was formed by the slide portion of a Nunc Slideflask (Life 
Technologies , Paisley, UK) that fitted into a recess in the metal base. The slit height 
of the chamber was 150 ).-tm, achieved using a PTFE gasket, and the slit width was 
1 cm. Perfusate was pumped through the chamber via holes drilled through the 
Perspex and nylon cannula tubing (Portex, Hythe, UK). For details of volume of 
perfusate, flow rates and shear rates, see Table 3.2. 
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Fig ure 3.9 Th e parallel plate flo \\ ' chambers 
Th e Tlpe l.flo\\ · challlber (left ). used fo r srudies ar rh e shear mre ol l 8 ./. alld (/// 
exalllple ol fh e Type 2.flOl\ · chamber (rig hr). used lor srudies af shear mfes ol l 78 
and 600 S·l . . 
Type 2: A set of custom-made fl ow chambers was commissioned from Barnard 
Engineering (Hertford , UK). A dual-chamber design was decided upon, as thi s 
allowed two perfusion experiments to be performed concunently, sav ing time and 
allowing more data to be ga thered before the plasma or platelet went beyond their 
useful lifespan (considered to be 4 hours). Tlu-ee chambers were manufac tured, a ll 
with a s lit w idth of 2 mm but w ith varied slit heights of 50, 75 and 15 0 ~m , ac hi eved 
us ing polyester gaskets (see Figure 3.9) . Perfusate was pumped through the chamber 
via hol es drilled through the Perspex . PTFE tubing wi th internal diameter 0.5 III III , 
designed for use in fa t protein liquid chromatography (FPLC ), was connected to the 
chamber using FPLC fittings (Amer ham Bio cience , Little Chalfont. UK). For 
d tail of vo lume ofperfu ate , fl ow rates and hem rat " ' ee Table 3.2 . 
10: 
Table 3.2 Summary of chamber dimensions, flow rates and perfusate volumes used in d(fferent 
shear rate experiments. 
Shear Slit Slit Flow Perfusate Plasma Subsample Number of 
rate width height rate volume volume volume subsamples 
(S-I) (cm) (J.lm) (J.lllmin) (J.lI) (J.lI) (J.ll) 
0 0 1000 800 20 32 
18 1.0 150 40 1500 1200 40 32 
178 0.2 50 20 1000 800 20 32 
600 0.2 75 30 1250 1000 30 32 
3.2.5 Software 
The software for controlling the flow system was a gift from Dr Yale Nemerson 
(Mount Sinai Medical Centre, New York, USA) and was modified by Unimatic 
Engineers (suppliers of the XYZ translation table) to suit the particular model of 
table and syringe pump chosen. The software enables the user to define flow rates 
and sampling times so that a wide range of shear rates can be generated and samples 
of a manageable size collected. The user may also choose to operate one or both 
syringes for each individual run. 
Printouts of the screen displays of the software are found in Appendix 2. 
106 
3.3 System validation 
Studies were undertaken to assess the suitability of the system for the study of 
coagulation under flow conditions. These included studies on the effect of flow on 
the endothelial cell monolayers, the effect of flow on thrombin generation in plasma, 
the effect of untreated tissue culture plastic on thrombin generation, the effect of 
shear stress on platelet activation markers and the effect of the presence of red blood 
cells on the adhesion of platelets. 
3.3.1 The effect of flow on endothelial cells 
Endothelial cells were prepared on Thermanox coverslips as described in Section 2.9, 
and were loaded into the flow chamber. Platelet poor plasma was reca1cified and 
perfused through the chamber at a flow rate that generated a wall shear rate of 178 S-1 
or 600 S-1 (equivalent to venous or arterial conditions, respectively) for 32 minutes. 
After the perfusion, the covers lips were carefully removed from the chamber, washed 
with TBS and viewed by light microscopy. Micrographs showing some shear-related 
changes in the morphology but no damage to the monolayer of endothelial cells are 
shown in Figure 3.10). 
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Figure 3, J 0 Micrographs of post-pellu ion endothelial cel/s, 
Platelet poor plasma was recalcified alld p el/i l ed m 'er HU I'EC 0 11 C() I't'n lif1' 
mounted in th e flo 1\ ' chamber, Th e COI'e!' lip lI'ere reJll OI'ed. \\'(/ hed and "iclI 'cd bl' 
light mi('1'0 copy throug h a g reell fi lter, 
A) Before expo lire to shear 
B) after 32 lIIillllle at J 7 S·I 
C) a/ier 3- minll te at 600 S· I 
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3.3.2 The effect of flow on platelets 
Platelets may become activated when they are exposed to shear stress and this 
activation can lead to the release of compounds from intracellular stores and the 
altered expression of receptors on the platelet membrane. These changes may affect 
the platelet's contribution to coagulation. 
A useful marker of platelet activation is P-selectin, which is an adhesive receptor 
stored in the a-granules of resting platelets but rapidly relocated to the outer 
membrane following activation of the platelet (Furie et ai, 2001). In order to 
establish the degree of platelet activation that is caused by flow, platelet plasma was 
prepared as described in Section 2.7 and recalcified with a final concentration of 
17.5 mM CaCho The plasma was then either pipetted onto a coverslip of HUVEC 
(static conditions), or perfused through the flow chamber at a shear rate of 600 S-1 for 
32 minutes (flow conditions). The covers lips were washed, fixed and stained using 
FITC-anti-P-selectin MAb (11100 dilution of ascites of Clone Thromb-6, CLB, The 
Netherlands) and actin and nuclear staining as described in Section 2.11. The cells 
were examined by confocal fluorescence microscopy, and representative images are 
shown in Figure 3.11. 
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Figure 3,11 
Platelet 
Endothelia l cell 
Immunoflu orescent staining of endothelial cells and platelets after exposure to stotic 
orflow conditions, 
Defibrinated plasma containing 375 x J(l ' pia telets/111 I was recalci/ied and 
A) incubated It 'ith HUVECfor 32 minufe , or B) ImILI ed af 600 s'/ across HL ' I EC 
in a flO \I ' cha lllber for 32 minute, Th e cells It 'ere then Fwd It 'ifh :: "" 
poraforl11oldeh,rde, incubafed with FITC onfi-P selecrill I//Onoc!on(/I allfihodl ' 
Thro /ll b 6 (green) for 30 111 in utes follolt 'ed by 66 nM A I('xa Fluor 53~ phalloidin Un 
fain aCfin red) in PB containing I () o Trifon X-IOO, 'vucll!i (/rl! Ifain cd Nut' 
/o llolt 'ing a 10 lIlinute incubafion It'irh Hoechl' f 333-12, 
1 10 
3.3.3 The thrombin generation test 
Background information and details of the materials and methods used in the 
thrombin generation tests are described in Section 2.8. Briefly, normal pooled 
plasma was defibrinated with ancrod and fresh platelets (obtained from a group 0 
donor by centrifugation of platelet rich plasma) were resuspended in this plasma at a 
physiological concentration to give 'platelet plasma'. Coagulation was initiated by 
the addition of an activator such as tissue factor and calcium chloride (TF /Ca2+). 
3.3.3.1 The effect offlow on thrombin generation in platelet poor plasma 
When defibrinated normal plasma without platelets was triggered with TF /Ca2+ and 
pumped through the flow chamber at a shear rate of 18 S-1 with an untreated plastic 
slide forming the base of the chamber, significantly more thrombin was generated 
than under static conditions (AUC of 2666 ± 694 and 1206 ± 170 IU.seconds/ml 
respectively; mean ± sd; n ~ 8; p < 0.01). When the plastic slide had been pre-treated 
for 1 hour at 37°C with a 1 % (v/v) solution of HSA (BPL, Elstree, UK) in TBS, 
significantly less thrombin generation was seen (AUC of 766 ± 202 IU.seconds/ml, 
n = 3; p < 0.01), suggesting that the negative charge on the tissue culture treated 
plastic provides a favourable surface for coagulation. 
To investigate this hypothesis, the non-activated partial thromboplastin time 
(NAPTT) assay was performed on defibrinated plasma that had been passed over an 
untreated plastic slide at a shear rate of 18 S-I. The NAPTT assay is highly sensitive 
to the presence of activated clotting factors, in particular FIXa (Prowse & Pepper, 
1980). The plasma was mixed in a 1: 1 ratio with a normal plasma (in order to 
provide enough fibrinogen for a detectable clot to form), and 100 )11 of this mix was 
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added to 100 JlI of 50 Jlg/ml bovine brain phospholipid reagent (NIBSC reagent 
911542, diluted in TBS) and 100 JlI of 25 mM CaCh in a plastic tube. The tubes 
were incubated at 37°C and the time taken for the mixture to clot (by visual 
determination) was recorded. The plasma that had been passed through the flow 
chamber clotted in 260 ± 8 seconds (mean of 8 samples, taken at 3 minute intervals 
during the 24 minute perfusion) compared to 299 ± 7 seconds (n = 2) for the control 
plasma. This shortening of the clotting time (p < 0.001) suggests that there may be 
some activation of components of the intrinsic coagulation pathway during the 
perfusion of the plasma through the flow chamber. It is therefore possible that 
negative charges found on the plastic slide or in the tubing may be facilitating the 
activation ofFXI, leading in tum to the activation of FIX. 
3.3.3.2 The effect a/platelets on thrombin generation 
The presence of platelets in the reaction mixture resulted III significantly more 
thrombin generation than in their absence. The platelet count that was required for 
maximal thrombin generation was studied in a series of single experiments using 
plastic tubes and static conditions and either HUVEC or ECM at venous or arterial 
shear rates (see Figure 3.12). 
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Th e effect of p latelet concentration on thrombin generation. 
Thrombin generation wa initiated in defibrinated plasma containing platelets II. ing 
35 pM TF and calcium. aJ Dose response curves under d[fferent . hear conditions 
and in the presence of HUVEC or ECM and 300 x } 06 platelet ml: b) thrombin 
gen ration wiles fro m the platelet dose response experiment over ECJ! at 600 . ·l 
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Under static conditions a dose response to platelet count was seen up to 240 x 106 
platelets/ml ('Plastic @ 0 S-I, in Figure 3.12a), the highest concentration of platelets 
tested, and this is similar to the results of Reverter et al (1996) who found that 
300 x 106 platelets/ml were required for near maximal thrombin generation under 
static conditions following similar activation with TF /Ca2+. The contribution of 
platelets is not surprising as they carry coagulation factors within and on the surface 
of their membrane and, once activated, they also provide a negatively charged 
phospholipid surface that acts as a catalytic template for the interaction of 
coagulation factors. Under flow conditions maximal thrombin generation was seen 
at 50 x 106 platelets/ml at a shear rate of 178 s -I and 100 x 106 platelets/ml at 600 s -I, 
with no further increase up to 300 x 106 platelets/ml (Figure 3.12a). In these single 
experiments, the maximum thrombin generation appeared to be higher at 600 S-I than 
at 178 S-I, but the difference between these shear rates was not significant when 
further experiments were perfonned (see Figure 3.13). In order to achieve maximal 
thrombin generation in the static system a final platelet concentration of 300 x 106 
per ml was chosen for subsequent experiments. For direct comparability with the 
static system, this concentration was also used for the flow experiments. 
Examples of the thrombin generation curves obtained with different platelet counts 
under flow conditions are shown in Figure 3.12b. An example of the effect of 
platelets on absolute values of AVC, peak thrombin and time of peak thrombin from 
a series of experiments using ECM and a shear rate of 178 S-I are shown in Table 3.3. 
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Table 3.3 
y (S·l) 
- platelets 
+ platelets 
To illustrate the effect of platelets on absolute values of A VC, peak thrombin and 
time of peak thrombin. 
Data are from ECM experiments at 178 S·l with no inhibitor, l1-'ith or without 300 x 
106 plateletslml and following initiation of thrombin generation with 35 pM TF and 
calcium. Data are expressed as mean ~ standard error of mean, n C 2. 
Aue (IU.seconds/ml) Peak (lU/ml) Peak time (seconds) 
0 178 0 178 0 178 
512±174 617 ± 42 0.5 ± 0.2 1.3 ± 0.2 1140 ± 300 830 ± 61 
3196 ± 134 3324 ± 164 5.2 ± 0.3 5.3 ± 0.4 967 ± 37 1000 ± 47 
3.3.3.3 The effect oft~ssue culture plastic on thrombin generation in platelet plasma 
Platelet plasma was triggered with TF /Ca2+ and pumped through the flow chamber at 
a shear rate of 18 S-1 with either an untreated plastic slide or a plastic slide pre-treated 
with a 1 % (v/v) solution of HSA (BPL, Elstree, UK) in TBS forming the base of the 
chamber. Pre-treatment with albumin resulted in a small but significant reduction in 
the amount of thrombin generated from 3915 ± 796 to 3661 ± 797 IU.seconds/ml 
respectively (mean ± sd; n ~ 5). The albumin pre-treatment was intended to block 
non-specific adsorption of plasma proteins to the slide, and the result suggests that 
the thrombin generation seen is not dependent upon adhesion of platelets to the 
adsorbed plasma proteins, leading to surface-bound coagulation reactions, but is also 
occurring on platelets in the fluid phase. 
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3.3.3.4 Th e effect of HUVEC or ECM on thrombin generation in platelet plasma 
Under static conditions significant ly less thrombin was generated in platelet pia ma 
in the presence of HUVEC than ECM (2582 ± 216 and 3196 ± 410 IU.seconds/ml 
respectively; n = 9; p < 0.001; Figure 3.13 ). At a shear rate of 178 S·I thrombin 
generation was significantly increased in the presence of HUVEC to 3132 ± 361 
IU .seconds/ml (n = 16; p < 0.001 ) but no further increase was seen in the presence of 
ECM, which remained at 3238 ± 609 IU .seconds/ml. 
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178 
Shear rate (s-l) 
- HlNEC 
ECM 
600 
Total thrombin generation at static, venous or arterial shear rates in the presence of 
HUVEC or ECM. 
Thrombin generation was initiated with 35 pM TF and calcium in defibrinated 
p lasma contain ing 300 x J 06 platelets/mI. At shear rate 0 s" , the activated plasm~~ 
was incubated in a culture well containing HUVEC or ECM andfo r J 7 and 600 s 
the activated plasma was perfused through a parallel plate flow chamber containing 
H UVEC or ECM. Mean :tstandard deviation; n 2 9; ***p < 0.00 1. 
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No further significant changes were seen in thrombin generation when the shear rate 
was increased to 600 S-1, with thrombin generation of 3135 ± 521 and 2967 ± 410 
IU.seconds/ml being seen in the presence ofHUVEC and ECM respectively (n = 11). 
This suggests that although intact HUVEC are less thrombogenic than ECM under 
static conditions, they lose some of their anti thrombotic character when exposed to 
shear stress. 
3.3.4 The effect of the presence of red blood cells 
Red blood cells may increase the rate of coagulation by releasing the platelet agonist 
ADP (Gaarder et ai, 1966), and by providing negatively charged phospholipid 
membranes for the assembly of coagulation factor complexes (Peyrou et ai, 1999). 
Platelet adhesion under flow conditions is also affected by the presence of red blood 
cells, as they occupy the central region around the axis of the vessel (Sakariassen et 
ai, 2001). This forces the platelets nearer to the vessel wall, where they are well 
placed to become activated and/or adherent following the interaction of their 
receptors with ligands exposed in the sub-endothelium. Experiments were performed 
in order to test whether this process could have an effect in the thrombin generation 
test under static and flow conditions, where red cells cannot be included due to their 
interference with the chromogenic determination of thrombin concentration. 
Washed red blood cells were prepared following the removal of PRP from whole 
blood, after centrifugation (150 g for 10 minutes). The red blood cells were diluted 
with an equal volume of PBS-A (0.17 M NaCI, 3.35 mM KCI, 10 mM Na2HP04, 
1.8 mM KH2P04; pH 7.4) with 5 mM glucose (all reagents from BDH, Poole, UK) 
and centrifuged at 1000 g for 5 minutes. The supernatant was discarded and the 
packed cells resuspended in PBS + glucose, centrifuged at 2000 g for 5 minutes and 
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the process repeated with a final spin of 2000 g for 15 minutes. The supernatant was 
discarded and the packed red blood cells were counted using a Coulter AcTS Cell 
Counter in pre-dilution mode. This method gave a haematocrit between SO and 90 % 
(Lankhof et ai, 1995). 
A reaction mixture was prepared with 40 % (v/v) packed red blood cells, 40 % 
platelet plasma (750 x 106 platelets/ml) and 2.5 % TBS. The mixture was activated 
by the addition of 17.5 % low TF/Ca2+ and perfused over HUVEC or ECM at 17S S-I 
and 600 S-I as described in Section 2.S.3. For static conditions, a variation from the 
method described in Section 2.S.2 was used, with an ECM-coated coverslip being 
placed in a culture well. Following the perfusion, the coverslips were fixed with 
0.5 % glutaraldehyde in PBS-A for 15 minutes and dehydrated in methanol for 
15 minutes prior to staining with a 1: 1 mixture of May-Grunwald and Giemsa stains 
(Sigma, Poole, UK) for 5 minutes. This mixture contains eosin, which stains the 
cytoplasm and acidic granules red, and azure blue, which stains nuclear material. 
After staining, the covers lips were mounted and viewed by light microscopy. 
Photomicrographs are shown in Figure 3.14. 
The effect of the increased dilution of plasma on thrombin generation, which could 
have a significant effect on the activation of platelets, was checked using 40 % (v/v) 
TBS in place of packed red blood cells. The extra dilution resulted in a 20 % 
decrease in thrombin generation (4476 and 3620 IU.seconds/ml with SO and 40 % 
plasma respectively). It has previously been reported that a reaction mixture 
containing red blood cells in platelet poor plasma may support 40 % more thrombin 
generation than platelet rich plasma, with this difference suggested to be due to the 
lIS 
enhanced inactivation of FV by Protein C on platelet membrane phospholipids (Tans 
et ai, 1991; Peyrou et ai, 1999). 
The presence of red blood cells did not appear to have an effect on platelet adhesion 
under static conditions (Figure 3.14 A and B). At 178 S-l more platelets appeared to 
adhere to ECM in the absence of red blood cells than in their presence (Figure 3.14 C 
and D). The opposite was true at 600 S-l, where a clear difference may be seen with 
large aggregates forming in the presence of red blood cells (Figure 3.14 E and F). 
Platelet adhesion to HUVEC may be seen following perfusion at 600 S-l both in the 
presence and absence of red blood cells (Figure 3.15), although larger aggregates 
appear in the presence of red blood cells. 
These results suggest that red blood cells have an effect on platelet adhesion under 
flow conditions. At the venous shear rate of 178 S-l, the reduced adhesion of 
platelets in the presence of red blood cells may be the result of less segregation of the 
cell types in the flowing perfusate, leading to reduced platelet-ECM interaction due 
to the presence of red blood cells in the boundary layer. Increased adhesion in the 
presence of red blood cells at the arterial shear rate 600 S-l suggests that segregation 
of the cell types may be occurring in the perfusate and that platelets are indeed forced 
closer to the coverslip, where they adhere to the adhesive proteins in the ECM and 
also to HUVEC. This is in agreement with published theories on blood flow 
(reviewed by Sakariassen et ai, 2001), and indicate that the presence of red blood 
cells is desirable in studies of platelet adhesion and thrombin generation under flow 
conditions. The absence of red blood cells from these studies, due to their 
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interference in the detection of thrombin, is a limitation of this study and a challenge 
to be addressed. 
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Figllre 3. 14 Phorolllicrographs o/platelet adhesion to [C\/ In [h e absencc or 1)J"(!SL' lI ce of /"(0 
blood cells. 
A reaction mixture lI 'as prepared l\ 'irh 4() °0 (1 ' 1') p([cked red h/ood cells, -/0 " 0 
platelet plasllla (75() x 1()6 plateletsl l71l) and 2.5 °0 TBS Th e lIlix[lIre \\'(IS Llc[il'([led 
by th e addilion of 17. 5 ~o lOll ' TFICa> (filial concelllratioll (~( TF = 35 pJ/) ([li d 
pelfu ed OI 'er [CM at 178 -I and 6()() s-I. For static cOlldi[iollS, on EC \/-col/lcd 
cO I'erslip lI 'as placed in a culture lI 'ell. Folloll 'ing pel/ ilsion tlt e CL' lls Il 'er c fixed l\ 'it lt 
(), 5 % glutaraldehyde and stained \I 'ith lIlixed May-CI'lI/l\I 'old ([li d CiclI/ w Ituilll. 
Adherent platelets and platelet aggregates are indiccllcd b.l· U"" O\l" . 
A) () S-I - RB 
C) I 8 -I - RBC 
£) 60() S-I - RB 
1- 1 
B) () ,-I RBC 
D) I 8.'i-1 -+- RBe 
F) 60(} .'I- I ~ RBC 
Figure 3.15 Platelet adhesion to HUVEC in th e absence or presence o{red blood cells. 
A reaction mixture \I 'as prepared \\ 'ith 40 % (I >lV) pocked red Mood cells, ..f() "I) 
platelet plasma (750 x 106 plateletslml) and 2. 5 ~ o TBS Th e mixture \1 '0 .1' octil 'oted 
by the addition of 17.5 % low TFICa> (fina l concentration of TF = 35 pM) ulld 
p el/used over HUVEC at 600 S·l Follo\I 'ing pel/usion th e cells \\ 'ere fix ed 1\ 'itll 
0.5 % glutara ldehyde and slained \I'ilh mixed Afa,r-Cnll1\\ 'ald and Ciemsa sta in\ . 
Adherent platelets are indicated by al'l'O\\ 'S. Follo1\ 'ing per/itsioll the cells \\'(!re/ixed 
with 0.5 % g lularaldehyde and stained H'ilh mixed May-Crunwuld (lnd Ciell/ \'(/ 
tains. H UVEC and adherent platelels are illdicated 1\ 'ilh o/'I'O\\ 'S . 
A) 600 s· / - RBC 
B) 600 ./ + RB 
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3.4 Discussion 
The effects of flow on the process of blood coagulation are numerous. Physical 
effects on vessel wall components such as endothelial cells and their extracellular 
matrix may be observed, and platelets circulating in the blood may become primed 
for adhesion and activation. By increasing the rate of diffusion, flow increases the 
rate of interaction of fluid phase substrates and vessel wall-bound enzymes, 
facilitating coagulation. When designing an assay system to study coagulation, it is 
therefore important that all these components are taken into consideration. 
In designing the NIBSC flow system, consideration was given to the inclusion of 
platelets and endothelial cells and to the range of in vivo flow conditions that could 
be modelled. A parallel plate design was the most suitable for the inclusion of 
endothelial cells and their removal for examination after completion of the 
experiment. The dimensions of the chambers to be used were calculated to give 
physiologically relevant shear rates without requiring a large volume of plasma, as 
this was usually the limiting factor. Collection of timed subsamples at the outlet of 
the chamber was easily achieved and the use of an EDT A-containing stop buffer 
allowed the thrombin concentration of each subsample to be determined at the end of 
each run. 
The shear rates studied were similar to those found in static, venous and arterial 
conditions, and these were seen to have some physical effects on both endothelial 
cells and platelets. The endothelial cells appear unaffected by shear stress when 
examined by light microscopy, but immunofluorescent examination revealed changes 
to the actin cytoskeleton that appeared to align with the direction of flow. The 
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activation marker P-selectin was not detected on the surface of the endothelial cells, 
suggesting that they were not activated by shear stress. Platelets adhered to 
endothelial cells regardless of the presence of flow, but larger aggregates were seen 
after perfusion than after static incubation. P-selectin was detected on the surface of 
platelets in both cases and may be the result of platelet activation by small amounts 
of thrombin generated in the recalcified plasma. 
Coagulation, as determined by measurement of thrombin generation, was seen to 
increase under flow conditions and to increase dramatically in the presence of 
platelets. Coagulation was seen to be occurring in the fluid phase and not to be 
restricted to the vicinity of the vessel wall, as coagulation still occurred when the 
vessel wall was pre-treated with albumin. However, the vessel wall did appear to 
have an influence under static conditions where significantly less thrombin was 
generated in the presence of intact endothelium than extracellular matrix. The 
absence of red blood cells in the perfusate is a limitation of the system that may 
reduce platelet interaction with endothelial cells or extracellular matrix, but was a 
necessary omission to enable the detection of thrombin. 
The NIBSC flow system is a useful device for the study of coagulation in the 
presence of the highly relevant factors such as shear stress, vessel wall components 
and platelets. The study of inhibitors of coagulation in this system may give in vitro 
data that is more pertinent to the in vivo situation than more conventional 
approaches. 
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CHAPTER 4 
ANTI-PLATELET ANTIBODIES 
l25 
4.1 Introduction 
Platelets playa critical role in primary and secondary haemostasis, and they are 
therefore potential targets for anti thrombotic agents. Inhibition of platelet function 
by aspirin is effective but non-specific, and inhibitors of platelet ADP receptors (such 
as clopidogrel) are under investigation as specific anti-platelet agents, as discussed in 
Section 1.3.7.4. Direct inhibition of the adhesive and aggregatory receptors and the 
inhibition of coagulation factor interaction on the platelet membrane are therefore 
alternative routes by which the contribution of platelets to coagulation may be 
specifically modulated. 
4.1.1 Inhibitors of GP lIb/IlIa 
Antagonists of GP lIb/IlIa, the main aggregatory receptor on the platelet membrane, 
will clearly inhibit the ability of activated platelets to aggregate. In addition to this 
effect, in vitro studies have shown that antibodies and peptide and non-peptide 
antagonists of GP lIb/IlIa can partially inhibit the generation of thrombin in a platelet 
dependent system, indicating that anti-platelet agents interfere with coagulation. 
(Reverter et ai, 1996; Pedicord et ai, 1998; Herault et ai, 1998; Butenas et ai, 2001). 
There is evidence that anti-GP lIb/IlIa agents inhibit the exposure of negatively 
charged phospholipids on the platelet membrane (Pedicord et ai, 1998). GP lIb/IlIa 
antibodies have also been reported to interfere with the shape change seen in 
activated platelets and it is possible that this may limit the activation of the platelet 
and the scrambling of the membrane (Isenberg et ai, 1990). This would contribute to 
their effectiveness as anti thrombotic drugs, as in addition to preventing the cross-
linking of platelets at sites of injury they may also be able to inhibit the coagulation 
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cascade. It has also been reported that prothrombin binds to resting GP lIb/IlIa on 
platelets (Byzova & Plow, 1997) where it is held in close proximity to the 
prothrombinase complex that assembles on the membrane, thus facilitating 
prothrombin conversion. An agent with higher affinity for GP lIb/IlIa may displace 
prothrombin from its convenient position and reduce the rate of conversion. 
4.1.2 Inhibitors of GP Ib/IXIV 
The main function of the GP Ib/IXIV complex is to mediate adhesion of the platelet 
to areas of damage to the vessel wall, as discussed in Section 1.2.1.1, and 
interference with this process will therefore inhibit primary haemostasis. The 
GP Ib/IXIV complex also functions as a high affinity receptor for thrombin (Hannon 
& Jamieson, 1986; Hannon & Jamieson, 1988; Dong et ai, 1997) and inhibition of 
the complex may interfere with platelet activation (De Marco et ai, 1991; Yamamoto 
et ai, 1991) and therefore have an effect on secondary haemostasis. A link between 
fibrin, vWF and GPIbu has also been demonstrated to play a role in platelet 
dependent thrombin generation (Beguin et ai, 1999). In addition, the GP Ib/IXIV 
complex has been shown to be a high affinity binding site for FXI, promoting its 
activation by thrombin and therefore potentiating intrinsic activation of coagulation 
(Baglia et ai, 2002). 
4.1.3 Studies undertaken 
Platelet aggregometry was used as a screening test to ensure that the antibodies used 
were indeed platelet inhibitors and to assess the effective concentrations to be studied 
further in other assay systems. The thrombin generation test was chosen as the most 
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appropriate method for the analysis of coagulation for reasons detailed in 
Section 2.8. Studies were performed using intrinsic stimulation and extrinsic 
stimulation with either high (630 pM) or low (35 pM) TF under static conditions 
using the clotting method for thrombin detection. When this section of work was 
begun, the software required for analysis of chromogenic thrombin detection data 
was not yet available. Following the studies using intrinsic and high TF extrinsic 
stimulation, and those of others (van't Veer & Mann, 1997; Cawthem et ai, 1998; 
Keularts et ai, 2001; Butenas et ai, 2001), it was decided to proceed with low TF 
extrinsic stimulation as the most physiologically relevant method, and studies began 
using the Type 1 flow chamber (see Section 3.2.4.2), using the chromogenic method 
of thrombin detection. It was only possible to generate a relatively low shear rate in 
the Type 1 flow chamber, so the Type 2 chambers were designed and commissioned, 
enabling studies at higher shear rates without excessive consumption of reagents. 
The inhibitory effects of the anti-platelet antibodies that were detected in the 
thrombin generation tests were analysed further. Flow cytometry was used to 
examine the effect of the antibodies on the exposure of negatively charged 
phospholipids on the surface of the platelet membrane. Assays to detect the presence 
of soluble fibrin in defibrinated plasma and the inclusion of an anti-vWF antibody in 
thrombin generation tests were used to examine the influence of the fibrin-vWF-
GP Iba pathway on thrombin generation. 
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4.2 Materials and Methods 
4.2.1 Antibodies 
RFGP56 is a murine monoclonal IgG 1 that binds to a complex-specific epitope on 
GP lIb/IlIa. It does not bind to platelets from patients with Glanzmann's 
Thrombasthenia (GT) or to EDT A-treated platelets, but it does bind to platelets from 
patients with Bernard-Soulier Syndrome (BSS). It totally inhibits platelet 
aggregatory responses to thrombin, collagen, ADP, arachidonate and calcium 
ionophore A23187. It also inhibits the binding of fibrinogen and vWF to platelets 
(Cox, 1991). The antibody was produced by Cymbus Biotechnology (Southampton, 
UK) under contract from the owner of the hybridoma, Dr Alison H. Goodall 
(University of Leicester, UK). 
RFGP37 is a murine monoclonal IgG1 that binds to GP Ibu. It binds to platelets 
from patients with GT but does not bind to platelets from patients with BSS. It 
completely inhibits ristocetin-induced platelet agglutination and adhesion of platelets 
to vWF under conditions of high shear (Cox, 1991). The antibody was produced by 
Cymbus Biotechnology (Southampton, UK) under contract from the owner of the 
hybridoma, Dr Alison H. Goodall. A single production batch was used for all 
experiments at 0 and 18 s -I and some experiments at 178 and 600 s -I. Subsequent 
batches gave conflicting results in routine platelet aggregometry tests, and 
investigations by Dr Goodall led to the conclusion that the batches were 
contaminated with another antibody, possibly RFGP56. Serotec (Oxford, UK), 
another biotechnology company, was then contracted to produce fresh antibody from 
hybridoma cells supplied by Dr Goodall. This antibody performed as expected in 
platelet aggregometry, in that it inhibited ristocetin-induced agglutination, and flo\\' 
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cytometry in Dr Goodall's laboratory. A full set of thrombin generation experiments 
were therefore performed at 178 and 600 S-I. Due to the different properties of 
RFGP37 produced by Cymbus or Serotec, the company name is reported alongside 
the antibody name in the results section. In addition, a small quantity of RFGP37 
(batch ST0802) was purified from supernatant harvested from cultures of the 
hybridoma in 1994 and stored at -80°C. Antibody from 25 ml of the supernatant 
was captured on a 1 ml Protein G column (Amersham Biosciences, Chalfont St 
Giles, UK), eluted at pH 2.7, and dialysed into TBS. 
c7E3 was a gift from Centocor Ltd, Malvern, USA. It is a chimeric Fab fragment, 
with mouse variable regions and human constant regions (Centocor commercial 
information), of a murine IgG immunoglobulin against GP lIb/IlIa and aV~3 (Coller 
et aI, 1983). 
Reg A, a MAb against the Rhesus D antigen on red blood cells (Bye et aI, 1992), was 
used as a negative control in platelet aggregation and flow cytometry assays. It was 
a gift from Dr Willem Ouwehand of the Division of Transfusion Medicine, 
University of Cambridge, UK. 
RFFVIll:Rll, a monoclonal antibody against the GP Iba binding site on vWF, was a 
gift from Dr Alison H Goodall of the Division of Clinical Biochemistry, University 
of Leicester, UK. The ammonium sulphate cut of ascites (> 9 mglml) was diluted in 
TBS before use. 
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4.2.2 Platelet aggregation 
Platelet aggregation assays were perfonned on a BioData P AP-4 Aggregometer 
(Alpha Laboratories, Eastleigh, UK). A platelet pellet was prepared as described in 
Section 2.7 and resuspended in 1 ml of TSHG buffer, which comprised 0.05 M 
Tris(hydroxymethyl) aminomethane 0.15 M NaCI, 5 mM glucose (BDH reagents 
from Merck, Poole, UK) and 0.5 % v/v HSA (Zenalb, BPL, Elstree, UK) adjusted to 
pH 7.4). The platelet count was adjusted to a final concentration of 250 x 106 per ml 
and 178 ~l of the platelet suspension and 22 ~l of either TBS or antibody (up to 
180 ~g/ml in TBS) were incubated at 37°C with stirring at 1000 rpm for 5 minutes. 
Aggregation was stimulated with 20 ~l of human a-thrombin solution (final 
concentration 0.05 - 0.5 ill/ml; NIBSC reagent 941708 diluted in TBS + 1 % HSA). 
Results were calculated from the aggregation seen 5 minutes after the addition of 
thrombin and aggregation seen in the absence of any antibody (TBS alone) was taken 
to be 100%. 
4.2.3 ELISA to evaluate specificity and inhibition of thrombin binding of 
anti-GP Iba antibodies 
These assays were perfonned by Mr Hans Ulrichts, University of Leuven, Kortrijk, 
Belgium. Unless otherwise stated, the reagents used were from Sigma, Bomem, 
Belgium and the monoclonal antibodies and recombinant proteins were made in 
house. 
131 
4.2.3.1 To evaluate the specificity of anti-GP fba monoclonal antibodies 
Ninety-six well microtiter plates (Greiner, Frickenhausen, Germany) were coated 
overnight at 4 °C with the antibodies (5 pglml in PBS), blocked with 250 pllwell of 
TBS + 3 % milk powder and incubated for 2 hours at 37°C with a dilution series of 
recombinant GP Ibal-289 in TBS + 0.1 % Tween-20 (TBST), starting from 2.5 pglml. 
Wells were washed 12 times with TBST, and bound recombinant GP Ibal-289 was 
detected with 1 pglml of biotinylated anti-GP Iba MAbs 6B4 and 12G 1 for 
90 minutes at room temperature. Bound biotinylated anti-GP Iba MAb 6B4 and 
MAb 12G 1 were detected with streptavidin conjugated horseradish peroxidase for 
45 minutes at room temperature. Visualisation was obtained with ortho-
phenylenediamine and the colour reaction was stopped with 4 M H2S04 after which 
the absorbance was determined at 490 nm. 
4.2.3.2 To evaluate inhibition of thrombin binding to recombinant GP fba. 
Wells were coated with 5 pglml of anti-GP Iba MAb 12G 1 overnight at 4 °C and 
blocked for 2 hours at room temperature with 1 % bovine serum albumin. After 
washing, wells were incubated for 60 minutes at 4 °C with 1 pglml recombinant 
GP Iba. Wells were washed and preincubated with a dilution series of the anti-
GP Iba MAbs, the positive control MAb 2D2 and negative control MAb 16G5. 
After 30 minutes at 4 °C a constant amount of a-thrombin was added (0.75 pM final 
concentration). After 60 minutes incubation at 4°C, wells were washed and residual 
bound a-thrombin was detected with the chromogenic substrate S-2238 
(Chromogenix-Instrumentation Laboratory, Milan, Italy). 
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4.2.3.3 To evaluate inhibition o/thrombin binding to glycocalicin 
Wells were coated with 2 }1g1ml recombinant glycocalicin overnight at 4 °C and 
blocked for 2 hours at room temperature with 1 % bovine serum albumin. After 
washing, wells were preincubated with a dilution series of the anti-GP Iba MAbs. 
the positive control MAb 2D2 and negative control MAb 16G5. After 30 minutes at 
4 °C a constant amount of a-thrombin was added (0.75 pM final concentration). 
After 60 minutes incubation at 4°C, wells were washed and residual bound a-
thrombin was detected with chromogenic substrate S-2238. 
4.2.4 Thrombin generation tests under static and flow conditions 
The inhibitory effects of the antiplatelet antibodies on thrombin generation were 
studied under static and flow conditions using low TF as a stimulus as described in 
Section 2.8. 
4.2.5 Expression of negatively charged phospholipids 
The 'flip-flop' of the platelet membrane leading to the exposure of negatively 
charged phospholipids was studied using fluorescein isothiocyanate conjugated 
(FITC) annexin-5A. Annexin-5A binds to phosphatidylserine (PS), one of the 
negatively charged phospholipids exposed during the 'flip-flop' (Reutelingsperger, 
2001). 
4.2.5.1 Annexin-5A binding 
Reaction mixtures were prepared as described for extrinsic thrombin generation (see 
Section 2.8.1.2). Thrombin generation was initiated by the addition of either low TF 
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(see Section 2.3) in 100 mM CaCh or eaCh alone for negative controls. Thrombin 
generation experiments had shown that maximum thrombin generation occurred after 
12 minutes. At this time, 20 J.ll subsamples were taken into 180 J.ll HEPES-buffered 
saline (HBS; 0.01 M HEPES, 0.14 M NaCl, 0.025 M CaCh, pH 7.4) containing 
20 J.lglml recombinant hirudin (Novartis, Basel, Switzerland), an approximate tenfold 
molar excess. Five J.ll samples of this mixture were mixed with 495 J.ll of HBS 
containing 1 J.lg of FITC-conjugated annexin-5A (Tau Technologies, Kattendijke, 
The Netherlands). The samples were incubated at room temperature for 10 minutes 
before analysis in a flow cytometer. 
4.2.5.2 Flow cytometry 
Binding of FITC-annexin-5A to the platelets was measured using a F ACScan flow 
cytometer (Becton Dickinson, San Jose, USA). Platelets were distinguished from 
other blood cells and debris based on their forward and 90° light scatter profile (dot 
plot). A region was drawn around the platelet population and 10 000 events were 
analysed with the gain setting in the logarithmic mode. The threshold above which 
the platelets were considered positive was determined by setting a cursor on the 
histogram so that < 30/0 of the unstimulated platelets incubated with TBS and Ca2+ 
alone showed fluorescence above this level. 
For each antibody treatment, the difference in the percentage of positive platelets 
between those stimulated with both TF and Ca2+ and those incubated with Ca2+ in the 
absence of TF was calculated (to correct for background levels caused by activation 
of platelets during handling). This value was then divided by that obtained from the 
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control (TBS treated) cells to obtain the percentage of control levels of annexin-5A 
binding. 
4.2.6 Measurement of soluble fibrin in defibrinated plasma 
The presence of soluble fibrin in defibrinated plasma was measured by ELISA 
(Edgell & Gaffney, 1996). A monoclonal capture antibody 5F3 (NIBSe in-house 
reagent), against fibrin and its fragments, was coated onto Maxisorp 96 well plates 
(Nunc Nalgene, from Invitrogen, Paisley, UK). Dilutions of the defibrinated plasma 
were prepared in citrate saline (150 mM NaCI, 109 mM trisodium citrate, BDH, 
Poole, UK) containing 1 mg/ml of the peptide Glycine-Proline-Arginine-Proline 
(Pentapharm, Basel, Switzerland) to inhibit cross-linking of fibrin. The sample 
dilutions were incubated in the coated wells before washing and detection with 
biotinylated MAb All, against the intact carboxy terminal of the Au chain of 
fibrin(ogen). The biotin was detected with streptavidin-HRP (Dako, Glostrup, 
Denmark), and o-toluidine (Sigma, Poole, UK) used as the substrate. Different 
defibrination methods were compared, including ancrod, (a venom protein from the 
snake Agkistrodron rhodostroma that cleaves fibrinopeptide A and slowly activates 
FXIII; Gaffney & Brasher, 1974), batroxobin (a venom protein from the snake 
Bothrops atrox moojeni that also cleaves fibrinopeptide A from fibrinogen, but does 
not activate FXIII (Gaffney & Edgell, 1998), immunoprecipitation and heat 
defibrination. 
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4.2.7 Immunofluorescent staining of platelets and HUVEC 
In order to visualise the binding of RFGP56 and RFGP37 to platelets, and to 
investigate potential cross-reactivity of the anti-platelet antibodies with HUVEC. 
immunofluoresence was perfonned as follows. 
Platelet plasma was prepared as detailed in Section 2.7 and incubated for 30 minutes 
at 37°C with 20 /-lg/ml of RFGP56, Serotec RFGP37 or rabbit anti-vWF polyclonal 
antibody (Dako, Glostrup, Denmark). A drop of the cell suspension was then applied 
to a glass coverslip and washed, fixed and stained as described in Section 2.11. 
HUVEC were cultured on Thennanox coverslips as described in Section 2.9, 
washed, fixed and incubated with antibodies, as before. The secondary antibodies 
were FITC rabbit anti-mouse or FITC swine anti-rabbit IgG (both from Dako, 
Glostrup, Denmark) and stains for actin and for nuclear material were also included, 
as detailed in Section 2.11. 
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4.3 Results 
4.3.1 Platelet aggregation 
The anti-GP lIb/IlIa antibody RFGP56 inhibited platelet aggregation with a final 
thrombin concentration of 0.5 ill/ml in a dose-dependent manner. Aggregation was 
reduced to 68.2 ± 3.2, 24.8 ± 9.5 and 19.0 ± 6.2 % with 5, 10 and 20 )lg/ml RFGP56 
respectively (all p < 0.01; see Figure 4.1). Similar inhibition was seen with c7E3 at 
20 /-lglml, reducing platelet aggregation to 24.7 ± 6.2 % (p < 0.01). The anti-GP Iba 
antibody RFGP37 did not inhibit platelet aggregation at 20 /-lglml (Cymbus 
113.0 ± 29.6 %, ns; Serotec 136.0 ± 77.2, % not shown) or at concentrations as high 
as 120 /-lglml (Cymbus 137.7 ± 28.8 %, not shown). 
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F(ab ')2 fragments of Cymbus RFGP37 also failed to inhibit thrombin-induced 
aggregation (103 .8 ± 13 .7 % at 20 )lg/ml ). Control antibody RegA had no effect on 
aggregation at 20 )lg/ml (93 .7 ± 5.8 %). 
As shown in Figure 4 .2, when concentrations of thrombin lower than 0.5 fU/ml were 
used, Cymbus RFGP3 7 became able to inhibit platelet aggregation. Increased 
inhibition was seen with 20 )lg/ml of Cymbus RFGP37 in response to progressively 
lower concentrations of thrombin. Serotec RFGP37 did not produce this inhibition. 
This effect was not seen with 20 )lg/ml of RFGP56, which gave maximal inhibition 
of aggregation at all concentrations of thrombin. 
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4.3.2 ELISA to evaluate the specificity and inhibition of thrombin binding of 
anti-GP lba antibodies 
Figure 4.3 shows that different batches of RFGP37 have differing abilities to bind to 
the recombinant fragment of GP lba consisting of residues 1 - 289 (GP lbUI -189). 
The batch that shows the best inhibition (ST0802) was purified using Protein G from 
cell culture supernatant frozen in 1994. All other batches were produced more 
recently by the biotechnology finns Cyrnbus and Serotec, using freshly grown 
hybridoma cells. The original batch of Cyrnbus RFG P3 7 used in platelet 
aggregation, flow cytometry and thrombin generation experiments (batch 297 J) was 
not available for testing. The Cyrnbus batches shown in Figure 4.3 were the 
replacement batches supplied when stocks of 297 J were exhausted. 
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reaction was stopped with 4 M H2S04. Data are from a single experiment. 
pel/o rmed by Mr Hans Ulrichts of Th e Un iver if) ' of Leuven. Kortrijk. Belgium. 
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Figure 4.4 shows that di fferent batche of RFGP37 have a variety of inhibitory 
activities against the binding of thrombin to glycocalicin or the recombinant 
fragment of GP Ibal -289 . The data are from a single assay, making stati stical analys is 
impossible, but it would be impossible to claim that any specific inhibition of 
thrombin binding was evident. 
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a-thrombin. After 60 minutes incubation at 4 "C the bound thrombin was detected 
with chromogenic substrate 52238. Data are fro m a single experiment, peljonned 
by Mr Hans Ulrichts, University of Leuven, Kortrijk, Belg ium. 
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4.3.3 Thrombin generation under static conditions following intrinsic stimulation 
Thrombin generation was performed in polystyrene tubes, using kaolin as the 
stimulus (as detailed in Section 2.8.1.1), and the clotting system for thrombin 
determination (see Section 2.8.4.1). Thrombin generation curves from sample 
experiments are shown in Figure 4.Sa to illustrate the effect of the antibodies on 
thrombin generation. No thrombin was detectable in the absence of platelets, 
indicating that this was a platelet-dependent system. 
From the platelet aggregation data in Section 4.3.1 and from previously published 
data for c7E3 (Reverter et ai, 1996), 20 f.lglml was judged to be a saturating 
concentration of antibody and selected for study in the thrombin generation test. 
Figure 4.Sb shows that at 20 f.lglml antibodies against both GP lIb/IlIa and GP Iba 
inhibited total thrombin generation in this system, measured by AUC. RFGPS6 
reduced thrombin generation to 2S.1 ± 2.9 % (p < 0.01) of control levels but c7E3 
was less effective, reducing thrombin generation to SO.4 ± 22.4 % (p < 0.01). 
Cymbus RFGP37 reduced thrombin generation to 69.1 ± 3.9 % of control levels 
(p < O.OS). No further inhibition was seen in a single experiment using 40 f.lglml of 
either RFGPS6 or RFGP3 7. Figure 4.Sc shows that similar effects were seen when 
peak thrombin generation was analysed. No significant differences were seen in the 
time of the thrombin peak in the presence of any antibody when compared with the 
control (Figure 4.Sd). 
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Inhibition of thrombin generation by anti-platelet antibodies following intrinsic 
stimulation under static conditions. 
800 J.11 of defibrinated p lasma containing 300 x 106 platelets was incubated for 
20 minutes at 37 DC with 25 J.11 ofTES containing the antibody under fest and 100 J.11 
of 100 mg/ml kaolin suspension in TES Thrombin generation was initiated with 
75 J.1 1 of 200 mM CaCl l and timed subsamples were taken info fibrinogen f or 
determination of thrombin concentration. 
a) Representative thrombin generation curves fro m single experiments and the effect 
of antibodies on b) A UC. c) peak thrombin and d) time of peak thrombin. *p < 0. 0 . 
**p < 0.01 . 
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Inhibition of thrombin generation by anti-platelet antibodies fo llowing intrinsic 
stimulation under static conditions. 
800 J.1 1 of defibrinated plasma containing 300 x 106 platelets was incubated for 
20 minutes at 37°C with 25 J.1 1 of TBS containing the antibody under test and 100 J.11 
of 100 mg/ml kaolin suspension in TBS Th rombin generation was initiated with 
75 J.11 of 200 mM CaCI2 and timed subsamples were taken into fibrinogen for 
determination of thrombin concentration. 
a) Representative thrombin generation curves from single experiments and the effect 
of antibodies on b) A UC, c) peak thrombin and d) time of peak thrombin. *p < 0.05, 
**p < 0.01 . 
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4.3.4 Thrombin generation under static conditions following high TF stimulation 
Thrombin generation was performed in polystyrene tubes as detailed in 
Section 2.8.1.2, using high TF as the stimulus (see Section 2.3) and the clotting 
system for thrombin determination, as detailed in Section 2.8.4.1. Thrombin 
generation curves from sample experiments are shown in Figure 4.6a to illustrate the 
effect of the antibodies on thrombin generation and shows that all of the antibodies 
tested had reduced inhibitory effects compared to those in the intrinsic system 
described in Section 4.3.3. At 20 J-lglml, RFGP56, c7E3 and Cymbus RFGP37 
caused reductions in thrombin generation measured by AVC to 76.6 ± 13.6 
(p < 0.05), 86.6 ± 2.0 (ns) and 83.4 ± 6.0 % (ns) of control levels respectively. In the 
absence of platelets, the addition of high TF resulted in 63.2 ± 17.2 % of control 
levels of thrombin being generated, suggesting that only approximately 40 % of 
thrombin generation in this system is platelet dependent (Figure 4.6b). Analysis of 
the peak concentration of thrombin gave similar results to the AVC data, with 
20 J-lglml of RFGP56, c7E3 and Cymbus RFGP37 reducing the peak to 64.4 ± 12.0 
(p < 0.05), 80.6 ± 21.8 (ns) and 73.3 ± 9.4 % (ns) of control levels respectively. In 
the absence of platelets, 52.2 ± 5.6 % of the peak thrombin concentration in control 
experiments was generated, confirming the significance of platelet-independent 
thrombin generation in this system (Figure 4.6c). The time of the peak concentration 
of thrombin was not significantly affected by the presence of antiplatelet antibodies 
but tended to be later at 138.2 ± 44.4, 151.9 ± 46.8 and 131.1 ± 19.9 with RFGP56, 
c7E3 and Cymbus RFGP37 respectively. In the absence of platelets the peak was 
seen at 151.9 ± 45.6 % of the time in the presence of platelets and, although this was 
not significant, it may suggest that platelets accelerate the generation of thrombin in 
this system (Figure 4.6d). 
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Figure 4.6 
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Inhibition of thrombin generation by anti-platelet antibodies following extrinsic 
stimulation with high TF under static conditions. 
800 )11 of defibrinated plasma containing 300 x 106 platelets was incubated fo r 
30 minutes at 37 °C with 25 )1 1 of TBS containing the antibody under test. Thrombin 
generation was initiated with 175 )1 1 of 100 mM CaCll containing recombinant 
tissue factor to g ive a final concentration of 630 pM. Tim ed subsamples were taken 
into fibrin ogen for determination of thrombin concentration. 
a) Representative thrombin generation curves fro m single e.xperiments and the effect 
of antibodies on b) A Uc, c) peak thrombin and d) time of peak thrombin. *p < 0.05. 
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Figure 4.6 
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Inhibition of thrombin generation by anti-platelet antibodies following extrinsic 
stimulation with high TF under static conditions. 
800 f.1 1 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 nc with 25 f.1 1 of TBS containing the antibody under test. Thrombin 
generation was initiated with 175 f.1 1 of 100 mM CaCl l containing recombinant 
tissue factor to g ive a final concentration of 630 pM. Timed subsamples were taken 
into fibrinogen for determination of thromb in concentration. 
a) Representative thrombin generation curves from sinole experiments and the effect 
of antibodies on b) A Uc. c) peak thrombin and d) time of peak thrombin. *p < 0.05. 
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4.3.5 Thrombin generation under static conditions following low TF stimulation 
Thrombin generation was perfonned in polystyrene tubes as detailed in 
Section 2.8.1.2, using low TF as the stimulus (see Section 2.3) and the clotting 
system for thrombin detennination, as detailed in Section 2.8.4.1. Anti-GP IlblIIIa 
antibodies had similar inhibitory effects in this system compared to the intrinsic 
system (see Table 4.1). Thrombin generation curves from sample experiments are 
shown in Figure 4.7a to illustrate the effect of the antibodies on thrombin generation. 
At 20 f.lglml, RFGP56 and c7E3 reduced thrombin generation detennined by AVC to 
47.3 ± 5.9 % and 59.9 ± 21.2 % of the control level respectively (p < 0.01; 
Figure 4.7b). Five f.lglml Cymbus RFGP37 reduced AVC thrombin generation to 
68.5 ± 14.3 % of the control level (p < 0.01), but there was no further increase at 
20 f.lglml (81.0 ± 1.3 %; ns). A dose response was seen with RFGP56, but linear 
regression showed this to be not significant (r2 = 0.44; P = 0.052). No significant 
dose response was seen with RFGP37. All antibodies were able to reduce the peak 
concentration of thrombin generated. Twenty f.lglml of RFGP56, c7E3 and RFGP37 
reduced the peak to 23.8 ± 5.7, 29.1 ± 13.0 and 74.9 ± 3.6 % of control values (all 
p < 0.01; Figure 4.7c) and RFGP56 reduced the peak thrombin generation in a dose-
dependent manner (r2 = 0.52; p < 0.05, not shown). None of the antibodies was able 
to delay significantly the peak of the thrombin generation curve (Figure 4.7d). 
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Table 4.1 Inhibition of thrombin generation by anti-platelet antibodies following different 
methods of stimulation. 
Intrinsic stimulation was achieved by incubating 800 J1l of defibrinated plasma 
containing 300 x 106 platelets for 20 minutes at 37 "C with 25 j.1/ of TBS containing 
the antibody under test and 100 j.11 of 100 mg/ml kaolin suspension in TBS. 
Thrombin generation was initiated with 75 j.11 of 200 mM CaCl~. Extrinsic 
stimulation was achieved by incubating 800 j.11 of defibrinated plasma containing 
300 x 106 platelets for 30 minutes at 37°C with 25 j.11 ofTBS containing the antibody 
under test. Thrombin generation was initiated with 175 j.11 of 100 mM CaCl] 
containing recombinant tissue factor to give a final concentration of either 630 or 
35 pMfor 'high' or 'low' TF respectively. In all cases timed subsamples were taken 
into fibrinogen for determination of thrombin concentration. Data are A UC as % 
control; mean I sd; n ~ 3; *p < 0.05; **p < 0.01 
Antibody (20 Jlglml) 
Stimulus 
RFGP56 c7E3 RFGP37 
Intrinsic 25.1 ± 2.9 ** 50.4 ± 22.4 ** 69.1 ± 3.9 * 
High TF Extrinsic 74.6 ± 13.6 ** 86.6 ± 2.0 83.4 ± 6.0 
Low TF Extrinsic 47.3 ± 5.9 ** 59.9 ± 2l.2 ** 8l.0 ± l.3 
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Inhibition of thrombin generation by anti-platelet antibodies fo llowing extrinsic 
stimulation with low TF under static conditions. 
800 pI of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 pI ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 pI of 100 mM CaCll containing recombinant 
tissue factor to give a final concentration of 35 pM. Timed subsamples were taken 
into fibrinogen fo r determination of thrombin concentration. 
a) Representative thrombin generation curves from inale experiments and the effect 
of antibodies on b) A Uc. c) peak thrombin and d) time of peak thrombin. 
**p < 0.01. 
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Inhibition of thrombin generation by anti-platelet antibodies following extrinsic 
stimulation with low TF under static conditions. 
800 j.1 1 of defibr inated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 j.11 ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 j.1 1 of 100 mM CaC/] containing recombinant 
tissue factor to g ive a fina l concentration of 35 pM. Timed subsamples were taken 
into fibr inogen for determination of thrombin concentration. 
a) Representative thrombin generation curves from single experiments and the effe t 
of antibodies on b) A UC, c) peak thrombin and d) time of peak thrombin. 
**p < 0.01 . 
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In the absence of platelets, none of the antibodies showed significant inhibition of 
thrombin generation following stimulation under static conditions with low TF (see 
Figure 4.8). 
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Effect of anti-platelet antibodies on thrombin generation fo llowing low TF 
stimulation in p latelet poor plasma. 
800 f.ll of defibr inated plasma without platelets was incubated fo r 30 minutes at 
37 "C with 25 f.l l of TBS containing the antibody under test. Thrombin generation 
was initiated with 175 f.ll of 100 mM CaCl] containing recombinant tissue fac tor to 
give a fina l concentration of 35 pM. Timed subsamples were taken into fibrinogen 
for determination of thrombin concentration. Mean j: sd: n = 3. 
It has previously been reported that concentrations of c7E3 above 10 Ilg/ml (200 nM 
of monovalent Fab) inhibited prothrombinase activity when phospholipid vesicles 
were used in place of platelets (Pedicord et aI, 1998). Experiments were therefore 
performed using a phospholipid preparation (NIBSC 91 /542 , diluted 11125 in TBS) 
in place of platelets. No significant inhibition of thrombin generation was een with 
20Ilg/ml (133 nM of bivalent IgG) of RFGP56 (96 .8 ± 18.3 %) Cymbu RFGP37 
(76.0 ± 20.5 %) or c7E3 (97.4 ± 23 .1 %). data not sho n. 
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In combination, RFGP56 and Cymbus RFGP37 had an additive effect, with 20 )1g!ml 
of each antibody reducing thrombin generation (AUC) to 28.1 ± 12.6 % of the 
control level (p < 0.01). This effect was dose dependent (r2 = 0.49 ; P < 0.01; see 
Figure 4 .9a) as 10 and 5 )1g!ml of both antibodies together reduced thrombin 
generation (AUC) to 46.6 ± 19.7 % and 77.6 ± 16.4 % respectively. A simi lar dose-
dependent reduction of peak thrombin generation was seen with both antibodies 
together (r2 = 0. 7; P < 0.001 ; see Figure 4.9b), but no effect was seen on the time of 
the peak of the thrombin generation curve (Figure 4.9c). 
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RFGP56 following extrinsic stimulation with low TF under static conditions. 
800 j.J I of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 j.JI ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 j.JI of 100 mM CaC/] containing recombinant 
tissue factor to give a final concentration of 35 pM. Timed subsamples were taken 
into fibrinogen for determination of thrombin concentration. 
a) A UC b) peak thrombin and c) time 0.[ peak thrombin. 
Mean :t sd; *p < 0.05, **p < 0.01 , ***p < 0.001 . 
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Dose response curves showing inhibition of thrombin generation by RFGP37 and 
RFGP56 following extrinsic stimulation with low TF under static conditions. 
800 j.ll of defibrin ated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 j.l l ofTBS containing the antibody under test. Thrombin 
generation was initiated with /75 j.l l of 100 mM CaC/2 containing recombinant 
tissue factor to g ive a final concentration of 35 pM. Timed subsamples were taken 
into fibrin ogen for determination of thrombin concentration. 
a) A UC b) p eak thrombin and c) time of peak thrombin. 
Mean :.t sd; *p < 0.05, **p < 0.01 , *-**p < 0.001 . 
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4.3.6 Thrombin generation under static or flow conditions in the presence of 
HUVEC or ECM following low TF extrinsic stimulation 
Thrombin generation was performed as detailed in Section 2.8.1.2, using low TF as 
the stimulus (see Section 2.3), in the presence of HUVEC or ECM under static or 
flow conditions, as detailed in Sections 2.8.2 and 2.8.3 respectively. The 
chromogenic system detailed in Section 2.8.4.2 was used for thrombin determination. 
Following on from the static studies that established the low TF extrinsic stimulation 
as a platelet-dependent thrombin generation system, the antiplatelet antibodies were 
studied in parallel plate flow chambers (described in Section 3.2.4.2) to examine 
their inhibitory effects under flow conditions. Early studies were performed using 
the Type 1 flow chamber at a relatively low shear rate of 18 S-l before the Type 2 
chambers became available for later studies at shear rates up to 600 S-l. The floor of 
the flow chambers comprised a tissue culture slide or coverslip upon which HUVEC 
had been cultured (and sometimes removed to expose ECM), and in order to make 
valid comparisons with results obtained under flow conditions, static experiments 
were repeated using culture wells containing HUVEC or ECM. 
4.3.6.1 RFGP56 
When thrombin generation was measured under static conditions in the presence or 
absence of HUVEC, there was no significant difference in the inhibitory effect of 
RFGP56. Twenty /-lg/ml RFGP56 inhibited AUC to 54.2 ± 10.2 % of control values 
in the presence of HUVEC, compared to 47.3 ± 5.9 % in the absence of HUVEC in 
polystyrene test tubes (as reported in Section 4.3.5, using the clotting method of 
thrombin determination). The introduction of shear stress led to reduced inhibition in 
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the presence of HUVEC by 20 !J.glml RFGP56, to 88.6 ± 22.4, 81.8 ± 5.7 and 
65.2±19.2 % of control AUC at 18, 178 and 600 s-' respectively (Figure4.10b). 
Increasing the concentration of RFGP56 up to 80 !J.glml did not have any further 
inhibitory effect, but over the full range of concentrations up to 80 !J.glml, ANOV A 
revealed that RFGP56 was a significantly better inhibitor under static (0 S-l) and 
arterial conditions (600 s-') when compared with venous conditions (18 and 178 s-'). 
This was the case when measuring AUC and peak thrombin concentration 
(Figure 4.1 Oc), but no significant differences were noted for the time of the peak 
(Figure 4.1 Od). 
In the presence of ECM, thrombin generation under static conditions was reduced to 
70.0 ± 18.6 % by 20 !J.glml RFGP56 (see Figure 4.11). The introduction of shear 
stress in the presence of ECM abolished the significance of this inhibitory effect, 
with AUC of 1l0.7± 19.7,79.6 ± 22.8 and 72.4 ± 20.6 at 18, 178 and 600 s-' 
respectively (Figure 4.11a). Increasing the concentration ofRFGP56 up to 80 !J.glml 
did not have any further inhibitory effect, but ANOV A revealed that RFGP56 was 
more effective at reducing the peak thrombin concentration under static (0 S-l) and 
arterial conditions (600 s-') when compared with venous conditions (18 and 178 s-'; 
Figure 4.11c). No significant differences were noted for AUC (Figure 4.11b) or time 
of peak thrombin (Figure 4.11 d). 
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Figure 4.10 
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Thrombin generation following extrinsic stimulation with low TF under flolV 
conditions in the presence of HUVEC and RFGP56. 
800 pi of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 pi of TBS containing the antibody under test. Thrombin 
generation was initiated with 175 pi of 100 mM CaC/] containing recombinant 
tissue factor to g ive a fina l concentration of 35 pM. Tim ed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
aJ Representative thrombin generation curve. fro m a . ingle experiment and the 
effect of RFGP56 on b) A Uc. c) peak thrombin and d) time of peak thrombin. 
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Figure 4. 10 
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Thrombin generation fo llowing extrinsic stimulation with lo w TF under flow 
conditions in the presence of HUVEC and RFGP56. 
800 J.1/ of defibrinated plasma contain ing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 J.1/ ofTBS containing the antibody under test. Thrombin 
generation was initiated with /75 J.1I of 100 mM CaC!2 containing recombinant 
tissue factor to give a final concentration of 35 pM. Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate 52238. 
a) Representative thrombin generation curves from a single experiment and the 
effect of RFGP56 on b) A Uc. c) peak thrombin and d) time ofpeak thrombin. 
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Figure 4. 11 
Fig 4.11 a ECM + RFGP56 
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Thrombin generation fo llowing extrinsic stimulation with low TF under flow 
conditions in the presence of ECM and RFGP56. 
800 Jl I of defibrinated p lasma contain ing 300 x 106 p latelets was incubated for 
30 minutes at 37°C with 25 JlI ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 Jl I of 100 mM CaCl2 containing recombinant 
tissue factor to give a final concentration of 35 pM Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a Single experiment and the 
effect of RFGP56 on b) A Uc, c) peak thrombin and d) time ofpeak thrombin. 
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Figure 4.11 
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Thrombin generation fo llowing extrinsic stimulation with low TF under flow 
conditions in the presence of ECM and RFGP56. 
800 f..I' of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 °C with 25 f..I l ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 f..I l of 100 mM CaCl] containing recombinant 
tissue factor to give a final concentration of 35 pM Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a ingle experiment alld the 
effect of RFGP56 on b) A UC, c) peak thrombin and d) time ofpeak thrombill. 
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4.3.6.2 RFGP37 
When thrombin generation was measured under static conditions in the presence or 
absence of HUVEC, there was no significant difference in the inhibitory effect of 
Cymbus RFGP37. Twenty Jlglml Cymbus RFGP37 inhibited AUC to 73.5 ± 26.8 % 
of control values in the presence of HUVEC, compared to 81.0 ± 1.3 % in the 
absence of HUVEC in polystyrene test tubes (as reported in Section 4.3.5, using the 
clotting method of thrombin determination). The introduction of shear stress had no 
significant effect on inhibition in the presence of HUVEC by 20 Jlglml Cymbus 
RFGP37, which remained at 88.9 ± 12.9, 85.8 ± 9.8 and 80.0 (n = 1) % of control 
AUC at 18,178 and 600 S-l respectively (main panel of Figure 4.12b). Increasing the 
concentration of Cymbus RFGP37 up to 80 Jlglml appeared to increase the inhibitory 
effect, although an insufficient number of repeats were perfonned before the 
antibody stock was exhausted. At 178 and 600 S-l, 80 Jlglml Cymbus RFGP37 
reduced thrombin generation to 47.1 ± 14.3 and 35.9 ± 3.9 % respectively (n = 2). 
Over the range of concentrations tested, ANOVA revealed that in the presence of 
HUVEC, Cymbus RFGP37 was a significantly better inhibitor of AUC under arterial 
conditions (600 S-l) compared with venous (18 S-l). No significant differences were 
seen in peak thrombin generation or the peak time (main panels of Figure 4.12c 
and d, respectively). 
In the presence of ECM, thrombin generation under static conditions was unaffected 
(98.4 ± 10.7 %) by 20 Jlglml Cymbus RFGP37 (Figure 4.l3a). The introduction of 
shear stress in the presence of ECM led to some differences, with AUC of 
105.9 ± 3.7,81.4 ± 1.8 and 112.0 ± 0.7 at 18, 178 and 600 S-l respectively (p < 0.01 
in all cases, but n = 2; Figure 4.13b). Increasing the concentration of Cymbus 
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RFGP37 up to 80 !J.glml led to significant inhibition, with AUC of 59.9 ± 28.6 and 
54.5 ± 16.2 % at 178 and 600 S-1 respectively (p < 0.01). ANOVA revealed that 
Cymbus RFGP37 was a significantly better inhibitor of AUC under venous 
conditions (178 S-I) than static conditions (p < 0.05). No significant differences were 
seen in peak thrombin generation or the peak time (main panels of Figure 4.13c 
and d respectively). 
Serotec RFGP37 had no significant effect (n ~ 3) on any of the parameters of 
thrombin generation in the presence of either HUVEC or ECM at any of the 
concentrations tested. It was tested at shear rates of 178 and 600 S-I, following 
exhaustion of the original stock of Cymbus RFGP37 (see inset panels in Figures 4.12 
and 4.13). 
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Figure 4. 12 
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RFG P37 (Jl g/ml) 
Thrombin generation fo llowing extrinsic stimulation with low TF under flow 
conditions in the presence of HUVEC and RFGP 37. 
800 )1 1 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 )11 of TBS containing the antibody under test. Thrombin 
generation was initiated with 175 )11 of 100 mM CaC/] containing recombinant 
tissue factor to g ive a fina l concentration of 35 pM. Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration }"\-·ith 
chromogenic substrate S2238. 
aJ Representative thrombin generation curves from a single experiment and the 
effect of Cymbus RFGP3 on b) AUe. c) peak thrombin and d) time of peak 
thrombin. Inset is Serotec RFGP3 . 
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Figure 4. i 2 
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RFGP37 (Jlg/ml) 
Thrombin generation fo llowing extrinsic stimulation with low TF under flow 
conditions in the presence of HUVEC and RFGP3 7. 
800 Iii of defibrinated p lasma containing 300 x i 06 platelets was incubated fo r 
30 minutes at 37°C with 25 Iii ofTBS containing the antibody under tes t. Th rombin 
generation was initiated with i 75 f..1/ of 100 mM CaC/] containing recombinant 
tissue factor to give a final concentration of 35 pM. Tim ed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves fro m a ingle experiment and the 
effect of Cymbus RFGP37 on b) AUe. c) peak thrombin and d) time of peak 
thrombin. inset is Serotec RFGP 3 . 
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Fig 4.13a ECM + Cy mbus RFGP3 7 
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RFGP37 (Jlg/ml) 
Thrombin generation following extrinsic stimulation .vith low TF under flow 
conditions in the presence of ECM and RFGP 37. 
800 f.J 1 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 DC with 25 f.J 1 ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 f.J 1 of 100 mM CaCl! containing recombinant 
tissue factor to give a final concentration of 35 pM. Timed subsamples lI'ere taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a ingle experiment and the 
effect of Cymbus RFGP3 7 on b) AVe. c) peak thrombin and d) time of pea/.. 
thrombin. In et is Serotec RFGP3 . 
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Figure 4.13 
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Thrombin generation following extrinsic stimulation with low TF under jlmv 
conditions in the presence of ECM and RFGP3 7. 
800 1'1 of defibrinated plasma containing 300 x 106 platelets was incubated fo r 
30 minutes at 37 DC with 25 1' 1 ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 1'1 of 100 mM CaCl] containing recombinant 
tissue factor to give a final concentration of 35 pM. Tim ed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves fro m a single experimel1l and tlie 
effect of Cymbus RFGP3 on b) AVe. c) peak thrombin and d) time of peak 
thrombin. Inset is Serotec RFGP 3 . 
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4.3.6.3 RFGP56 and RFGP37 in combination 
When thrombin generation was measured under flow conditions in the presence of 
HUVEC (Figure 4.14), the combination of 20 !J.glml each of RFGP56 and Cymbus 
RFGP37 significantly inhibited AUC to 62.2 ± 6.8 % (p < 0.01) at 18 S-I. No further 
effects were seen at concentrations up to 80 !J.glml, and similar results were seen at 
178 S-I (n = 2) and 600 S-I (n = 1). No significant differences could be detected by 
ANOV A in AUC, peak thrombin or time of peak (main panels of Figures 4.14b, c 
and d, respectively). 
The combination of RFGP56 and Serotec RFGP37 at 20 !J.glml each in the presence 
of HUVEC inhibited AUC under static conditions to 64.l ± 13.5 % (p < 0.01), with 
no further effect at concentrations up to 80 !J.glml (Figure 4.14b inset). AN OVA 
revealed that the combination of RFGP56 and Serotec RFGP37 was significantly 
more effective in reducing the AUC under static and arterial (600 S-I) conditions than 
venous conditions (178 S-I). However, in terms of peak height, this combination was 
significantly more effective under static conditions than venous (178 S-I) or arterial 
(600 S-I) conditions (Figure 4.14c inset). No significant differences were seen in 
terms of peak time (Figure 4.14d inset). 
When thrombin generation was measured under flow conditions in the presence of 
ECM (Figure 4.15), the combination of 20 !J.glml of both RFGP56 and Cymbus 
RFGP37 significantly inhibited AUC to 73.2 ± 14.8, 58.5 ± 14.6 and 37.9 ± 11.3 % 
(p < 0.05, 0.01, 0.01 respectively) at 18 S-I. Similar, but non-significant results were 
seen at 600 S-I (n = 2). No significant differences could be detected by ANOV A in 
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AUC, peak thrombin or time of peak (main panels of Figures 4.15b, c and d, 
respectively). 
The combination of RFGP56 and Serotec RFGP37 at concentrations as high as 
80 Ilglml each in the presence of HUVEC had no significant effect on any of the 
parameters measured (n 2 3; see inset panels in Figures 4.14 and 4.15). 
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Figure 4.14 
Fig 4.14a HUVEC + RFGP56 + Cymbus RFGP3 7; 600 s·l 
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Thrombin generation fo llowing extrinsic stimulation with low TF under jim\! 
conditions in the presence ofHUVEC, RFGP56 and RFGP37. 
800 J.1 1 of defibrin ated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 °C with 25 J.1 1 ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 J.11 of 100 mM CaCl3 containing recombinant 
tissue fac tor to g ive a final concentration of 35 p M. Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a single experiment and the 
effect of RFGP56 + Cymbus RFGP 37 on b) A Uc. c) peak thrombin and d) time of 
peak thrombin. In et is RFGP56 + Sero tec RFGP 3 
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Thrombin generation fo llowing extrinsic stimulation with low TF under flow 
conditions in the presence of HUVEC, RFGP56 and RFGP37. 
800 ;.iI of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 Ji l ofTBS containing the antibody under test. Thrombin 
generation was initiated with 175 f.iI of 100 mM CaCl] containing recombinant 
tissue fac tor to g ive a fina l concentration of 35 pM Timed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a single experiment and the 
effect of RFGP56 + Cymbus RFGP3 7 on b) AUC, c) peak thrombin and d) time of 
peak thrombin. Inset is RFGP56 + Serotec RFGP3 . 
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Figure 4.15 
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RFGP56 & RFGP37 ( J.lg/ml of each) 
Thrombin generation following extrinsic stimulation with low TF under flow 
conditions in the presence of ECM, RFGP56 and RFGP3 7. 
800 )1 / of defibrinated plasma containing 300 x 106 platelets was incubated fo r 
30 minutes at 37°C with 25 )11 ofTBS containing the antibody under test. Th rombin 
generation was initiated with 175 )11 of 100 mM CaCl l containing recombinant 
tissue factor to give a final concentration of 35 pM. Tim ed subsamples were taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate 52238. 
a) Representative thrombin generation curves fro m a s ingle experiment and the 
effect of RFGP56 + C mbus RFGP3 on b) AVC, c) peak thrombin and d) time of 
peak thrombin. Inset is RFGP56 + Serotec RFGP3 . 
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Figure 4. 15 
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Thrombin generation following extrinsic stimulation with low TF under jlm1.' 
conditions in the presence of ECM, RFGP56 and RFGP3 7. 
800 fl l of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 fl / of TBS containing the antibody under test. Thrombin 
generation was initiated with 175 fl l of 100 mM CaCl l containing recombinant 
tissue factor to g ive a fin al concentration of 35 pM. Timed subsamples were taken 
into EDTA stop buffer for determina tion of thrombin concentration with 
chromogenic substrate S2238. 
a) Representative thrombin generation curves from a ingle experiment and the 
effect of RFGP56 + Cymbus RFGP3 on b) AVe, c) peak thrombin and d) time of 
peak thrombin. Inset is RFGP56 + Serotec RFGP3 . 
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4.3.7 Expression of negatively charged phospholipids 
Flow cytometry was performed to detect FITC-annexin-5A binding to unstimulated 
and TF stimulated platelets following incubation with 20 ~glml of antibody. The 
data obtained were analysed to determine the percentage of platelets positive for 
annexin-5A binding (Figure 4.16). 
Annexin-5A binding to platelets stimulated with TF was reduced by the presence of 
20 ~glml of anti-GP lIb/IlIa antibodies. RFGP56 and c7E3 reduced the percentage 
of annexin-5A positive platelets to 33.3 ± 13.8 % (p < 0.01) and 34.7 ± 9.2 0/0 
(p < 0.01) of control levels respectively (Figure 4.16c). In contrast, the presence of 
20 ~glml of the anti-GP Iba antibody Cymbus RFGP37 or its F(ab')2 fragment (in 
order to investigate the possibility of stimulation via the Fc receptor; Cauwenberghs 
et ai, 2001) caused increased binding of annexin-5A, to 121.6 ± 16.4 % (ns) and 
142.1 ± 19.5 % (p < 0.01), respectively. However, when 20 ~glml of both RFGP56 
and Cymbus RFGP37 were present, the overall effect was a reduction in annexin-5a 
binding to 44.2 ± 6.97 % (p < 0.01). No significant effect was seen in the presence 
of the irrelevant anti-D control antibody, Reg A, at either 20 or 40 ~glml 
(Figure 4.16c). 
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Fig 4.16a 
Events 
Fig 4.16b 
Events 
Figure 4.16 
IF stimulated plate lets 
Unstimulated platelets 
FLl·H 
RegA 
F1TC-annexin-5A binding to unstimulated and TF-stimulated platelets. 
a) Defibrinated plasma containing 300 x 106 platelets/ml was stimulated with either 
17.5 mM calcium alone (unstimulated platelets) or with lo w TF and 17.5 mM 
calcium (TF-stimulated platelets). After 12 minutes, a subsample \·vas taken into 
HBS containing hirudin, a subsample of this mixture was taken into HBS containing 
F1TC-Annexin-5A and 10000 events counted on a flow cytometer. 
b) As for a), but platelets were incubated with 20 ,ug/ml of antibody for 20 minute 
prior to stimulation with low TF and 17.5 mM calcium. 
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Anti body (20 J..lg/ml) 
FITC-annexin-SA binding to unstimulated and TF-stimulated platelets. 
c) For each antibody treatment, the difference in the percentage of positive platelets 
between the TF-stimulated cells and the unstimulated cells was calculated and 
compared with the control (TBS treated) cells. n c 3; * * p < 0.01 
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4.3.8 Measurement of soluble fibrin in defibrinated plasma 
Soluble fibrin was easily detected in plasma that had been defibrinated with ancrod, 
and little difference was seen between 0.5 and 1.0 IU/ml of ancrod for 20 minutes at 
37°C (Figure 4.17 main panel). No soluble fibrin was detected following 
immunoprecipitation with the ELISA capture antibody 5F3 after defibrination with 
ancrod. Plasma that had been defibrinated with batroxobin (5 units/ml) al so had 
measurable levels of soluble fibrin (Figure 4.17 inset). Heat defibrination (56 °C for 
60 minutes) was highly effective in the removal of soluble fibrin (Figure 4.17 main 
panel), but the potential effects of heat on other clotting factors prevented this being 
used as a practical alternative method. 
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Incubating at 37 °e with 0.5 IU/ml ancrod for longer (50 or 70 minutes) had no 
further effect compared to 20 minutes incubation, but incubation at 4 °C overnight 
following 20 minutes at 37 °e reduced soluble fibrin to bel ow detectable levels. 
However, when plasma defibrinated in this way was used in a thrombin generation 
test, very low levels of thrombin were detected (585 IU.seconds/ml ; Figure 4. 18) 
suggesting that other coagulation factors such as FVIlI had been depleted or 
destroyed by the incubation. This was studied with a one stage clotting assay for 
FVIII (Austen & Rhymes , 1975) that confirmed a relative potency of 0.31 compared 
with normal plasma. In order to perform a comparable thrombin generation test, 
0.6 IU/ml of recombinant FVIIl (96/598 , NIBSe, UK) was added back to the 
defibrinated plasma, resulting in comparable levels of thrombin generation (4582 and 
4692 ru.seconds/ml for overnight defibrination + rFVIlI and freshly defibrinated 
plasma, respectively; Figure 4.18). 
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Thrombin generation in various defibrinated plasmas 
Platelets (300 x J06/ml) were resuspended in plasma defibrinated by incubation with 
0.5 u/ml ancrod at 37 "C for 20 minutes I4 "Cfor f6hours I rF~ 'ffJ. After 
30 minutes incubation with 20 Jig/ml RFCP3 7, thrombin generation \I 'OS triggered 
under slatic conditions with 35 pM TF and Ca> (n = I) . Th e effect of RFCPJ7 \1'(/\' 
s ludied to determine II'hether soluble fibrin \Vas stimuloting plotelets by hinding to 
vWF and enabling it 10 interact \\'ith CP fba. 
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Soluble fibrin in defibrinated plasma may bind to vWF and change its conformation 
sufficiently to allow vWF to interact with GP Iba, leading to the activation of the 
platelet (Beguin et ai, 1999). RFGP37 binds to the vWF-binding site on GPIba and 
this may explain its inhibitory action in thrombin generation (Cox, 1991). In order to 
test this theory, thrombin generation tests were performed using platelet plasma 
prepared with plasma defibrinated by incubation at 37°C for 20 minutes with or 
without a further 16 hours at 4°C, with rFVIII added back to the former. As shown 
in Figure 4.18, the presence of 20 !J.glml Cymbus RFGP37 had no appreciable 
inhibitory effect in either plasma, suggesting that the presence of soluble fibrin has 
no influence on the mode of action of RFGP37 in the inhibition of thrombin 
generation. 
Static thrombin generation tests were also performed usmg RFFVIII:Rll, a 
monoclonal antibody against the GP Iba-binding site on vWF that completely 
inhibited ristocetin-stimulated platelet agglutination at 40 !J.glml. Thrombin 
generation, measured by AUC, was not significantly inhibited by either 40 !J.glml 
RFFVIII:RlI (90.0 ± 9.6 %), or 20 !J.glml Cymbus RFGP37 (89.2 ± 20.5 %), or both 
antibodies together (97.1 ± 8.7 %; Figure 4.19). IfRFGP37 was inhibiting thrombin 
generation by interfering with a stimulatory pathway involving soluble fibrin, vWF 
and GP Iba, it would have an equivalent effect as RFFVIII:Rll, and when tested 
together, no further inhibition would be seen. RFFVIII:Rll would also have an 
additive effect with RFGP56 as they would be operating by inhibiting two distinct 
pathways. However, inhibition by 20 flglml RFGP56 (70.1 ± 14.1 %) was 
unaffected by the presence of 40 !J.g/ml RFFVIII:RlI (71.9 ± 11.4 0/0). 
177 
125 
=- 100 
0 
l-
-C 
0 75 u 
~ Q 
--U 50 
;:J 
~ 
25 
0 
Figure 4.19 
** 
** 
TBS 
~ RFFVIII :RJt 
- RFGP56 
~ RFGP56 
+ RFFVIII:RJl 
- Cymbus RFGP37 
~ Cymbus RFGP37 
+ RFFVIII:RJl 
Thrombin generation with anti-vWF monoclonal antibody, RFCP56 and RFCP37. 
RFF VIII: RJl blocks the CP Ib a binding site on vWF and was used to investigate the 
mode of action of Cymbus RFCP3 7. 800 j..11 of defibrinated plasma con tain ing 
375 x 106 plateletslml was incubated for 30 minutes at 37 °C with 25 j..11 of TBS 
containing RFFVIII:RJI at 40 j..1glml, RFCP56 and RFCP37 at 20 j..1glml or 
combinations as indicated. Thrombin generation was initiated with 175 j..11 of 100 
mM CaCl2 containing recombinant tissue fac tor to give a fina l concentration of 35 
pM. Timed subsamples were taken into EDTA stop buffer for chromogenic 
determinationof thrombin concentration. 
Mean 1: standard deviation; n ;:: 5; p < 0.0/) . 
4.3.9 Immunofluorescent staining of platelets and HUVEC 
The antiplatelet antibodies RFGP56 and Serotec RFGP37 were clearly seen to bind 
to platelets, visualised with FITC-rabbit anti-mouse IgG (Figure 4.20). No cross-
reactivity was seen with HUVEC, which clearly stained with anti-vWF polyclonal 
antibody, visualised with FITC-swine anti-rabbit IgG. Platelets did not stain for 
vWF. 
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Figure 4.20 Immun oflu orescent staining o.[antibody binding to platelets and HUiEC 
Defibrinated plasma containing 375 x 10° plateletsl1l11 was incubated lI 'ith 20 ,ug 1111 
0.[ th e indica ted antibodies for 30 min utes at 37 "C A drop 0.[ this cell sllspension 
was th en applied to a glass cO l'erslip treated \I 'ith po~\' DL (\'sine and fixed Il 'ith 2 fJ fJ 
parafo,.,naldehyde. Th e coverslips 'vi 'ere th en incubated H'itlT 10 ,ug 1111 
FlTC-secondalY antibody (green) to th e primary antibodie detailed befoll' olld 
66 nM Alexa Fluor 532 phalloidin to stain actin (red) in PBS containing I 1111 
Triton X-JOO. uclei are stained blue fo lloll 'ing a 10 l7linute incubation 1\'itII 
Hoechst 33342. 
A) Platelet + RFCP56 
C) Platelet + RFCP3 
£) Platelet + anti-l'WF 
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B) H I 'EC RFCP56 
D) HUI'EC + RFCP3 7 
F) HUJ'EC + onti-1'I1'F 
4.4 Discussion 
The effects of antibodies against platelet membrane glycoproteins (GP) lIb/IlIa and 
Iba on thrombin generation were studied under static and flow conditions in the 
presence of intact endothelial cells or their extracellular matrix. Further 
investigations were undertaken in order to elucidate the mode of action of these 
antibodies. 
GP lIb/IlIa acts as a receptor for fibrinogen, vWF, vitronectin and fibronectin, and as 
such plays a number of roles in the coagulation process. In resting platelets 
GP lib/IlIa is expressed in a low affinity form that only becomes activated enabling 
high affinity binding to ligands following stimulation of the platelet. Suitable stimuli 
include ADP, collagen and thrombin, all of which are found at sites of vessel injury. 
Following platelet activation, the increased affinity of GP lib/IlIa to bind the 
multivalent ligands fibrinogen and vWF facilitates cross-linking of platelets leading 
to the development of a platelet plug, or aggregate (Nurden & Nurden, 1993). It is 
therefore logical that agents that can inhibit the binding of ligands to GP lib/IlIa may 
inhibit the aggregation of activated platelets. 
The results of the platelet aggregation assays show that at a final concentration of 
0.5 ill/ml thrombin, the presence of 20 flglml of either of the anti-GP IlblIIIa 
antibodies RFGP56 or c7E3 was sufficient to prevent aggregation. This is consistent 
with previous in vitro findings (Reverter et ai, 1996; Pedicord et ai, 1998) and the 
clinical benefits of ReoPro ™ in the prevention of vessel occlusion following 
vascular surgical procedures, where the local generation of thrombin and the 
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exposure of subendothelial proteins may lead to the aggregation of platelets (Califf et 
ai, 1995; EPILOG Investigators, 1997; CAPTURE Investigators, 1997). 
RFGP37 binds to a vWF binding site on the GPIba receptor, located in the first 
leucine rich repeat region near or between residues 35 and 81 (Stephen F Garner, 
Personal Communication, 1999). Antibodies from both Cymbus and Serotec were 
able to completely inhibit ristocetin-induced platelet agglutination, confirming that 
RFGP37 interferes with the binding of vWF to GP Iba. As discussed in 
Section 1.2.1.1, there are three vWF binding regions on GP Iba, one of which is also 
involved in the binding of thrombin. 
The presence of 20 Jlglml of Cymbus RFGP37, as intact antibody or F(ab'h 
fragment, against GP Iba did not inhibit platelet aggregation following stimulation 
with 0.5 IV/ml of thrombin. However, stimulation of platelets with lower 
concentrations of thrombin led to increasing inhibition by this antibody, which led to 
the hypothesis that the role of the GP Ib/IXN complex as a high affinity thrombin 
receptor may be significant (De Marco et ai, 1991). The vWF binding site that 
includes the epitope for RFGP37 is discrete from the high affinity thrombin binding 
site, which is located at amino acids 269 - 287 (De Marco et ai, 1994), but it is 
possible that steric hindrance or conformational change resulting from the interaction 
of RFGP37 with GP Iba may interfere with the interaction of thrombin with its 
binding site. However, subsequent investigation using fragments of GP Iba proved 
this not to be the case, although the use of an ELISA method may have resulted in 
certain epitopes being obscured so this result cannot be definitive. 
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The possibility that the inhibitory effects of Cymbus RFGP3 7, in platelet aggregation 
and thrombin generation, were artefactual was raised when at 20 Ilglml Serotec 
RFGP37 failed to inhibit platelet aggregation at any of the concentrations of 
thrombin tested, despite being able to bind to the GP Iba fragments. In fact. Serotec 
RFGP37 appeared to stimulate platelet aggregation, although this was not 
statistically significant. This indicated different properties of antibodies from the 
two different manufacturers and also of variable inter-batch properties, and suggested 
that the inhibitory effect of the original batch of Cymbus RFGP37 (297 J) was due to 
a contaminant that could interfere with the platelet response to weak aggregatory 
stimuli, such as low concentrations of thrombin. The unavailability of any further 
supplies of batch 297J made it impossible to identify the differences between the 
batches. 
The intrinsic thrombin generation system described is a platelet-dependent system, 
demonstrated by the lack of detectable thrombin generation in the absence of 
platelets. The intrinsic pathway (described in Section 1.1.1) may be supported by the 
ability of platelets to bind FXII, FXI, FX and HMWK and their provision of 
negatively charged phospholipids for the interaction of these activated clotting 
factors (Saito, 1994). The early activation of platelets is indicated by the steep 
incline and early peak of the control curve in Figure 4.5a. 
The presence of anti-GP lIb/lIla antibodies RFGP56 or c7E3 significantly reduced 
thrombin generation in the intrinsic system to levels similar to that previously 
reported in an extrinsic system (Reverter et ai, 1996), confinning the inhibitory 
effect of these agents in platelet dependent thrombin generation Cymbus RFGP37 
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inhibited thrombin generation in the intrinsic system, although to a lesser extent than 
the anti-GP lIb/IlIa antibodies, and as this was prior to the discovery of the problems 
with Cymbus RFGP3 7, this was interpreted as an indication that GP Iba may also 
have a stimulatory role in platelet dependent thrombin generation. 
Extrinsic thrombin generation using high (630 pM) TF as the stimulus was not 
inhibited as effectively by the antibodies. Only the strongest inhibitor under intrinsic 
stimulation, RFGP56, had a significant effect on AVC and peak thrombin 
concentration. The high level of TF was probably sufficient in itself to drive platelet-
independent thrombin generation via interaction with FVII and activation of FX. 
This theory is reinforced by the high level of thrombin generation seen in the absence 
of platelets and the absence of any lag time in the control curve in Figure 4.6a. The 
relatively low inhibition of thrombin generation by all the antibodies may therefore 
be due to the comparatively minor role being played here by the membrane of 
activated platelets, as enough FXa may be generated by the high levels of the 
TF-FVIIa complex to be able to cleave prothrombin in the absence of platelet 
phospholipid. This is consistent with a previous report that found no inhibition of 
thrombin generation with c7E3 following stimulation with 200 pM TF (Butenas et ai, 
2001). 
When low TF (35 pM) was used to stimulate thrombin generation under static 
conditions no significant thrombin generation was seen in the absence of platelets, 
indicating that the thrombin generation here is platelet dependent. This is confirmed 
by the long lag time before any thrombin is detected in the control curve in 
Figure 4.7a, which reflects the initiation phase of coagulation before enough 
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thrombin to activate platelets has been generated. The inhibitory actions of all the 
antibodies were similar to those seen in the intrinsic system, with the anti-GP lIb/lIla 
antibodies RFGP56 and c7E3 reducing the AUC and all antibodies reducing peak 
thrombin concentration. These results are in agreement with previous reports that 
showed c7E3 (Reverter et ai, 1996; Butenas et ai, 2001) and a specific non-peptide 
antagonist of GP lIb/IlIa (Herault et ai, 1998) to affect thrombin generation in a 
physiologically relevant system similar to that used here. The clinically used 
concentration of c7E3 is around 3 JJ.glml (following a bolus of 0.25 mgikg) and 
provides 80 % blockade of GP lIb/lIla (Centocor product information), therefore the 
20 JJ.glml of anti-GP lIb/lIla antibodies used here should be sufficient to provide a 
similar degree of receptor blockade. 
The anti-aggregatory action of anti-GP lIb/IlIa antibodies is one mechanism by 
which they inhibit platelets. However, anti-GP lIb/lIla antibodies also interfere with 
the intracellular processes that follow ligation of GP lIb/lIla. Isenberg et al (1990) 
demonstrated that after ligand binding, GP lIb/lIla is internalised in a cytoskeleton-
mediated process. It was also shown that antibodies bound to both GP lIb and 
GP lIla are internalised in this manner, but their interference with the cytoskeleton 
results in inhibition of the formation of filopodia. It is therefore possible that the 
antibodies used here can also interfere with this process, as engagement of the 
cytoskeleton precedes and facilitates the formation of filopodia and procoagulant 
microparticles, formed by pinching off sections of the scrambled platelet membrane 
(Sims et ai, 1989). 
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Neither antibody significantly affected the time of peak thrombin concentration, 
indicating that the initiation phase of coagulation, prior to platelet activation, is 
unaffected. The decreased thrombin generation may therefore reflect the expression 
of a reduced amount of phospholipid that can support fewer tenase and 
prothrombinase complexes. The exposure of negatively charged phospholipids, as 
determined by annexin-A5 binding, was indeed reduced by anti-GP lib/IlIa 
antibodies to a similar degree as the reduction in thrombin generation. This is in 
agreement with a previous study that correlated a reduced prothrombinase activity on 
platelets with reduced exposure of negatively charged phospholipids following 
treatment with GP lib/IlIa antagonists (Pedicord et ai, 1998). The incomplete 
inhibition of thrombin generation by anti-GP lib/IlIa antibodies may be the result of 
stimulation via other pathways such as the PAR-l thrombin receptor, and may also 
be due to increased expression of GP lib/IlIa on the surface of the activated platelet. 
This is the result of transport from internal stores in the open canalicular system and 
a-granules, where the inhibitory antibodies may not be able to bind to the receptor, 
thus facilitating aggregation following the fusion of a-granules with the plasma 
membrane (Nurden et ai, 1999). 
The presence of HUVEC did not affect the inhibitory action of RFGP56 under static 
conditions. RFGP56 binds to a conformational epitope across the two subunits of 
GP lib/IlIa (Cox, 1991) and is therefore unable to bind to endothelial cells, despite 
their expression of GP IlIa as part of the vitronectin receptor (integrin aV~3) 
(Nurden, 1994), and this was confirmed by immunofluoresence. The presence of 
ECM led to a reduction in the inhibitory capacity of RFGP56, possibly due to platelet 
activation via other receptors such as the collagen receptors GP lalIIa and GP VI, 
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reducing the contribution of GP lIb/IlIa mediated signalling to the procoagulant 
activity of the platelet. The introduction of shear stress showed that, independent of 
the presence of HUVEC or ECM, RFGP56 was most effective under static 
conditions where the procoagulant activity of platelets follows their activation by 
thrombin, or arterial conditions where platelet aggregation is critical in order to retain 
a catalytic surface of activated platelet membranes for the interaction of clotting 
factor complexes at the site of vascular damage. 
Under static conditions neither HUVEC nor ECM had any effect on thrombin 
generation in the presence of Cymbus RFGP3 7, which had an apparent, but not 
statistically significant, inhibitory effect in polystyrene tubes. Reduced effectiveness 
of RFGP37 may have been expected in the presence of endothelial cells, which 
express GP Iba (Wu et ai, 1997). However, endothelial cells were not seen to bind 
Serotec RFGP37 by immunofluorescence. The introduction of shear stress led to a 
dose dependent inhibition of thrombin generation in the presence of both HUVEC 
and ECM, suggesting that GP Iba was playing an increased role in platelet 
activation, possibly by its thrombin receptor function, by its stimulation of platelets 
via the collagen-vWF pathway, or by its tethering effect under high shear conditions 
and that RFGP37 was able to inhibit this. 
The inhibitory effect of Cymbus RFGP37 in platelet aggregation in response to low 
concentrations of thrombin indicated that this might be its mode of action in 
inhibition of thrombin generation. Inhibition of the thrombin receptor function of 
GP Iba would reduce the effects of low levels of thrombin in activating platelets, and 
may therefore act to increase the delay before the peak of the thrombin generation 
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curve was seen. However, the data were unable to confinn this hypothesis. The 
inhibition of platelet mediated thrombin generation by an antibody against GP Iba 
was contrary to a previous report where the antibody used (6DI) was directed against 
a different vWF binding region in the leucine rich repeats of the receptor (Reverter et 
ai, 1996) from that of RFGP3 7. Antibody 6D 1 has since been shown to inhibit 
enhanced thrombin generation seen in the presence of fibrin clots (Beguin et ai, 
1999), suggesting an alternative mode of action for this antibody. Detectable levels 
of soluble fibrin were found in the defibrinated plasma used in the thrombin 
generation system, and it was therefore possible that the baseline thrombin 
generation had been potentiated by the presence of soluble fibrin. RFGP37 blocks 
the binding of vWF to OP Iba and may therefore interfere with the indirect 
interaction of fibrin with GP Iba, thus preventing this potentiation and reducing 
baseline thrombin generation to nonnal. However, no difference in the effect of 
Cymbus RFGP37 was seen when all the soluble fibrin was removed from the 
defibrinated plasma. In addition, had interference with this pathway been the mode 
of action of RFGP37, an antibody directed against the GP Iba binding site on vWF 
would be expected to show a similar inhibitory effect. However, when the effect of 
RFFVIII:RlI on thrombin generation in defibrinated plasma containing soluble fibrin 
was tested, no inhibition was seen. This indicates that the fibrin-vWF-GP Iba 
pathway is not the site of Cymbus RFGP3 7' s inhibitory effect. Previous reports have 
confinned the role of GP Iba in the tethering of platelets to areas of vascular damage 
under conditions of high shear stress, as described in Section 1.2.1.1. If Cymbus 
RFGP37 was able to interfere with this function of GP Iba then it may inhibit 
thrombin generation by preventing the accumulation of platelets with negati\'ely-
charged phospholipids exposed on their membranes at the vessel wall. No 
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significant inhibitory effects were seen with Serotec RFGP37 under any of the 
conditions tested, lending more weight to the hypothesis that the inhibitory effects of 
Cymbus RFGP37 had been artefactual and that although RFGP37 is able to inhibit 
vWF binding to GP Iba, it does not have a sufficient inhibitory effect on platelet-
mediated thrombin generation. 
As both RFGP56 and Cymbus RFGP37 were exhibiting inhibitory effects on 
thrombin generation, and are directed against different platelet membrane receptors, 
studies where the antibodies were used in combination were perfonned to detennine 
if an additive or synergistic effect could be seen. In the presence of HUVEC, no 
differences were seen between the effects of RFGP56 alone and in combination with 
RFGP37, from either source, at any shear rate tested. However, in the presence of 
ECM, an additive effect of RFGP56 and Cymbus RFGP37 was seen under low 
venous shear conditions (18 s -1), especially at the highest concentration tested 
(80Ilglml). This result may have indicated a role for both receptors in the 
procoagulant activity of platelets under flow conditions in areas of vascular damage 
and led to the initiation of the further studies at higher shear rates. Further 
investigations using Serotec RFGP37 were unable to reproduce the original data and 
further work was perfonned to characterise the Serotec antibody. These experiments 
showed that Serotec RFGP37 was able to bind to GP Iba and inhibit its vWF binding 
function, but not its function as a thrombin receptor. 
The studies on the exposure of negatively charged phospholipids on the platelet 
membrane revealed more infonnation about the mode of action of anti-GP IIblllIa 
antibodies, which reduced the number of platelets that had undergone membrane 
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scrambling and therefore limited the assembly of phospholipid-dependent enzymatic 
complexes. Stimulatory effects of anti-GP Iba antibodies have been noted 
previously (Deckmyn et ai, 1997; Yanabu et ai, 1997; Cauwenberghs et ai, 2001). 
but the apparent Fc-independent stimulatory effect of Cymbus RFGP37 was 
paradoxical to the antibody's effect in the thrombin generation tests, where it was 
inhibitory under certain conditions, although a non-significant increase in platelet 
aggregation was noted with Serotec RFGP37 following thrombin stimulation, and 
also indicated by its aggregatory effect on platelets studied usmg 
immunofluoresence. The possibility of a platelet-independent effect of Cymbus 
RFGP37 on thrombin generation was considered, but no statistically significant 
inhibition was seen in thrombin generation tests performed with platelet poor plasma. 
There is no clear explanation for these results, and without further supplies of the 
suspect batch of antibody it is impossible to test any hypotheses. The most likely 
explanation is the presence of a soluble contaminant, but a candidate that activates 
platelets yet inhibits coagulation is not obvious. The results of the Serotec RFGP37 
confirm that the original choice of this antibody as a negative control for RFGP56 in 
the thrombin generation experiments was appropriate, and had the early results been 
viewed more sceptically further analysis may have revealed the reason for the 
unusual behaviour of Cymbus RFGP3 7. 
4.5 Summary 
A platelet-dependent thrombin generation system was established, and the inhibitory 
effects of antibodies against GP lIb/IlIa (RFGP56 and c7E3) and GP Iba (RFGP37) 
were investigated. RFGP37 manufactured by Cymbus showed inhibitory activity 
that platelet aggregation studies suggested was due to inhibition of the thrombin 
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receptor function of GP Iba. However, RFGP37 made by Serotec showed no 
inhibitory effect on thrombin generation and was unable to inhibit thrombin binding 
to GP Iba, leading to the conclusion that the inhibitory effects of Cymbus RFGP37 
were the result of a soluble contaminant, and that inhibition of vWF binding to 
GP Iba is not sufficient to inhibit the contribution of platelets to coagulation. 
RFGP56 was able to inhibit thrombin generation, and was most effective under either 
static or arterial flow conditions and in the presence of HUVEC rather than ECM. 
Only partial inhibition of thrombin generation was possible, suggesting that platelets 
may also become activated via other pathways, such as ligation of collagen receptors. 
In addition to the anti-aggregatory activity of RFGP56, its mode of action in 
inhibiting coagulation was shown to be a reduction of the exposure of negatively 
charged phospholipids that serve as templates for the assembly of complexes of 
coagulation enzymes on the outer membrane of platelets. 
CHAPTERS 
HEPARIN & HIRUDIN 
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5.1 Introduction 
Unfractionated and low molecular weight heparins are widely used anti thrombotic 
drugs, and small-molecule thrombin inhibitors such as hirudin are becoming 
established as alternatives to heparin. The relative benefits of these different agents 
in different clinical indications may be due to pharmacokinetic or physiochemical 
differences but may also be due to the different specificities of these agents against 
individual proteases of the coagulation cascade. 
5.1.1 The relative contribution of anti-Xa and anti-lla activity 
A number of experimental studies have investigated the contribution of anti-Xa and 
anti-lla activities to the inhibition of coagulation. The results do not all agree, and 
vary depending on the procoagulant stimulus, the flow conditions, the reactive 
surface and whether the model is in vivo or in vitro (Buchanan et ai, 1985; Amar et 
ai, 1990; Vlasuk et ai, 1991; Orvim et ai, 1995; Diquelou et ai, 1995b; Bossavy et ai, 
1998; Bossavy et ai, 1999; Shimbo et ai, 2002). Standardised studies with 
physiologically relevant flow conditions, procoagulant stimuli and reactive surfaces 
would therefore be useful in determining the relative contributions of anti-Xa and 
anti-lla activity. 
Unfractionated heparin, low molecular weight heparin and hirudin are useful tools 
for this study as they have varied inhibitory activities against FXa and thrombin, but 
it is difficult to make direct potency comparisons between them. Comparisons on a 
molar basis are not possible as heparin is a heterogeneous mixture of different length 
polysaccharide chains. Comparison on a functional basis is also difficult as heparin 
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acts indirectly as a catalyst for antithrombin, whereas hirudin inhibits thrombin 
directly. In order to avoid confusion between the catalytic activity of heparin, 
usually referred to as anti-lla activity, and the direct inhibition of thrombin by 
hirudin, the term 'thrombin inhibitory activity' will be used to refer to the activities 
of both heparin and hirudin. The difference in the mode of action leads to non-
parallelism when dilution series of heparin and hirudin are tested in coagulation-
based assays such as the activated partial thromboplastin time (APTT), making 
comparative potency analysis invalid (European Pharmacopoeia, 2002). The APTT 
is routinely used as a laboratory test for the monitoring of patients receiving 
antithrombotic therapy, and the therapeutic range is considered to be a 1.5 - 2.5 fold 
increase of the control clotting time (Hirsh et ai, 2001). The concentration (in J.lglml) 
of each inhibitor required to double the control APTT (a ratio of 2.0) was therefore 
determined in order to allow a single-point comparison between the compounds and 
to provide a reference point for comparison with clinical data. 
Platelet factor 4 (PF4) is a 70 amino acid protein (MW 7 800) that is stored in the 
a-granules of platelets. It is released when platelets become activated and circulates 
as a tetramer or bound to a proteoglycan carrier. It also binds to heparin, neutralising 
its activity, and binds with lower affinity to heparin-like molecules on the 
endothelium from where it is released following heparin therapy (Niewiarowski, 
1994). It is possible that the activation of platelets in these studies may lead to the 
release of PF4 from platelets and the presence of heparin may release PF4 from 
HUVEC, resulting in the neutralisation of some heparin activity and thereby 
influencing the results. An investigation into the concentration of PF4 in post-shear 
platelet plasma was therefore undertaken. 
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Studies were designed to investigate how the anti-Xa and thrombin-inhibitory 
activities of the different compounds contribute to their antithrombotic effects under 
different physiological conditions. Consideration was given to the differences in the 
modes of action of the inhibitors, and the influence of shear stress on the process of 
coagulation. 
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5.2 Materials and methods 
5.2.1 Inhibitors 
Unfractionated heparin was the 5th International Standard (97/578, NIBSC, UK) with 
a specific activity of 230 IU/mg (for both anti-Xa and anti-IIa). Low molecular 
weight heparin was Bemiparin (Rovi, Spain) with a specific activity of 100 anti-Xa 
ill/mg and 10 anti-lla ill/mg. Hirudin was Refludan (Hoechst Marion Roussel, 
Frankfurt am Main, Germany), a recombinant desulfato hirudin with a specific 
activity of 20 000 anti-thrombin units (ATU)/mg (Colin Longstaff, Personal 
Communication, 2002). For further information on potency assays of hirudin see 
Longstaff et al (1993). 
5.2.2 Activated partial thromboplastin time (APTT) 
The APTT test was performed on Amelung KC4A coagulometers (Brownes, 
Reading, UK) using APTT reagent from Dade Behring (Marburg, Germany) 
consisting of purified soy phosphatides in 10-4 M ellagic acid (Dade® Actin® FS 
Activated PTT Reagent) and 25 mM CaCho Dilutions of the inhibitors were 
prepared in TBS and 100 J.lI of each dilution was added to a cuvette. This dilution 
was mixed with 100 J.lI of normal pooled plasma (prepared from a minimum of 
4 donors; North London Blood Transfusion Centre, Colindale, UK), and 100 J.lI of 
APTT reagent was then added. This mixture was incubated at 37°C for 5 minutes 
before the addition of 100 J.lI of CaCho The clotting times were recorded and dose 
response curves prepared. 
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5.2.3 Thrombin generation tests under static and flow conditions 
The inhibitory effects of UFH, LMWH and hirudin on thrombin generation were 
studied under static and flow conditions in the presence of HUVEC or ECM using 
low TF (35 pM) as the stimulus as described in Section 2.8. 
5.2.4 Platelet Factor 4 assay 
The Hyphen Biomed Zymutest PF4 kit (Quadratech, Epsom, UK) was used to 
quantify the amount of PF4 that was released by platelets during the course of a 
perfusion experiment. This is a sandwich ELISA kit that uses rabbit anti-human PF4 
polyclonal antibodies to capture and detect PF4 in diluted samples of plasma. The 
recommended anticoagulants for the collection of blood were ETP (EDT A, 
theophylline and prostaglandin E1) or CT AD (citrate, theophylline, adenosine and 
dipyridamole), which are designed to inhibit platelet activation, and therefore any 
further release of PF4. In order to adapt this method for use on samples of plasma 
that had been exposed to shear stress in the flow system, an isotonic collection buffer 
that included these platelet inhibitors was required. A modified citrate saline 
(150 mM NaCI, 109 mM trisodium citrate; reagents from BDH, Poole, UK) was 
prepared containing 15 mM theophylline, 3.7 mM adenosine and 0.17 mM 
dipyridamole (all from Sigma, Poole, UK), with the concentrations of the inhibitors 
based on advice received from the suppliers of the kit and from a manufacturer of 
blood collection tubes (Sarstedt, Leicester, UK). 
Platelet plasma was prepared as usual and either stimulated with TF ICa2+ or Ca2+ 
alone and then passed through the flow chamber, which contained a HUVEC-coated 
coverslip. A control where the TF/Ca2+ stimulated plasma was transferred to a 
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culture well containing a HUVEC-coated coverslip was also included. Subsamples 
of 20 ~l were collected at 60 second intervals for 32 minutes and then centrifuged 
(l 000 g for 5 minutes) to remove any platelets from the supernatant, which \vas then 
aspirated and assayed for PF4 content. 
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5.3 Results 
5.3 .1 APTT 
Dose response curves were prepared on a weight basis in order to compare the 
inhibitory effects of UFH, LMWH and hirudin, and are shown in Figure 5.1. The 
clotting time of the normal plasma in the absence of any inhibitors was 38.3 ± 0.68 
seconds (n = 6). Lines were fitted to the data points with Microsoft Excel and the 
equation of each fitted line was used to calculate the dose required to double the 
APTT to 76.5 seconds (an APTT ratio of 2.0). The concentrations (with 95 % 
confidence intervals) required to achieve this effect were 1.03 (1.01 - 1.06), 16.49 
(15.64 - 17.36) and 0.56 (0.47 - 0.67) j.lg/ml for UFH, LMWH and hirudin 
respectively. 
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Th e inhibitory effects of UFH, LMWH and hirudin in the APTT assay. 
Dilutions of the inhibitors were prepared in TBS and 100 J.11 of the dilution 
incubated ~ith 100 J.11 of normal pooled plasma and 100 J.11 of Dad Actin FS 
APIT reagent at 37 DC for 5 minutes. 100 J.11 of CaClc was added and the clo ffing 
time recorded on Amelung KC4A coagulometers. Each point is the mean of 
duplicate determinations; the error bars for standard error of the mean (SEAl) are 
smaller than the data point . 
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5.3.2 Thrombin generation under static and flow conditions 
Examples of thrombin generation curves from single experiments are shown in 
Figure 5.2 to illustrate the effect of the inhibitors under static, venous and arterial 
shear conditions in the presence of ECM. Figure 5.2a shows that under static 
conditions hirudin delays the peak of the curve but has little effect on the shape or 
height of the curve at concentrations up to 0.5 J..1g1ml. In contrast, Figure 5.2b shows 
the effect of LMWH under venous conditions to be reduction of the height of the 
curves as well as delaying them. UFH was less effective in the reduction of peak 
height under these conditions (not shown, see Figures 5.3a, 5.7a, & 5.10a). Under 
arterial conditions, UFH shows both reduction and delay of the peak (Figure 5.2c), 
with a delayed peak being followed by reduced peaks as the inhibitor concentration 
increased. LMWH was more effective in the reduction of peak height and delay of 
the peak (not shown, see Figures 5.3b, 5.7b & 5.10b). 
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Figure 5.2 
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Representative thrombin generation curves from single experiments in the presence 
ofECM. 
800 J.11 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 °C with 25 J.1 1 ofTB5 containing the inhibitor under test. Thrombin 
generation was initiated with 175 j..d of 100 mM CaC/] containing recombinant 
tissue fac tor to give a final concentration of 35 pM. Timed subsamples h.'ere taken 
into EDTA stop buffer for determination of thrombin concentration wirh 
chromogenic substrate 52238. 
aJ static conditions and varying concentrations of hirudin: 
b) venous shear and LMWH; 
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Figure 5.2 
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Representative thrombin generation curves from single experiments in the presence 
ofECM. 
800 pi of defibrinated plasma containing 300 x J 06 platelets was incubated for 
30 minutes at 37 "C with 25 p i of TES containing the inhibitor under test. Thrombin 
generation was initiated with J 75 p i of JOO mM CaCil containing recombinant 
tissue factor to g ive a final concentration of 35 pM. Timed subsamples )1}ere taken 
into EDTA stop buffer for determination of thrombin concentration with 
chromogenic substrate S2238. 
c) arterial shear and UFH. 
Data from individual experiments were combined by calculating the area under the 
curve (AUC), the peak height and the time of the peak as a percentage of that seen in 
the absence of any inhibitor. This allowed data from separate experiments to be 
combined in a manner that controlled for variability in the platelets from individual 
donors. Dose response curves for each parameter were then compiled for each 
inhibitor in the presence of either BUVEC or ECM and under each shear condition 
(static, venous or arterial) . These curves are presented in Figures 5.3 to 5.13 , 
showing arithmetic mean ± standard deviation from at least 3 experiments . Curve 
were fitted to the data points as described in Section 2.12 in order to calculate the 
ICso for each inhibitor under each set of conditions and these are presented for the 
AUC and peak height in Tables 5.1 and 5.2 , respecti ely. 
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5.3.2.1 Effect of inhibitors on total thrombin generation (A UC) under static 
conditions 
Under static conditions, significantly more of each inhibitor was required to inhibit 
thrombin generation to 50% of control levels (lCso) over ECM than over HUVEC 
(p < 0.00 I in all cases). The ICso data were determined from weighted regression of 
logit response on log dose and are shown in Table 5.1, with the LMWH data 
calculated on the basis of anti-Xa potency. These results are consistent with the 
observation that under static conditions ECM is more thrombogenic than HUVEC 
and therefore a greater quantity of inhibitor is required to reduce thrombin generation 
by 50%. 
Table 5.1 IC50 data (with 95% confidence limits) for total thrombin generation (AVC). 
HUVEC ECM 
LMWH Hirudin UFH LMWH Hirudin Shear rate UFH 
(S-I) (IV/ml) (AlXa (Jlglml) (IV/ml) (AlXa (Jlg/ml) IV/ml) IV/ml) 
0 0.18 0.27 0.98 0.34 0.57 2.79 (O.os - 0.70) (0.14-0.S1) (0.62 - I.S2) (0.2S - 0.46) (0.39 - 0.85) (1.12 - 6.98) 
178 0.40 0.68 >4.00t 0.41 0.44 >4.00t (0.28 - 0.55) (0.31 - 1.58) (0.18-0.76) (0.18 - 1.04) 
600 0.54 0.53 >4.00t 0.47 0.59 >4.00t (0.41 - 0.72) (0.41 - 0.69) (0.28 - 0.78) (0.31-1.12) 
t The 50% response is outside the range of observed responses. 
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5.3.2.2 Effect of inhibitors on total thrombin generation (AVe) under jlOH· 
conditions 
As summarised in Table 5.1, a higher concentration of each inhibitor was required 
for inhibition of total thrombin generation under flow conditions compared to static 
conditions. Figures 5.3a and 5.4a show the dose response curves for UFH and 
LMWH in the presence of HUVEC. Statistical analysis of these dose response 
curves showed a significant shift to the right under both venous (178 S -I) and arterial 
(600 S-I) shear conditions (p < 0.001). In the presence of ECM the shift in the UFH 
and LMWH dose response curves is less significant (p = 0.053) and confirms the 
relatively procoagulant condition of the ECM independent of the shear rate 
(Figures 5.3b and 5.4b). 
Hirudin was less effective in reducing total thrombin generation than UFH and 
LMWH under flow conditions. After the initial 40 % reduction in thrombin 
generation with concentrations of hirudin up to 1 Jlglml, no further decrease was 
observed with increased concentrations of hirudin. Consequently, it was not possible 
to derive valid IC50 values as the 50 % response was outside the range of observed 
responses (Figure 5.5). 
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Figure 5.3 
Fig 5.3a HUVEC 
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Dose response curvesfor inhibition of total thrombin generation (AVC) by V FH. 
800 Jil of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 Jil of TES containing VFH. Thrombin generation wa. 
initiated in the presence of a) HVVEC or b) ECM. with 175 Ji l of 100 mM CaCi l 
containing recombinant tissue factor to give a final concentration of 35 pM. Tim ed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5.4 
Fig 5.4a HUVEC 
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Dose response curves for inhibition of total thrombin generation (A UC) by LMWH. 
800 f.1 / of defibrinated p lasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 f.1 1 ofTBS containing LMWH. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM with 175 f.11 of 100 mM CaCl., 
containing recombinant tissue factor to g ive a fina l concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5.5 
Fig 5.5a HUVEC 
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Dose response curves for inhibition of total thrombin generation (A UC) by hirudin. 
800 fl l of defibrinated plasma containing 300 x ] 06 p latelets was incubated for 
30 minutes at 37°C with 25 fll ofTBS containing hirudin. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM with 175 fll of ]00 mM CaCll 
containing recombinant tissue factor to g ive a final concentration of 35 pM. Tim ed 
subsamples were collected into EDTA stop buffer fo r determination of thrombin 
concentration with chromogenic substrate S22 38. 
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5.3.2.3 Comparison of UFH, LMWH and hirudin on the basis of thrombin-
inhibitory activity 
Under static conditions and compared on an anti-Xa unit basis, the IC50 is 
significantly higher for LMWH than for UFH (p < 0.00 I), indicating the efficacy of 
thrombin-inhibitory activity. A comparison on the basis of thrombin-inhibitory units 
in Figure 5.6 shows that the ICso for LMWH is significantly lower than for UFH 
(p < 0.001). The reason for this difference is likely to be the anti-Xa activity of 
LMWH (which is 10-fold higher than its thrombin-inhibitory activity) contributing to 
the inhibitory effect. This indicates that under static conditions both thrombin-
inhibitory activity and anti-Xa activity are effective in the inhibition of thrombin 
generation. 
Comparisons of heparin with hirudin are difficult for reasons discussed previously, 
but Figure 5.6 shows the dose response curves for hirudin expressed in ATU, 
alongside UFH and LMWH on the basis of anti-lla IU. Although these units are not 
comparable this illustrates that high concentrations of hirudin can, like heparin, 
completely inhibit thrombin generation under static conditions, confirming the 
efficacy of thrombin-inhibitory activity. 
207 
~ 
-0 
"""" 
;..; 
= 0 
~ 
~ ~ 
'-' 
U 
~ 
--- UFH 
125 -"- LMWH 
100 
75 
50 
25 
o~--------~------~ 
0.01 0.1 1 1 
Anti -ITa IU/ml 
----.- Hi ru di n 
10 
ATU 
100 
Figure 5.6 Dose response curves for the inhibition of total thrombin generation under static 
conditions by UFH. LMWH and hirudin. 
Data are plotted on the x-axis according to anti-Ila international units (IU) fo r UFH 
& LMWH or anti-thrombin units (A TU) for hirudin. Th ese units are not 
comparable, but g ive an indication of the efficacy of the different inhibitors. 
208 
5.3.3 Peak thrombin generation 
The height of the thrombin generation curve at its peak was measured in order to 
characterise the nature of any inhibition seen, and the IC50 data are shown in 
Table 5.2. These data are quite disperse with some non-linear responses and it was 
difficult to find significant differences between the treatments. However, a trend was 
seen for a decrease in the peak height as inhibitor concentration increased (following 
the pattern seen with AUC). No significant differences were seen within the UFH 
data (Figure 5.7). With LMWH the only significant difference was a higher peak at 
178 S-I over HUVEC (p < 0.01, Figure 5.8). Analysis of variance (accounting for 
shear rate and HUVEC/ECM differences) revealed UFH was less effective in 
reducing the peak height than LMWH (p < 0.05). 
Hirudin significantly reduced the peak height in static conditions over HUVEC when 
compared to all other shear conditions and all ECM results (p < 0.01, Figure 5.9). 
This is in keeping with the observation that the least amount of thrombin is generated 
in static conditions in the presence of HUVEC (see Section 3.3.3.4). 
Table 5.2 IC50 data (with 95% confidence limits) for peak height 
HUVEC ECM 
LMWH Hirudin UFH LMWH Shear rate UFH (AlXa (S-I) (IV/ml) (AlXa (J.!g/ml) (IV/ml) IV/ml) IV/ml) 
0 0.19 0.27 1.17 0.41 0.47tt (0.08 - 0.29) (0.06 - 1.47) (0.70 - 1.87) (0.05 - 0.55) (0.33 - 0.66) 
0.39tt 0.62 >4.00t 0.43 0.49 178 (0.16 0.54) (0.09 - 3.11) (0.23 - 0.69) (0.20 - 0.93) 
0.61 0.51 >4.00t 0.59 0.62 600 (0.24 0.91) (0.03 - 8.64) (0.29 - 1.30) (0.15 - 2.58) 
t Estimated values only as the 50% response is outside the range of observed responses. 
t t Analysis was statistically non-linear 
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Dose response curves for inhibition of peak thrombin generation by UFH. 
800 1-'1 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 1-'1 of TBS containing UFH. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM. with 175 1-'1 of 100 mM eaCl} 
containing recombinant tissue factor to g ive a final concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5.8 
Fig 5.80 HUVEC 
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Dose response curves f or inhibition of peak thrombin generation by LMWH. 
800 f.1 1 of defibrinated p lasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 f.1 1 ofTBS containing LMWH. Thrombin generation was 
in itiated in the presence of a) HUVEC or b) ECM. with 175 f.1 1 of 100 mM CaC(, 
containing recombinant tissue f actor to g ive a fina l concentration of 35 pM. Tim ed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5.9 
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Dose response curves for inhibition of peak thrombin generation by hinldin. 
800 J.11 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 J.11 ofTES containing hinldin. Thrombin generation was 
initiated in the presence of aJ HUVEC or b) ECM. with 175 J.11 of 100 mM CaCl} 
containing recombinant tissue factor to give a final concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
212 
5.3.4 Time of peak thrombin generation 
The time at which the peak of the thrombin generation curve was reached was also 
studied. In some, but not all, experiments with high concentrations of inhibitors no 
thrombin generation at all was seen during the subsampling period (even when this 
was extended to 64 minutes) and this variation made it difficult to assign statistical 
significance to any differences seen. However, there was a trend for the thrombin 
peak to occur later in the presence of any of the inhibitors. 
The different shear rates did not affect the delay before the peak was seen in the 
presence of either UFH or LMWH (Figures 5.10 and 5.11). However, with hirudin 
the introduction of shear stress caused the peak to appear earlier than in static 
conditions. This was significant with hirudin at concentrations between 
2 and 4 flg/ml in the presence of HUVEC, when the peak time under static conditions 
was earlier than at 178 or 600 S-1 (both p < 0.01; Figure 5.12). Over ECM, the peak 
time was significantly earlier at 600 S-1 than in static conditions for concentrations of 
hirudin between 1 and 4 flg/ml (p < 0.01). 
Representative thrombin generation curves using the dose approximately equivalent 
to the static AUC ICso for hirudin (see Table 5.1) over HUVEC (1 flglml) and ECM 
(3 flg/ml) are shown in Figure 5.13 to illustrate the delay in the appearance of the 
thrombin generation peak. 
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Figure 5.10 
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Dose response curves fo r time of peak thrombin with UFH. 
800 1-' 1 of defibrinated plasma containing 300 x 106 p latelets was incubated fo r 
30 minutes at 37°C with 25 1-' 1 of TBS containing UFH. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM. with 175 1-' 1 of 100 mM CaCl: 
containing recombinant tissue factor to g ive a fina l concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5. J J 
Fig 5.11 a HUVEC 
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Dose response curves for time of peak thrombin with LMWH. 
800 J.11 of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37 °C with 25 J.1/ ofTES containing LMWH. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM. with J 75 J.1 1 of 100 mM CaCf~ 
containing recombinant tissue factor to give a final concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. 
215 
Figure 5.12 
Fig 5.12a HUVEC 
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Dose response curves for time of peak thrombin with hinldin. 
800 1-" of defibrinated plasma containing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 J..II ofTBS containing hirudin. Thrombin generation was 
initiated in the presence of a) H UVEC or b) ECM. with 175 J..I I of 100 mM CaC/J 
containing recombinant tissue factor to give a final concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer fo r determination of thrombin 
concentration with chromogenic substrate S2238. 
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Figure 5. 13 
Fig 5.l3a HUVEC + J j..lg/ml hirudin 
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Representative thrombin generation curves from single experiments to shm ... the 
inhibitory effect of hirudin. 
800 j.1 1 of defibrinated plasma contain ing 300 x 106 platelets was incubated for 
30 minutes at 37°C with 25 j.1 1 of TBS containing hirudin. Thrombin generation was 
initiated in the presence of a) HUVEC or b) ECM. with 175 j.1 1 of 100 mM CaC/; 
containing recombinant tissue factor to give a final concentration of 35 pM. Timed 
subsamples were collected into EDTA stop buffer for determination of thrombin 
concentration with chromogenic substrate S2238. Th e concentration ofhirudin was 
approximately the A UC IC50 under static conditions and was I and 3 j.1glml in the 
presence of HUVEC and ECM respectively. 
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5.3.5 Platelet Factor 4 
Assays were performed on subsamples of platelet plasma that had been recalcified 
only or recalcified and stimulated with TF before being subjected to shear stress at 
178 S-I. A control test where the TF/Ca2+ stimulated platelet plasma was not 
subjected to shear stress (0 S-I) was included. No differences were seen between any 
of the treatments or any of the timepoints assayed (8, 16, 24 and 32 minutes after 
stimulation) and all of the results were in the region of 700 ng PF4 per ml. A 
previous experiment had also shown that supernatants from freeze-thawed platelets 
also contained around 700 nglml, and that the background concentration in the 
absence of platelets and shear stress was around 14 nglml. 
218 
5.4 Discussion 
Unfractionated heparin, low molecular weight heparin and hirudin were studied to 
define the relative contributions of anti-Xa and thrombin-inhibitory activity to the 
effectiveness of antithrombotic agents under different physiological conditions. 
The APTT assay was used as a simple test to compare the activities of the inhibitors 
on a weight basis. Hirudin was the most effective inhibitor of the APTT, with twice 
as much UFH and thirty times more LMWH required to double the blank clotting 
time. This test was performed in the absence of platelets but in the presence of 
phospholipid as a platelet substitute and under static conditions, and is a measure of 
the time taken to generate sufficient thrombin to clot the plasma. The concentration 
of thrombin required is around 20 nM or 2 IV/ml and is reached early in the 
propagation phase of coagulation (Hemker, 1994). The propagation phase follows 
the initiation phase where trace amounts of thrombin have positive feedback effects 
on the activation of cofactors FV and FVIII leading to the amplified burst of 
thrombin generation. These results indicate that inhibition of thrombin generated in 
the initiation phase prevents the positive feedback, delaying the propagation phase 
and the appearance of the clot. The irreversible and specific binding of hirudin to 
thrombin appears to be more effective than the catalytic anti-lla and anti-Xa effects 
of UFH. The LMWH tested has one-tenth the thrombin-inhibitory activity of UFH 
when their anti-Xa potencies are equal and, consistent with this, sixteen times more 
LMWH than UFH was required to double APTT. This indicates that inhibition of 
thrombin is effective in the inhibition of coagulation under static conditions. 
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When analysing the data from the thrombin generation studies, the ANOV A 
statistical analysis allowed the influence of some variables to be accounted for when 
comparing other variables. Thus it was possible to determine that under static 
conditions and accounting for the presence of HUVEC or ECM, a significantly 
higher concentration (on an anti-Xa unit basis) ofLMWH than UFH was required to 
inhibit thrombin generation. The ICso for LMWH was 1.5 times that of UFH, but 
when these preparations have equal anti-Xa potencies, UFH has 10 times more 
thrombin-inhibitory activity. This indicates that the thrombin-inhibitory activity of 
UFH may be responsible for its relatively higher efficacy, but that this is only part of 
its overall activity and that anti-Xa activity also contributes to the inhibition of 
thrombin generation. When the data are analysed on a thrombin-inhibitory unit 
basis, a significantly higher concentration of UFH than LMWH is required, 
confirming that the higher proportion of anti-Xa activity in LMWH also contributes 
to its effectiveness. Hirudin was also able to significantly inhibit thrombin 
generation under static conditions, to a greater degree in the presence of HUVEC 
than ECM and this was significant in terms of both area under the curve and peak 
thrombin generation. The specific thrombin inhibitory activity of hirudin is clearly 
effective under these conditions, and this supports the observations with UFH and 
LMWH. 
The effectiveness of all inhibitors was reduced under flow conditions. As seen in 
Section 3.3.3.4, compared with static conditions, there was no increase in free 
thrombin in the presence of ECM under flow conditions. The decrease in the 
effectiveness of the inhibitors may therefore be due to changes in the interaction of 
plasma coagulation factors and the inhibitors caused by increased rates of diffusion 
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in the fluid phase and increased rates of diffusion of substrates and products to and 
from the boundary layer of the vessel wall under flow conditions (Nemerson, 1995). 
The reduced effectiveness of the inhibitors is unlikely to be due to the neutralising 
action of PF4 released from platelets under shear stress for two reasons. Firstly, PF4 
is not an inhibitor of hirudin, and therefore cannot be responsible for hirudin's 
reduced activity under flow conditions. Secondly, the results of the assays of PF4 
release suggest that the release reaction occurred as a result of the TF stimulation, 
and that shear stress does not significantly influence this. The release of PF4 is not 
likely to influence the thrombin generation results as the stoichiometry of the 
PF4-heparin interaction is such that 700 ng/ml of PF4 will neutralise 0.02 IV/ml of 
UFH, and probably less LMWH due to the reduced charge of the shorter 
polysaccharide chains (Barrowc1iffe et ai, 1992). This is only 40 % of the very 
lowest concentration of heparin that was studied in the thrombin generation tests, and 
despite the possible presence of PF4 this concentration showed a significant 
inhibitory activity suggesting that PF4 does not have a significant influence in this 
assay system. 
On an anti-Xa unit basis, significantly more LMWH than UFH was required for 
inhibition under static (p < 0.01) and venous (p < 0.05) conditions, but under arterial 
conditions the IC50 for UFH and LMWH were similar and the anti-lla IC50 for 
LMWH was significantly lower than for UFH (p < 0.001), indicating the contribution 
of anti-Xa activity under arterial conditions. This suggests that at higher shear rates, 
anti-Xa activity becomes more relevant than it was under static conditions and that 
thrombin-inhibitory activity becomes less important. This hypothesis is supported by 
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the hirudin data, which show that under flow conditions it was not possible to inhibit 
total thrombin generation to below 60 % of control levels with thrombin inhibitory 
activity alone. 
Under flow conditions, hirudin was significantly less effective than UFH and 
LMWH, and UFH was less effective than LMWH in their abilities to reduce peak 
thrombin generation. This observation supports the theory that anti-Xa activity is 
more effective in the inhibition of thrombin generation under flow conditions. 
The peak concentration of thrombin was seen later in the presence of inhibitors, in a 
dose-dependent manner, although this was not statistically significant. This increase 
in the lag time suggests that the feedback activation reactions that lead to the 
propagation phase of thrombin generation are being inhibited and is consistent with a 
previous report that found the inhibition of FXa by TFPI reduced thrombin 
generation in a purified, static system by interfering with the feedback activation of 
FV (van't Veer & Mann, 1997). The introduction of shear stress did not affect the 
delay caused by UFH or LMWH, but with hirudin the peak appeared significantly 
earlier than under static conditions. This suggests that FXa may be playing an 
important role in the propagation phase of thrombin generation under flow 
conditions, and therefore a specific thrombin inhibitory agent such as hirudin may be 
less effective. 
Comparison of the activity of heparins and hirudin is very difficult due to their 
different modes of action (catalysts versus irreversible stoichiometric inhibitor) and 
the molecular heterogeneity of heparin (making gravimetric and molar comparisons 
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difficult). Under static conditions hirudin can completely inhibit thrombin 
generation but under flow conditions it loses this ability, unlike UFH and LM\VH. 
The catalytic effect of the heparins may make them more efficient inhibitors of 
thrombin generation than hirudin, which may have decreased efficacy because it 
cannot be recycled - each molecule binds irreversibly to one molecule of thrombin 
and the hirudin is therefore consumed as thrombin generation proceeds. In addition, 
the thrombin-inhibitory activity of hirudin may not be as effective an inhibitor under 
flow conditions compared to anti-Xa activity. Inhibition of FXa, further up the 
coagulation cascade, reduces the amplification effect of this step and may effectively 
inhibit the more efficient process of thrombin generation under flow. The delay in 
the appearance of the thrombin generation peak under static conditions with hirudin 
suggests that it is inhibiting the trace amounts of thrombin that are generated in the 
initiation phase of coagulation, thus preventing the positive feedback effects that lead 
to the propagation phase. The earlier appearance of the peak in flow conditions 
indicates a decrease in effectiveness - the hirudin may be used up more quickly, 
possibly due to increased thrombin generation that anti-Xa activity is able to inhibit 
more effectively. 
Previous studies have found that inhibition of thrombin is important in the inhibition 
of coagulation under static conditions. Two separate studies have shown that 
TF-stimulated static coagulation in vivo was effectively inhibited by UFH but that 
LMWH, an octasaccharide fraction, or purified pentasaccharide had decreased 
effectiveness (Buchanan et ai, 1985; Amar et ai, 1990). The same was seen in an in 
vivo study where coagulation was stimulated via the intrinsic pathway (Thomas et aI, 
1989). In addition, studies employing venous conditions in vivo and ex vivo have 
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demonstrated the effectiveness of anti-Xa agents in the inhibition of thrombosis. In 
vivo TF-stimulated venous thrombosis was inhibited by the specific anti-Xa agent 
recombinant tick anticoagulant peptide (rT AP) more effectively than by UFH 
(Vlasuk et aI, 1991) and ex vivo venous thrombosis in response to TF expressed on 
activated HUVEC was inhibited for a longer period with LMWH than UFH 
(Diquelou et aI, 1995b). More recently, a specific direct inhibitor of FXa, DX-9065a 
was more effective in the inhibition of ex vivo thrombus formation under arterial 
conditions than venous conditions (Shimbo et aI, 2002), confirming an earlier report 
of weak in vivo inhibition in a venous model (Rogers et aI, 1999). LMWH has been 
demonstrated to be more effective than UFH in the inhibition of fibrinogen 
deposition on injured artery wall (Roque et aI, 2000), and the antithrombin binding 
pentasaccharide has proven to be effective in models of arterial thrombosis (Vogel et 
aI, 2000). The present results that show an increased role for thrombin-inhibitory 
activity under static conditions, and for anti-Xa activity under venous conditions, are 
consistent with these reports. 
There are, however, studies that indicate the increased effectiveness of thrombin 
inhibitory agents over heparin at arterial shear rates. Bossavy et al (1998; 1999) 
have shown that heparin is ineffective at preventing platelet and fibrin deposition 
onto TF surfaces under arterial conditions, but that hirudin is an effective inhibitor. 
It must be noted that these experiments employed a shear rate of 2600 S-I, similar to 
that found in stenosed arteries, whereas our study used a shear rate of 600 s -1 which 
is typical of that found in medium sized arteries. Conversely, a study examining the 
effectiveness of rT AP under arterial shear conditions showed that selective inhibition 
of FXa was in fact effective in inhibiting thrombosis on a TF surface at both 600 and 
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2600 S-1 (Orvim et ai, 1995). It is plausible that the balance between the importance 
of inhibition of FXa and thrombin may continue to shift as the shear conditions 
change and that both become significant at extreme shear rates, depending on the 
parameter that is being measured. 
5.5 Summary 
The present results show that increasing concentrations of the inhibitors UFH, 
LMWH and hirudin are required to inhibit thrombin generation as the shear rate is 
increased. They also show that the effectiveness of the specific thrombin inhibitor 
hirudin decreased as the shear rate increased, in contrast to the predominantly 
anti-Xa agent LMWH, which became as effective as UFH at higher shear rates. This 
suggests that different approaches may be required for the prevention and treatment 
of different clinical conditions - heparin may be appropriate for venous thrombosis, 
but arterial syndromes may require the use of predominantly anti-Xa agents. Studies 
using a direct anti-Xa agent such as DX-9065a and the heparin pentasaccharide 
would be of interest to examine the contribution of direct over indirect 
(AT -mediated) FXa inhibition in arterial conditions. 
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CHAPTER 6 
DISCUSSION 
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6.1 Background 
This thesis describes the design and use of a system that enables the study of 
antithrombotic agents under flow conditions and in the presence of relevant cellular 
components. The system was based upon that designed in the laboratory of Dr Yale 
Nemerson (Contino et ai, 1991) who used capillary tubes to study the influence of 
flow on the reaction kinetics of coagulation. His theory that the transport rate of 
substrates and products to and from vessel wall enzymes are the rate limiting steps in 
coagulation has proved that it is crucial to include flow conditions in these studies as , 
the transport rates are influenced by the shear rate (Nemerson, 1995). The group 
published numerous papers, using purified components of the extrinsic tenase 
complex and glass capillaries to prove the influence of flow on the rate of FXa 
generation (Gemmell et ai, 1988; Gemmell et ai, 1991; Andree et ai, 1994; Andree & 
Nemerson, 1995; Gentry et ai, 1995). This work was continued in the laboratory of 
Dr Theo Lindhout, who also used a capillary system to study the effects of flow on 
the assembly and activity of the prothrombinase complex from purified components 
(Schoen et ai, 1990; Billy et ai, 1995b). This group extended their studies to 
examine the effects of flow on the action of anticoagulants such as heparin and 
pentasaccharide, showing that antithrombin depletion in the boundary layer limits the 
effectiveness of these agents at the vessel wall and that their main inhibitory effect is 
exhibited in the fluid phase (Lindhout et ai, 1995; Billy et ai, 1995a). The difficulty 
in establishing intact mono layers of cells inside capillary tubing has only been 
overcome once, when Lindhout et al (1992) studied the inhibitory effect of TFPI on 
the extrinsic tenase complex, finding that even activated endothelial cells were much 
less procoagulant than the extracellular matrix. A more practical approach to the 
study of endothelial cells under flow conditions was pioneered by Dr Kjell 
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Sakariassen, who developed the parallel plate flow chamber that could generate a 
defined shear rate across a coverslip coated with cells, or other substrates of interest 
(Sakariassen et ai, 1983; Sakariassen et ai, 1984). Among the numerous studies 
performed in this chamber was the early characterisation of GP Ib/IXN as an 
adhesive receptor and GP lIb/IlIa as an aggregatory receptor (Sakariassen et al. 
1986). The wide range of applications of this and other chambers have been recently 
reviewed by Sakariassen et al (2001). 
6.2 The flow system 
By combining the principles of Nemer son's flow reactor with the inhibitor studies of 
Lindhout and the cellular components of Sakariassen, the studies detailed in this 
thesis aimed to establish a test system for antithrombotic agents that included some 
of the critical in vivo influences that are often missing from in vitro assays. The 
discrepancies that are noted between in vitro results and the true in vivo situation, 
such as in the measurement of APTT following heparin therapy (Hirsh et ai, 2001) 
may, inter alia, be the result of the different reaction rates that are possible in a 
closed static system and a flow system where fresh reactants are constantly being 
delivered, and products removed. In addition, the presence of the endothelial cells 
that line every blood vessel and play an active anti- or pro-coagulant role depending 
on their state of activation, and of platelets, the blood cell critical to coagulation, 
were expected to make a major difference to the results obtained. 
A number of validation studies were carried out on the flow system to ensure that it 
performed reliably and to examine the effects of flow on the cellular components of 
the system. The thrombin generation test was selected as the most suitable method to 
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measure coagulation in this system, and the effects of flow and the presence of cells 
were determined. Once the system had been validated and a suitable , 
physiologically-relevant, platelet-dependent thrombin generation system established, 
studies were performed to investigate the effects of anti thrombotic agents under flow 
conditions. 
6.3 Studies with anti-platelet antibodies 
Studies were performed to evaluate the inhibitory effect of antibodies against the two 
major adhesive receptors of the platelet, OP lIb/IlIa and OP Iba, part of the 
OP Ib/IXN complex. The antibody to OP Iba was initially included as a negative 
control, but proved to have significant inhibitory activity which was pursued as an 
interesting finding. However, further investigation led to the conclusion that this 
activity was the artefactual result of a contaminant in the original batch of antibody. 
This suggests that antibodies directed against the vWF-binding function of OP Iba 
are not effective in the inhibition of thrombin generation. 
The results for the anti-OP lIb/IlIa antibody showed a clear reduction in the 
anti thrombotic efficacy of the antibodies under venous flow conditions compared to 
static or arterial flow conditions. This is an interesting finding that fits with the 
accepted theory that arterial thrombosis is mostly mediated by platelets and thus an 
inhibitor of the major aggregatory receptor on platelets will be effective. There are 
no similar reports to this in the literature, although an increase in the ICso of small 
molecule inhibitors of OP lIb/IlIa have been reported in comparisons of platelet 
aggregation with adhesion to collagen under flow conditions (Mousa et aI, 2002; 
Wang et aI, 2002) and shear-induced platelet adhesion (Abulencia et aI, 2001). The 
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clinical expenence with antagonists of GP lIb/IlIa also supports the theory _ 
abciximab is effective when used in during percutaneous surgical intervention, but 
not for any venous conditions. This confirms the utility of the flow system in 
predicting the in vivo efficacy of agents that have proven effective in closed systems 
under static conditions in vitro. In support of this, a flow chamber system has 
recently been found to be useful in the assessment of the efficacy of antiplatelet 
agents and an anti-GP lIb/lIla antibody on stent-induced thrombosis (Sakakibara et 
ai, 2002). 
6.4 Studies with heparin and hirudin 
Platelets play a key role in primary haemostasis, adhering and aggregating to seal 
breaches in the vessel wall. These processes are mediated by platelet membrane 
glycoprotein receptors, and antagonists of these receptors may interfere with both 
their adhesive function and the outside-in signalling that would activate the platelet, 
as has been noted with anti-GP lIb/IlIa agents (Reverter et ai, 1996; Pedicord et ai, 
1998; Herault et ai, 1998). The second phase of haemostasis is the development of a 
stable fibrin clot, following activation of the coagulation cascade, a process to which 
platelets contribute by the release of coagulation factors and the expression of a 
catalytic surface for their interaction. The most potent activator of platelets is 
thrombin, generated in the initiation phase of coagulation, which has an explosive 
positive feedback effect on coagulation. An alternative approach to the inhibition of 
thrombosis is therefore to inhibit the generation of thrombin through the use of 
anticoagulants, and studies were performed to assess the effects of different flow 
conditions on heparin and hirudin. 
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The anticoagulants heparin and hirudin were also seen to have reduced effectiyeness 
in the inhibition of thrombin generation under flow conditions. Clear differences 
were seen between unfractionated and low molecular weight heparin, and these 
changed with the shear rate. Under static and venous conditions, significantly more 
LMWH than UFH was required for inhibition, as was seen in the APTT assay, but 
this difference was eliminated under arterial conditions. This suggests that the 
anti-Xa activity of the compounds increased in importance as the shear rate 
increased. Although the direct thrombin inhibitor hirudin is not strictly comparable 
with heparin, its effectiveness in the inhibition of thrombin generation under static 
conditions and in the APTT, coupled with its inability to inhibit thrombin generation 
to any great extent under flow conditions, supports the hypothesis that anti-thrombin 
activity is less relevant under conditions of increased shear stress. These findings are 
consistent with previous reports that have found UFH to be more effective than 
LMWHs in models of in vivo stasis (Buchanan et ai, 1985; Thomas et ai, 1989; 
Amar et ai, 1990), and studies that showed anti-Xa agents to be effective in the 
inhibition of in vivo and ex vivo venous thrombosis (Vlasuk et ai, 1991; Diquelou et 
ai, 1995b). This again illustrates how the flow system can provide data that is 
relevant to the in vivo situation without the need for invasive procedures. However, 
a limitation of the flow system as a model of in vivo coagulation may be revealed 
when analysing the hirudin results. One of the benefits of hirudin is its ability to 
inhibit clot-bound thrombin and thus prevent expansion of an existing thrombus. 
This is a clinical situation that may not be adequately represented in these 
experiments, although future work could include experiments with fibrin clots 
generated on coverslips. Hirudin is also a more effective inhibitor of fibrin 
deposition and platelet adhesion than heparin (Bossavy ef al. 1999) due to its 
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irreversible inhibition of thrombin, a major activator of platelets. Clinically, UFH 
and LMWH have traditionally been used for the treatment and prevention of yenous 
thrombosis, but are increasingly used for treatment of acute coronary syndromes 
(Hirsh et ai, 2001). Further confirming the potential of anti-Xa agents in arterial 
conditions, the new pentasaccharide drug Fondaparinux is entering phase III clinical 
trials for use in acute coronary syndromes, as well as for venous thromboembolism 
(Lensing, 2002). 
6.5 Conclusions 
The results presented in Chapters 4 and 5 allow a theory to be formulated regarding 
the process of coagulation under flow conditions, in contrast with the static studies, 
and outlined in Figure 6.1. Coagulation was stimulated with a low concentration of 
TF to mimic low-level damage within the vasculature. The inhibition of GP Ib/IXN 
at one of its vWF adhesion sites was not effective in the inhibition of coagulation 
under these conditions, but inhibition of GP lIb/IlIa was particularly effective under 
static or arterial conditions, illustrating the importance of flow in the consideration of 
in vitro data. The efficacy of the anti-GP IIb/lIla antibody at arterial shear rates 
suggests that platelet-platelet interaction is important in the amplification of the 
response, but also that platelet activation via GP lIb/IlIa may be important in the 
development of the platelet-mediated coagulation response. The efficacy of 
anticoagulants was also markedly reduced under flow conditions. Under arterial 
conditions coagulation was most effectively inhibited by anti-Xa agents and direct or 
indirect inhibition of thrombin was less effective. The results suggest that under 
arterial conditions, the assembly and activity of the prothrombinase complex is the 
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Figure 6.1 
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A simplified theory of the inhibition of coagulation under flow conditions 
Red indicates targets of strong inhibition; .!Jt III indicates targets of lveak inhibition. 
P = resting platelet (with GP lib/lila and a bound inhibitory antibody shown). 
AP = activated platelet. 
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critical stage of coagulation and that inhibition of free thrombin is of limited 
effectiveness. Under venous conditions, inhibition of platelets via GP lIb/lIla is 
weak, and coagulation is more effectively inhibited by anti-Xa agents than by anti-
thrombin agents. 
6.6 Future work 
The flow system used in this study does have some limitations, which may be 
addressed in future work. The design of the flow chamber made it difficult to study 
the adhesion of platelets to the endothelial cells or their matrix. This would have 
been useful, as the antibodies used are against adhesive receptors (although the 
antibodies are still able to prevent activation via the receptors), and platelet adhesion 
plays an important role in the coagulation process. These studies were primarily 
concerned with the 'end-product' of the coagulation process, measured as the 
generation of thrombin, but it would have been helpful to visualise the interactions 
that were occurring at the 'vessel wall'. Post-perfusion analysis of the coverslips 
was also more difficult than had been hoped, as the coverslips were liable to stick to 
the gasket and then slip across it when the flow chamber was dismantled, thus 
removing any cells before microscopy. Redesign of the chambers may allow in situ 
microscopy, if the top block was thinner and a transparent base was used, and this 
should not prove to be an overly expensive commission. Real-time microscopy of 
the perfusion, with image capture equipment would allow studies of the interaction 
of platelets with the (sub )endothelium, and allow the process of clot fonnation, and 
how inhibitors affect it, to be studied dynamically. In addition, the use of fluorescent 
labels on antibodies, inhibitory agents or tissue factor would allow their detection 
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during the course of a perfusion, and the assembly of the clot could be yisualised in 
situ - arrangements are in progress for a rheological microscope stage to be modified 
for this purpose. Alternatively, the DiaMed Impact (DiaMed, Cressier sur Morat. 
Switzerland) is a new diagnostic device that analyses the adhesive capacity of 
platelets in whole blood, using a cone and plate system to apply shear stress and 
providing image analysis and quantitation. This machine has potential for rapid 
assessment of the anti-adhesive capacity of inhibitors using different substrates and 
shear rates, and could be of use alongside the flow system for the analysis of 
coagulation under matched conditions. Contacts have been made with the 
manufacturer and a collaboration is being arranged. 
The absence of red blood cells, leukocytes and fibrinogen and the presence of citrate 
detract somewhat from the physiological relevance of the system, but all are 
necessary for practicality. The ideal system would allow studies with 
non-anticoagulated whole blood. This would incorporate the physical interactions 
between red cells and platelets, the contribution of red cells to coagulation, the 
potentially pro-inflammatory and pro-coagulant interaction of platelets with 
leukocytes, and the roles of fibrinogen in platelet aggregation and coagulation. 
However if whole blood were to be used the red cells would interfere with the , 
detection of thrombin by a chromogenic substrate. In addition, the red cells would 
also interfere with the real-time microscopy studies suggested above. The use of a 
fluorogenic substrate for thrombin detection is a potential solution to the interference 
of red cells with chomogenic substrates, but strict standardisation would be required 
as the haematocrit would still have a strong influence on the results. It would be 
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difficult to perform a thrombin generation test in parallel with this system, but it may 
be possible with manual sampling in an anticoagulated system. 
Another area that could be standardised in future studies is the surface area to 
volume ratio of the plasma and the cells. This was directly comparable in the venous 
and arterial experiments, but different for the static and low shear (18 s -1) 
experiments, as a result of the design of the Type 2 flow chambers that were built to 
maximise the length of the experiments where volume of perfusate was the limiting 
factor, and recirculation was not desirable. Due to the anticoagulant nature of the 
endothelial cells and the procoagulant nature of the extracellular matrix, the volume 
of plasma that is in contact with them and the duration of contact will have an effect 
on the coagulation that is proceeding. This difference may be partly responsible for 
the reduced effectiveness of the inhibitors under static conditions in the presence of 
ECM compared to HUVEC, and the lack of difference when shear stress was 
applied, suggesting either that the reduced surface area available for contact with the 
plasma was having a lesser effect on coagulation, or that the cells were becoming 
procoagulant. Further studies to determine the activating effect of short-term shear 
stress on HUVEC will be needed to answer this question fully. 
Other agents that would be interesting to study in the flow system include antibodies 
against the other adhesive and activating receptors on the platelet membrane such as 
GP IaJIIa, GP VI and other epitopes on GP Iba such as the thrombin binding site. It 
would be particularly interesting if a combination of antibodies against a number of 
receptors used together could completely inhibit platelet activation in an additi\'e 
manner, as has been seen to some extent with antibodies to GP lib/IlIa and GP Iba 
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(Wu et ai, 2002a). Studies of direct anti-Xa agents such as DX-9065a and rT AP 
would allow direct comparison with hirudin, and studies with the pentasaccharide 
would add to the UFH and LMWH data. Combination studies would also be 
interesting, as many patients do not receive a single drug in isolation. The majority 
of at-risk patients take aspirin or c1opidogrel routinely, and the flow system is 
particularly suited to the study of combined anticoagulant and antiplatelet agents as it 
incorporates both platelet and plasma components of coagulation. 
6.7 Summary 
The results presented indicate clear differences in the mode of action of 
anti thrombotic agents under flow conditions. The experimental conditions used were 
an approximation of clinical situations where coagulation is initiated at one point in 
the vasculature and the activated blood is washed downstream, passing over intact or 
damaged endothelium where the extracellular matrix is exposed. The effect of this 
(non-) reactive surface on the progress of coagulation is clearly important, for 
instance in invasive procedures where endothelial damage is inevitable and 
anti thrombotic agents are used to prevent occlusive thrombi forming. The results 
that were obtained show significant differences in the efficacy of antithrombotic 
agents under a variety of physiological conditions and that this flow system is 
capable of providing data relevant to the in vivo situation. 
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APPENDIX 1: (l2M-THROMBIN CALCULATION 
The method used to calculate the amidolytic activity of the u2M-thrombin complex 
followed the methods of Hemker et al (1986). The following explanation and the 
computer programme used to automate the calculation procedure were both written 
by Peter Rigsby, Informatics Laboratory, NIBSC, UK. 
Let A(t) denote the total amidolytic activity at time t, T(t) denote the thrombin 
concentration at time t and aCt) denote the a2m-thrombin concentration at time t. 
The relationships ~a(t) = k2T(t) and A(t) = T(t) + ja(t) are then solved, for the 
dt 
discrete case (tpt2 ,t3 ••• ), with constants k2 and j as described by Hemker et al 
(1986). The area under the T(t) curve is then calculated - again for the discrete case. 
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APPENDIX 2: FLOW SYSTEM SOFTWARE 
The syringe pump and XYZ-translation table of the flow system was controlled by a 
personal computer running software written by Dr Paul Contino of the Department of 
Medicine, Mount Sinai School of Medicine, City University of New York, USA. 
(Contino et ai, 1991). This software was kindly donated by Dr Yale Nemerson and 
was adapted for use with the particular models of pump and table by the suppliers of 
the table, Unimatic Engineers, London UK. 
Print outs of the user interface are found on the following pages. 
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Main menu ... 
Origin is set at (X, Y position in mm) : 80.0, 77.0 
Upper/Lower limits are (mm): 
1 START (PLATE TEMPLATE) . 
2 START (COBAS TEMPLATE) . 
3 Modify origin. 
4 Modify Upper/Lower limits. 
Upper limit = 
Lower limit = 
62.0 
72.0 
Not active in this version 
5 Set Pump & Experiment Parameters. 
6 Save present settings. 
7 Get settings from disk. 
8 Set up table parameters Not yet active 
Press one of the highlighted keys to perform action ... 
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Set origin 
Co-ordinate in X direction: 
Co-ordinate in Y direction: 
Move to indicated X, Y position 
Finetuning: 
1 X direction 
2 Y direction 
80.0 rrun 
77.0 rrun 
Origin set correctly (Center of well Ai). Continue. 
Press one of the highlighted keys to perform action ... 
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Set Upper/Lower limits ... 
CAUTION: Upper limit is the level at which the arm moves from one 
well to another, and Lower limit is the level to which the arm 
lowers when collecting samples. 
As the <reset> position of the arm in the Z-direction is the 
HIGHEST position of the arm, and the arm moves downwards, the 
distance to the Upper level is smaller than the distance to the 
Lower level. Therefore under all conditions Upper limit should 
be smaller than the Lower limit ! 
The software is safeguarded for this. 
Press any key to continue ... 
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Set Upper/Lower limits '" 
Upper limit: 
Lower limit: 
62.0 mm 
72.0 mm 
Move to, and finetune on: 1 Upper limit 
2 Lower limit 
Upper/Lower limit set correctly. Continue. 
Press one of the highlighted keys to perform action ... 
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Pump Mode Setup Screen 
Current Pump Mode:- Proportional 
( Press A to select Auto Stop Mode ) 
( Press P to select Proportional Mode ) 
( Press T to select Continuous Mode ) 
More ... Next Page 
Press one of the highlighted keys to select pump mode ... 
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Setup Pump 2 
Number of wells is calculated at"- 32 
Use a start value of "0" if syringe 2 not used 
Start syringe 2 at well number 1 - Enter a number between 0 and 96 
Stop syringe 2 at well number 32 - Enter a number between 0 and 96 
Continue? 
Press one of the highlighted keys to select pump mode """ 
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Save present settings ... 
Save as: 600 
Filename correct. Perform save action. 
Continue. 
Press one of the highlighted keys to perform action ... 
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Get settings from disk ... 
Source file: 600 
Filename correct. Get settings 
Continue. 
Press one of the highlighted keys to perform action ... 
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Press <space bar> to stop NB 
- Only acts at end of a well 
Current well no. 1 
Time remaining (Secs) 
60 
Flow rate "1": 30.0 ~l/min 
Estimated experiment time: 
Approx Time Remaining, Mins, 
32 
32 min. 
Secs 
Flow rate "2": 
inclusive 
30.0 ~l/min - ONLY between Well No 1 & No 32 
Total number of wells will be: 32 
You will be collecting 60.0 ~l/well 
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